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Pharmacologic reversal of epigenetic events including histone modification and DNA 
methylation has a therapeutic potential in cancer treatment through inducing cancer cell 
apoptosis. 3-deazaneplanocin A (DZNep) appears to be a unique chromatin remodelling 
(epigenetic) compound that can deplete the cellular enhancer of zeste homolog 2 (EZH2) 
protein, an enzyme responsible for modulation of histone methylation and in turn specifically 
induce breast cancer apoptosis. Hence, DZNep, alone or together with the other two 
epigenetic agents trichostatin A (TSA) and 5-Aza-2’-deoxycytidine (AZA), were used to 
probe the role of EZH2 in coordination with other epigenetic components in gene regulation 
in breast cancer cells and to identify a comprehensive set of genes functionally enriched in 
inflammation network and abnormally regulated by EZH2 in breast cancer cells. From this set 
of genes, TNF, a cell death gene, was found to be associated with the DZNep plus TSA 
induced cell death in breast cancer cells. As the only antitumor agent through inhibition of 
EZH2 protein to date, the preclinical study of DZNep was thus performed. No observable 
adverse effect dose (NOAEL) of DZNep determined was 10 mg/kg in Sprague Dawley (SD) 
rats. DZNep caused nephrotoxicity and renal atrophy in rats in a dose-dependent manner but 
had no apparent effect on the hematological system of rats. A sensitive and reliable liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was 
developed for the quantification of DZNep in rat biosamples (rat plasma, urine, feces, and 
tissues). Following an intravenous bolus administration, DZNep had a dose-independent tri-
 VIII
exponential disposition profile with a short plasma elimination half-life (1.1 h) in SD rats. 
DZNep also showed a low protein binding in plasma (18.5 %) and a low partitioning to 
erythrocyte (0.78), but had extensive tissue distribution, especially in kidney (21.25 ± 2.12 
µg/g at 5 min), and predominant renal excretion (80.3 % recovered as the unchanged drug by 
72 h). DZNep was not extensively metabolized in vivo (86.80 % recovery of DZNep 
unchanged from urine and feces by 72 h). A unilamellar pegylated liposomal formulation 
containing DZNep (L-DZNep) was developed using a remote-loading method in the presence 
of phenylboronic acid and the encapsulation efficiency of DZNep in L-DZNep reached 47.5 
%. Importantly, the entrapment of DZNep within the pegylated liposomal carrier noticeably 
ameliorated the pharmacokinetic characteristics of DZNep in vivo (e.g. elimination half-life, 
8.0 h). The overall findings of these studies support that DZNep not only can serve as a 
molecular pharmacological tool to probe the complex interaction between epigenetic events 
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1.1 The application of epigenetic principle in tumor therapy 
1.1.2 Tumorigenesis and epigenetic events 
For decades, scientists have been engaged in dissecting the origins of human cancer, and 
the relative roles of genetic versus epigenetic abnormalities have been hotly debated. 
Epigenetics refers to the heritable alterations in gene expression with a reversible and dynamic 
manner that does not directly change the DNA sequence (1). Gene silencing at the level of 
chromatin regulated by epigenetic events is required for the life of eukaryotic organisms and is 
particularly important in modulating key biological processes, including differentiation, 
imprinting, and silencing of large chromosomal domain such as the X chromosome. Like most 
biological processes, silencing can become dysregulated, resulting in the development of 
disease states, including cancer. Epigenetic abnormalities in cancer comprise a multitude of 
aberrations in virtually every component of chromatin involved in packaging the human 
genome. Since epigenetic silencing processes are mitotically heritable, they can play the same 
roles and undergo the same selective processes as genetic alterations in the development of a 
cancer.  
Heritable gene silencing involves the interplay between DNA methylation and histone 
modifications, two predominant epigenetic events. Abnormal epigenetic changes have been 
implicated in cancer development through abnormal gene silencing (2), which were extensively 
discussed in this project. 
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1.1.2.1 DNA methylation 
DNA methylation refers to the addition or subtraction of a methyl group to a cytosine 
residue in a sequence of DNA. Global (genome-wide) decreases in methylation, or 
hypomethylation, are most functionally relevant when they occur in coding regions of genes, 
leading to alternative versions or levels of mRNA. The addition of methyl groups, or 
hypermethylation, is much more gene specific. Regions of the genome that are rich in the 
sequence of a cytosine preceding a guanine (CpG dinucleotide) are known as CpG islands. In 
particular, CpG islands exist in the promoter regions of approximately half of all genes. 
Hypermethylation of CpG islands around the promoter region of a gene results in its 
transcriptional silencing and loss of protein expression. Hypermethylation of genes involved in 
the cell cycle, DNA repair, angiogenesis, metabolism of carcinogens, apoptosis, and cell-cell 
interaction has been implicated in carcinogenesis (3).   
Three active DNA methyltransferases (DNMTs), including DNMT1, DNMT3a, and 
DNMT3b, which catalyze the covalent addition of methyl groups to cytosines in the CpG 
dinucleotide context, have been incriminated in the DNA methylation abnormalities in cancer (3-5).  
Dnmt3a and Dnmt3b primarily methylate DNA de novo while Dnmt1 principally maintains heritable 
methylation patterns during DNA replication (6, 7). Elevated levels of DNMTs proteins and 




1.1.2.2 Histone modifications 
Histones are subject to a wide variety of posttranslational modifications including but 
not limited to, lysine acetylation, lysine and arginine methylation, serine and threonine 
phosphorylation, and lysine ubiquitination and sumoylation (12). Histone modifications are 
proposed to affect chromosome function through at least two distinct mechanisms. The first 
mechanism suggests modifications may alter the electrostatic charge of the histone resulting in a 
structural change in histones or their binding to DNA. The second mechanism proposes that 
these modifications are binding sites for protein recognition modules, such as the 
bromodomains or chromodomains, which recognize acetylated lysines or methylated lysine, 
respectively. The existence of these modifications and recognition modules led to a well 
established ‘histone code’ hypothesis proposed by Strahl and Allis (13). Among various forms 
of histone modifications, histone lysine acetylation and methylation are of particular interest 
owing to their established roles in gene regulation  (14, 15).  
Generally, actively transcribed genes are surrounded by acetylated histones but by 
deacetylated histones (13, 15). The acetylation dynamics are balanced by opposing actions of 
histone acetyltransferases (HATs) and histone deacetylases (HDACs) (16, 17). HATs transfer 
acetyl groups to amino-terminal lysine residues in histones, which results in local expansion of 
chromatin and increased accessibility of regulatory proteins to DNA (16), whereas HDACs 
catalyze the removal of acetyl groups, leading to chromatin condensation and transcriptional 
repression (17). It has been widely recognized in recent years that HDACs (18 members into 4 
classes) are promising targets for therapeutic interventions intended to reverse aberrant 
epigenetic states associated with cancer (2, 18). It is because that the aberrant recruitment of 
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HDACs to promoters through their physical association with oncogenic DNA-binding fusion 
protein. For example, the oncogenic PML-RARα, PLZF-RARα and AML1-ETO fusion proteins 
induce acute promyelocytic leukaemia (APL) and acute myeloid leukaemia (AML) by 
recruiting HDACl-containing repressor complexes to constitutively repress expression of 
specific target genes (18, 19). In addition, the abnormal expression of individual HDACs in 
tumor samples has also been reported. For example, HDAC1 is overexpressed in prostate, 
gastric, colon and breast carcinomas (20-23); while HDAC2 is overexpressed in colorectal, 
cervical and gastric cancer (22, 24-26).  
Methylation of histone lysines associates with either active or repressive states of the 
chromatin depending upon the modified site (27). Specifically, methylation of histone H3 at 
lysine 4  is an active histone mark, while methylation of H3 at lysine 27 o and lysine 9 (H3K9) 
are repressive ones (27, 28). These modifications are mediated through two distinct histone 
lysine methyltransferase (HKMTs), Trithorax (TrxG) and Polycomb (PcG) protein complexes, 
and play critical roles in lineage-specific developmental programs (29). In contrast to H3K4 
methylation, H3K9 and H3K27 methylations are generally associated with silenced regions (14, 
27, 30). In mammals, histone lysine 27 trimethylation (H3K27me3) mark the heterochromatic 
and inactive X chromosome (31, 32). Among PcG proteins, the polycomb-repressive complexes 
2 (PRC2) is of particular importance since it not only maintains gene repression through 
intrinsic HMTs activity (33-35) but also has been linked to stem cell biology and cancer (36-40). 
PRC2 contains three core components: EZH2, SUZ12, and EED (41, 42). EZH2 contains the 
HMTase activity, and SUZ12 and EED are required for this activity (30). EZH2 catalyzes 
H3K27me3 and is indispensable for PRC2-mediated gene repression (34, 43). Human EZH2 
 6
has been linked to cancer. It is overexpressed in metastatic prostate and breast cancer and has 
been associated with breast cancer aggressiveness (44-47). In addition to EZH2, SUZ12 is also 
up-regulated in several human tumors including those of the colon, breast, and liver (43, 48). In 
cultured cells, EZH2 was found to be essential for cell proliferation, and overexpression of 
EZH2 promoted cell transformation (45, 46). Thus, as a potential repressor of tumor suppressor 
genes, the PRC2 complex appears to be an attractive target for therapeutic intervention. 
1.1.2.3 The connections of DNA methylation, histone deacetylation, and histone 
methylation 
Increasing evidence indicates that various epigenetic changes are often interconnected 
and act in a coordinated manner (49). Early reports showed the HDACs are associated with both 
DNMTs and a family of methyl cytosine-binding proteins (MBDs), which interpret and mediate 
the transcriptional repressive activities of DNA methylation (50-52). Typically, actively 
transcribed genes are surrounded by deacetylated histones when aberrantly silenced in cancer in 
association with DNA methylation (53, 54). In this apparent collaboration between DNA 
methylation and lysine deacetylation, the methylation appears dominant in that it must be 
diminished by the demethylating agent, 5-aza-2’-deoxycytidine (AZA), before cellular 
inhibition of the HDACs can effectively achieve transcriptional reactivation of genes (53, 55). 
This demethylation also causes release of the MBDs, and presumably of the HDACs, from the 
promoters (56, 57).  
As for the relation between DNA methylation (DNMTs) and H3K27me3 (EZH2), the 
some paradoxical findings have been reported. It has been previously suggested that EZH2 may 
directly control the DNA methylation for gene silencing (58, 59). As such, inhibition of EZH2 
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is sufficient to remove DNA methylation and reactivate DNA methylated genes. These data 
suggested that the two silencing pathways may be functionally interconnected. However, one 
recent study using high-resolution, genome wide mapping of histone modification and DNA 
methylation revealed that the two silencing pathways target different set of genes (59, 60). In 
fact, only less than 10% of DNA methylated genes were found to be enriched for H3K27me3 in 
both breast and prostate cancer cells. The discrepancy between this study and the previous one 
might be due to tissue specificity. However, it should be pointed out that a functional link 
between the two signaling pathways may still occur indirectly or in gene- and context-
dependent manner. Of notice, a small set of genes are marked by both H3K27me3 and DNA 
methylation, and thus it remains to be determined in our project whether the two epigenetic 
events are connected functionally in regulating this small set of genes.  
A highly specific, physical interaction between PRC2 protein complex and class I 
HDAC has been reported by Van der Vlag et al. (61). In addition, a reduction of EZH2 and 
other PCR2 proteins after treatment of primary acute leukemia cells with a HDACs inhibitor, 
LBH589 (62). This report even pointed out that HDAC activity is necessary to make 
H3K27me3 accessible to PRC2. This is somehow consistent with Jiang’s conclusion, inhibition 
of repressive histone methylation by EZH2 inhibitors creates a favorable chromatin 
environment for histone acetylation (63). Although the inherent interaction mechanism of EZH2 
and HDAC is unknown by far, cotreatment of EZH2 inhibitors and HDAC inhibitors already 
was verified to an effective strategy to reactivate abnormally EZH2-suppressed genes and 
induce synergistic apoptosis of human breast, colorectal cancer cells, human acute myeloid 
leukemia, myeloma cells and astrocytoma cells but not corresponding normal cells (63-69).  
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1.1.2.4 Semi-heterochromatic state in cancer cells 
In McGarvey’s report (70), an intermediate transcription state for aberrantly silenced 
genes in cancer cells has been put forward (Figure 1.1). Despite induction of active transcription 
sufficient to provide function protein, the partially reactivated genes, such as hMLH1, dose not 
return to the full euchromatic state in SW480 cells (colorectal cancer). After gene reexpression 
was induced by DNMTs and HDAC inhibitors (53), retention of repressive methyation marks, 
H3K9me3 or H3K27me3, also characterizes the activated genes (e.g. SFRP1 and GATA5) in a 
semi-heterochromatic state that may facilitate recurring gene silencing. These scenarios suggest 
that only certain distinct chromatin marks need to be associated with transcriptional reactivation, 
such as H3K4me3, H3K9/14 acetylation, and depletion of H3K9me2. By contrast, H3K9me3 
and H3K27me3 may not directly impair transcriptional reactivation but may serve to index the 
promoter region for additional epigenetic control. These latter marks may be involved in 
compromising promoter function and provide imprints to facilitate subsequent silencing if the 
activating signals decay. This semi-heterochromatic state of tumor suppressor genes may likely 
explain why DNA-hypermethylated genes, after demethylation and activation by AZA 
treatment of cells, readily reaccumulate DNA methylation and return to a gene silencing state 
once the drug is removed (71). In this regard, the retention of all the H3K27 methylation, and 
some H3K9 methylation marks which have been associated with recruitment of DNA 
methylation (72-74), may render the promoter primed to reassure a DNA-hypermethylated and 
resilenced state associated with gain of the critical H3K9me2 mark. The author suggests this 
adverse condition may be overcome through continuous and/or repeated drug administration, in 
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an attempt to continue maximizing the efficacy of therapeutic strategies targeting reversal of 
tumor suppressor gene silencing. 
 By contrast, the effective strategy, in our opinion, is to remove the H3K27me3 and/or 
H3K9me3 marks during the intermediate transcription state via pharmacological approach, 
which may facilitate the transfer of chromatin from semi-heterochromatic to euchromatic state. 
Based on this scenario, combination of possible histone methylation remodeling agents and 
DNA methylation inhibitors would eventually solve the problem of semi-chromatic states of 
tumor suppressor genes in cancers. However, our proposition is dependent on the advent of 
such histone methylation remodeling agents in the arsenal of epigenetic agents. 
 
Figure 1.1 A model of chromatin states for the genes in cancer cells (adapted from (70)). Top, 
actively transcribed genes show no promoter DNA methylation (white circles) and histone is 
preferentially modified with active chromatin marks (green ovals). Bottom, conversely, a 
hypermethylated (black circles) and silenced gene promoter (red ‘X’) is associated with histone 
arranged in a more nuceosomal configuration. On these histones (red ovals), H3 is preferentially 





and HP1α, silencing mark H3K9me3, and H3K27me3 (silencing) are present. The 
corresponding remodeling enzymes (DNMTs, HDACs and EZH2) are also present. Middle, 
depleting DNA methylation can partially induce gene expression, but the gene does not return 
to the full euchromatic state seen at a normally transcribed gene. In this intermediate state, the 
histones contain the transcriptional activating marks H3K4me3 and H3K9/14ac and HP1α is not 
present. However, several repressive histone methylation marks and EZH2 remain. Histone 
retaining this mixture of activating and repressive chromatin marks (mixed green and red ovals) 
remains in a compacted, closed, nucleosomal arrangement.  
 
1.1.3 Cancer prevention by pharmacologically targeting the epigenetic 
events 
1.1.3.1 Inhibitors of DNA methylation and histone deacetylase  
Since epigenetic changes, unlike mutations, could be reversible through 
pharmacological methods, they make attractive targets for therapeutical interventions. 
Epigenetic alterations allow the cancer cell to adapt to changes in its microenvironment, but 
dormant, hypermethylated tumor-suppressor genes can be awakened with drugs. 
The first reported DNMTs inihibitors (DNMTi) were two cytidine analogues, 5-
azacytidine (5-aza-CR, Azacytidine, Vidaza) and 5-aza-2’-deoxycytidine (AZA, decitabine) 
(Table 1.1) (75). Such compounds display antiproliferative properties against cancer cells and 
have been approved by the Food and Drug Administration (FDA) for the treatment for the 
myelodysplastic syndrome (76). However, they suffer from chemical instability in water, 
toxicity, and scarce bioavailability (77-79). Thus, three further cytidine analogues, dihydro-5-
azacytidine (DHAC), 5-fluoro-2’-deoxycytidine (FCDR) and zebularine (Table 1.1), that are 
stable in aqueous solution and less toxic than 5-aza-CR are in clinical trials for the treatment of 
haematological malignancies as well as solid tumors (80-82). All these nucleoside analogues are 
incorporated into the DNA, and then they undergo at the pyrimidine-C6 position the 
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nucleophilic attach from a thiol group of the enzyme. Then, the formation of stable complexes 
between the molecules and DNMTs effectively prevents the DNA methyation at the C5 position 
of cytosine in CpG dinucleotides (83). These DNA demethylating drugs in low doses are of 
general benefit for the reversion of epigenetic lesions in cancer (84, 85). There are several non-
nucleoside analogue molecules including hydralazine, (-)-epigallocatechin-3-gallate, RG108, 
which have been recently described to induce demethylation in cancer cells (Table 1.1) (86-88).  
Table 1.1 DNMTs inhibitors discussed in Chapter 1. 
Name Chemical nature Clinical status 
5-azacytidine  Nucleoside analogue Approved myelodysplastic syndrome
5-aza-2’-deoxycytidine  Nucleoside analogue Approved myelodysplastic syndrome
dihydro-5-azacytidine  Nucleoside analogue Phase I, II 
Zebularine Nucleoside analogue Not in clinical trial 
5-fluoro-2'-deoxycytidine Nucleoside analogue Phase I 
(-)-epigallocatechin-3-gallate non-Nucleoside analogue Phase I, II 
Hydralazine non-Nucleoside analogue Phase I, II, III 
RG108 non-Nucleoside analogue Not in clinical trial 
HDAC inhibitors (HDACi) are thought to be able to interact with the catalytic domain 
of histone deacetylases to block the substrate recognition ability of these enzymes, thus 
resulting in restoration of relevant gene expression (89, 90). The main biological effects of 
HDACi are cell cycle arrest, induction of differentiation and promotion of apoptosis (91, 92). 
Moreover, HDACi can enhance the sensitivity to chemotherapy for cancers and inhibit 
angiogenesis (93, 94). Chemically, HDACi can be divided into four classes: short-chain fatty 
acids, hydroxamic acids, cyclic peptides, and benzamides (Table 1.2). The hydroxamic acids 
comprise one class of HDACi, which inhibit Zinc-dependent HDACs, including trchostatin A, 
vorinostat, panobinostat and belinostat (Table 1.2). They all have a zinc-binding group (ZBG) 
that is analogue to the acetyl group of the histone N-acetylated-lysine. The ZBG chelates the 
zinc ion near the bottom of the cylindrical pocket (90, 95). Of notice, the suberoylanilide 
hydroxamic acid (Vorinostat, SAHA; Merck), has been approved as the first HDACi by the 
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USA FDA for the treatment of cutaneous T-cell lymphoma (CTCL) (96). Trichostatin A (TSA), 
is capable of inhibiting HDAC1, 2, 3 (Class I) and HDAC4, 6, 7 (Class II) at single-digit 
nanomolar (97). In non-small cell lung cancer cells or in melanoma, TSA induces histone 
acetylation and the expression of p21 mostly independently of p53. It has been demonstrated 
that TSA inhibits cyclin D1 expression in an NF-κB dependent manner in JB6 mouse epidermal 
cells (98). TSA has a wide range of anti-cancer effects, but it has not so far been used in clinical 
trials, due to its side effects. Additionally, the short-chain fatty acids comprise another class of 
HDACi including sodium phenylbutyrate, sodium butyrate and valproic acid (Table 1.2). 
However, high millimolar concentrations are required for their antitumor effects (99, 100). In 
contrast, another phenylbutyrate derived HDACi, OSU-HDAC42 (Table 1.2), exhibited greater 
low-micromolar potency in inducing apoptosis (101). A third class of HDACi includes the 
cyclic peptide romidepsin (Table 1.2), which have shown in vivo antitumor activity against both 
human tumor xenografts and murine tumors (102). A fourth class of HDACi is the benzamide, 
including entinostat (also known as MS-275) and MGCD-0103 (Table 1.2). These compounds 
have a 2’-aminoanilide moiety that acts as a weak zinc-chelating group that interferes with the 
catalytic domain of HDACs (103). 
Table 1.2 HDACs inhibitors discussed in Chapter 1 
Name Chemical nature Clinical status 
Sodium phenylbutyrate Short-chain fatty acid Phase I, II 
Sodium butyrate Short-chain fatty acid Phase I 
valproic acid Short-chain fatty acid Phase I, II 
OSU-HDAC42 Short-chain fatty acid Not in Clinical trial 
Trichostatin A Hydroxamic acid Not in Clinical trial 
Vorinostat Hydroxamic acid Approved for CTCL 
Panobinostat Hydroxamic acid Phase I, II, III 
Belinostat Hydroxamic acid Phase I, II 
Romidepsin Cylic peptide Phase I, II 
Entinostat Benzamide Phase I, II 
MGCD-0103 Benzamide Phase I, II 
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The non-specific effects of DNMTi and HDACi could have unintended consequences 
with regard to gene expression, and as a paradoxical result, they may have growth-promoting 
effects on a tumor. However, there are prospects for directed epigenetic-specific therapy with 
the use of transcription factors that target particular gene promoters (104). For instance, the 
engineered zinc finger proteins target unique sequences in the MASPIN promoter; these proteins 
not only reactivate the epigenetically silenced gene but also inhibit tumor growth in vitro (105).  
Until now, therapy with DNMTi and HDACi has been based on classic protein-coding 
tumor-suppressor genes, but the possibility of rescuing the growth-inhibitory effects of 
immuno-modulator and microRNA suggests other new epigenetic treatments strategies that are 
worthy of further exploration (Figure 1.2). In addition, because of the relationship between 
epigenetic processes involved in silencing and the synergistic activities of DNA methylation 
and HDAC inhibitors (53, 106, 107), there is much interest in combination therapies. In this 
regard, it is likely that the future of epigenetic therapy will involve the utilization of multiple 
drugs that individually affect epigenetic silencing but that might be expected to have synergistic 
effects (Figure 1.2) (1). 
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Figure 1.2 Strategies for epigenetic therapy (adapted from (1)). Epigenetic therapy with DNA 
methylation inhibitor (DNMTi) and HDAC inhibitors (HDACi) is available now. While these 
agents are currently approved as single agents, combination therapies are likely to gain traction 
because of the inherent self-reinforcing nature of silencing mechanism. 
 
1.1.3.2 An important Inhibitor of histone methylation, 3-deazaneplanocin A 
In addition to DNA methylation and histone deacetylation, histone lysine methylation 
(e.g., H3K4, H3K9, H3K36, H3K27) has also shown important in epigenetic regulation of gene 
expression. Thus, histone lysine methyltransferases (HKMTs), are the valuable targets for 
anticancer therapy. Nevertheless, up to now only three compounds have been described to 
interact with specific HKMTs, the chaetocin, the s-adenosylhomocysteine hydrolase inhibitor 3-
deazaneplanocin A (DZNep), and the bunazosin analogue BIX-01294. Chaetocin is a specific 
inhibitor of the SUV39 family of HKMTs against D. melanogaster SUV39, human SUV39, 
mouse G9a (108, 109). BIX-01294, selectively inhibit the G9a-mediated H3K9me2 in vitro and 
in vivo, giving significant reduction of promoter-proximal H3K9me2 marks in mouse ES cells 
and fibroblasts (110). Since SUV39 and G9a have not directly been involved in tumorigenesis, 
the application of Chaetocin and BIX-01294 in anti-cancer field may be limited at present. In 
the following section, an important HKMT inhibitor, DZNep would be described in detail.  
3-Deazaneplanocin A, a cyclopentenyl analog of 3-deazaadenosine that was first 
synthesized by Glazer et al., has broad and potent antiviral activity (111) (Figure 1.3). With a 
chemical structure similar to other adenosine analogues such as neplanocin A and carbocyclic 
3-deazaadenosine, the antiviral effect of DZNep is attributable to inhibition of S-
adenosylhomocysteine (AdoHcy) hydrolase (SAHH), which catalyzes the reversible hydrolysis 
of AdoHcy to adenosine and homocysteine. This results in the intracellular accumulation of 
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AdoHcy, which leads to inhibition of the S-adenosylmethionine (AdoMet)-dependent KMTase 
activity (Figure 1.4). DZNep has also been shown to inhibit the activity of the methyltransferase, 
resulting in undermethylation of mRNAs (112). As shown in our previous report, DZNep can 
cause the efficient depletion of the three components of PRC2 protein complex, including 
EZH2, SUZ12 and EED by an uncertain mechanism, joined to selective inhibition of 
H3K27me3 (64). However, Tanja Musch pointed out that DZNep-mediated EZH2 depletion 
and H3K27me3 reduction is not caused by SAHH inhibition at least in human embryonic 
teratocarcinoma cells (NT2) (113). Although DZNep presumably can inhibit multiple 
methylation reactions, it seems to have not much effect on gene silenced predominately by 
DNA methylation (63, 64, 114). Therefore, the effects of DZNep on chromatin are 
distinguishable from other chromatin remodelling agents such as DNMTi and HDACi, and 
DZNep can be considered as a very useful reagent in epigenetic research. Upon removal of 
DZNep, gene expression is reduced to its original state, suggesting there is a homeostatic 
mechanism that returns the histone modifications to their ‘ground state’ after DZNep treatment 
and the changes were not somatically heritable (114).  
    
 












Figure 1.4 Schematic of S-adenosylmethionine (Adomet) metabolism and its inhibition. 
AdoMet is the methyl donor for methylation reactions. AdoMet is metabolized to AdoHcy by 
methyltransferases. AdoHcy is then converted into adenosine and homocysteine (Hcy) by 
AdoHcy hydrolase. DZNep inhibits AdoHcy hydrolase, causing an increase in AdoHcy levels. 
AdoHcy in turn inhibits the methyltransferases.  
Due to the reactivation of an EZH2-repressed apoptosis affector, FBXO32, DZNep 
could specifically induce apoptosis in breast cancer MCF-7 and colorectal HCT116 cells 
without affecting corresponding normal cells (64). In addition, DZNep selectively inhibits 
BRCA1-deficient but not BRCA1-proficient mammary tumor cells, because of the fact that 
BRCA1-deficient cells are dependent on EZH2, whereas BRCA1-proficient cells are not (115). 
1.1.3.3 Synergistic reactivation of silenced genes through multiple treatments of 
inhibitors with distinct pharmacologic mechanisms 
Given the complexity and diversity of epigenetic regulation in human cancer, targeting 
multiple epigenetic components through combinatory approach seems to be required. The 
unique effect of DZNep on chromatin remodelling makes its use in combination with other 
chromatin remodelling agents an attractive approach for synergistic restoration of abnormally 
silenced genes in cancer. A striking observation is the synergistic effect of DZNep with HDACi 
on overall histone modifications. This drug combination appears to switch a repressive 
chromatin state into an active one by simultaneously reducing repressive histone marks 
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(H3K27me3) and increasing activating marks (H3K4me3 and H3K9/14ac), leading to an 
epigenetic reprogramming (63). This pharmacologic approach is expected to result in strong 
reactivation of many potential tumor suppressor genes silenced by EZH2-H3K27me3 pathway. 
Indeed, DACT3, a negative regulator of Wnt/β-catenin signalling pathway and epigenetically 
inactivated in colon cancer, is strongly induced by combined treatment of DZNep with TSA, 
resulting in inhibition of this pathway and apoptosis in colon cancer cells (63). Similarly, 
cotreatment with DZNep and another HDACi panobinostat induced more EZH2-repressed 
tumor suppressor genes, p16, p21, and p27 as well as synergistically induced apoptosis of the 
AML cells but not normal bone marrow progenitor cells (65).  The same combination treatment 
with DZNep and panobinostat were reported to induce similar cell death in multiple myeloma 
cells (67). 
By far, no report has been involved in the triple combination of three histone 
remodelling machinery (HDACs, EZH2 and DNMTs) inhibitors. Hence, the EZH2-H3K27me3 
inhibitor DZNep, together with histone deacetylation and DNA methylation inhibitors, would 
make it possible to perturb multiple epigenetic process in a given model system and be shown 
to be very useful tool to understand the complexity of epigenetic mechanism and to facilitate the 
discovery of tumor suppressors that are silenced through alternative mechanism other than 
DNA methylation and histone deacetylation.  
1.2 Physicochemical, metabolism, toxicity, pharmacokinetic, 
and systemic delivery characteristics of DZNep in animals 
The AdoHcy hydrolase inhibitor DZNep, which can reverse PRC2 and histone 
methylation-mediated gene silencing and effectively induce cancer cell death, opens the 
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therapeutic potential of inhibiting this epigenetic regulator (64). Although DZNep acts globally 
in inhibiting repressive histone marks, DZNep may still be clinically useful. It is well known 
that the HDACi are also global inhibitors that affect the deacetylation of other proteins as well 
as histones but are still successfully used in the treatment of cancer (116). Thus, In addition to 
using DZNep to further elucidate how chromatin structure affects gene expression, the further 
investigation of the potential of DZNep as an epigenetic therapeutic was warranted. As the 
specific antitumor function of DZNep in vitro was firstly reported by Tan et al. (64), it would be 
of our prime interest for further exploration of its preclinical research. The preclinical study of 
DZNep may pave the way for the potential clinical application of DZNep alone or in 
combination with other chromatin remodeling inhibitors. On the other hand, it may provide the 
basis for extending the observation of the epigenetic antitumor mechanism from in vitro to in 
vivo.  
Since limited literature information is available for the DZNep in vivo, it is reasonable to 
predict the potential properties of DZNep through the overview and comparison of the 
nucleoside analogs (NAs) in vivo, especially for cyclopentenyl NAs.  
1.2.1 Chemistry 
3-Deazaneplanocin A, a cyclopentenyl analog of 3-deazaadenosine that was first 
synthesized by Glazer et al., has broad and potent antiviral activity (111). Its composition is 
C12H14N4O3 with molecular weight 262.26 Da. Its structure (Figure 1.3) was elucidated to be, 
(1S,2R,5R)-5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-
1,2-diol, a cyclopentenyl-3-deazaadenine with a glycosidic bond. DZNep is highly hydrophilic 
(ACD/LogKow: -2.21 for pH 5.5, -0.71 for pH 7.4) and has very good water solubility. 
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Generally, this compound was dissolved in physiological phosphate-buffered saline (PBS) for 
injection (117, 118). The logarithmic measurement of acid dissociation constant (pKa) of 
DZNep is around 6.22 (Sparc on-line calculator), suggesting DZNep is very weakly alkaline. 
The UV spectra of DZNep was shown as λmax values at 263 and 217 nm (pH 7) (119). 
For the preparation of 3-deazaneplanocin A (1), the Mitsunobu reaction was employed  
(Figure 1.5) (119, 120). Thus, the (1S, 4R, 5S)-(+)-3-(trityloxymethyl)-4, 5-O-isopropylidene-2-
cyclopenten-1-ol (2) was reacted with the sodium salt of 4-chloro-1H-imidazo [4, 5-C] pyridine 
(3-deaza-6-chloropurine) to give a mixture of N1 and N3 isomers. The major isomer, identified 
as the desired N1 isomer (4), was obtained after purification by column chromatography. The 
simultaneous removal of both trityloxymethyl (TrO) and isopropylidene moieties from 
compound 4 afforded the corresponding chloropurine 5, which was subsequently reacted with 
anhydrous hydrazine to give the intermediate hydrazine compound. This compound was 
reduced with Raney nickel, and the resulting target compound, 3-deazaneplanocin A (1), was 





































Figure 1.5 Synthesis of 3-deazaneplanocin A with the Mitsunobu reaction. 
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1.2.2 Potential Metabolism and Transport pathway of DZNep 
The mechanism of antiviral and antitumor activity of nucleoside analogs is through 
competition with natural 2’-deoxynucleoside triphosphates (dNTPs) or ribonucleoside TPs 
(rNTPs) for incorporation by polymerases, resulting in either chain termination or mutagenesis 
of viral or tumor replicates. Hence, in parent form they are inactive and have to enter cells and 
be activated by viral or tumoral kinases to their NTP analog forms in order to exert antiviral or 
antitumoral effect. Figure 1.6 presents a general scheme for entry into cells and the anabolic and 
catabolic metabolism of nucleoside analogs. 
 
Figure 1.6 Generic pathways for the permeation, anabolism, and catabolism of nucleoside 
analogs. Nucleoside analogs can enter the cell through passive diffusion or solute carrier potein-
mediated transporters: equilibrative nucleoside transporter (ENTs) or concentrative nucleoside 
transporter (CNTs). Once in the cell, nucleoside analogs can be sequentially phosphorylated by 
nucleoside kinases (NK), NMP kinases (NMPK), and NDP kinase (NDPK) to their respective 
NMP, NDP, and NTP analog forms. Nucleoside analogs can be eliminated by catabolic process 
or effluxed from the cell by ATP binding cassette transporters (ABC). 
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1.2.2.1 Nucleoside transporters and ATP binding cassette transporters 
Nucleoside analogs are hydrophilic compounds, and nucleoside transporters (NTs) can 
play an important role in their absorption, distribution, and excretion (121). Two NT families 
have been identified to be responsible for the uptake of natural nucleosides in mammals: the 
concentrative nucleoside transporters (CNTs), which mediate a unidirectional sodium-
dependent transport and consist of three members: CNT1, CNT2, and CNT3 (122); the 
equilibrative nucleoside transporters (ENTs), mediate a facilitated diffusion or bidirectional 
diffusion, sodium-independent transport and consists of four members (ENT1-4) (123). CNTs 
mediate the unidirectional flow of nucleosides in an active energy costly process coupled to the 
transmembrane sodium gradient. They show a high affinity for their substrates (most are in the 
low micromolar range, 10-100 µM), but are more selective for them than ENTs (123). Tissue 
distribution of NTs shows mammalian cells express more than one type of NT proteins, often 
combining members of both gene families, CNT and ENT, in a single cell type. The asymmetric 
distribution of CNTs and ENTs in apical and basolateral membranes of epithelial cells, 
respectively, results in vectorial fluxes of nucleosides from the lumen to the interstitial space 
across epithelia (124, 125). This putative role of nucleoside transporters in the 
absorption/reabsorpation processes is supported by its localization along both the intestinal tract 
and the renal tubule. In renal tubule, three CNT transporters are expressed in the proximal 
convoluted and straight tubule (PCT and PST), segments that are implicated in (re)absorption of 
nucleoside analogs or their metabolites (126, 127). The vectorial (re)absorption of nucleosides 
and their derivatives can contribute to whole body nucleoside homeostasis. Thus, this broad 
distribution of NTs anticipates a major role of these membrane proteins in the regulation of 
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nucleoside homeostasis, the adenosine levels or in the pharmacokinetics of most nucleoside-
derived drugs used in anticancer and antiviral therapies. In addition, the amount or even the 
mere presence or absence of a particular transporter protein may determine drug sensitivity. 
Several nucleoside-derivatives are currently used in antiviral and antitumoral therapies. 
These compounds show slight structural modifications with respect to natural nucleosides and 
retain most of the metabolic properties of parent compounds. The anticancer drugs currently 
used clinically comprise pyrimidine analogs such as cytarabine, gemcitabine and capecitabine 
and purine analogs such as cladribine and fludarabine. As for their natural substrates, CNTs and 
ENT2 show broad substrate selectivity (128, 129). Zidovudine, stavudine, lamivudine, 
zalcitabine and didanosine are nucleoside derivatives used in HIV therapy. In contrast to 
anticancer drugs, these compounds can interact with NTs but in most cases they are not suitable 
substrates (130). The difference between the antitumoral and antiviral drugs is that the latter 
lack the 3’ hydroxyl group of the sugar. Analysis of substrate structural determinants 
demonstrates that this residue is relevant for nucleoside recognition and translocation (131, 132), 
indicating that a slight structural modification provokes a dramatic change in transportability. 
DZNep possesses 3’ hydroxyl group in cyclopentenyl moiety, which may render it the 
substrates of nucleoside transporters. 
While influx pumps can serve to distribute nucleoside analogs to their pharmacologic 
sites of action, efflux pumps can increase excretion. Members of the ATP binding cassette 
(ABC) family of efflux pumps can interact with nucleoside analogs. The anti-HIV drugs 
abacavir and zidovudine are substrates for the breast cancer resistance protein. Both in vitro and 
in vivo abacavir has also been shown to be a substrate for the multidrug resistance protein 1 (p-
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glycoprotein), potentially limiting its penetration through the blood-brain barrier. Although 
abacavir is a carbocyclic nucleoside analog, it lacks the 2’ and 3’ hydroxyl group in 
cyclopentenyl moiety. Thus, its interaction with ABC tansporters can not be extrapolated to 
another carbocyclic nucleoside analog, DZNep.  
1.2.2.2 Anabolism of nucleoside analogs 
In order to form their active nucleoside triphosphates (NTP) metabolites and exert 
antitumoral and antiviral activity, nucleoside analogs have to interact with the cellular 
machinery responsible for maintaining natural nucleoside pools. The first phosphorylation step 
can be catalyzed by a number of cytosolic or mitochondrial nucleoside kinases or 
phosphotransferases that are part of the nucleoside salvage pathway (133, 134). Ribonucleoside 
kinases have been shown to phosphorylate nucleoside analogs including the two isoforms of 
uridine-cytidine kinase, nicotinamide ribonucleotide kinase (135), and adenosine kinase (136). 
Nucleoside kinases are balanced by the activity of 5’ nucleotidases, a diverse group of enzymes 
that dephosphorylate nucleoside monophosphate (NMPs) (137). The second and third 
phosphorylation steps are catalyzed by the NMP kinases and nucleoside diphosphate (NDP) 
kinase, respectively (138, 139). Many herpes viruses encode a broad-specificity thymidine 
kinase, presenting a unique opportunity for nucleoside therapy. Acyclovir has selective anti-
herpes virus activity due to the conversion to acyclovir-MP by herpes-encoded thymidine 
kinase activity (140). In addition, the levels of the pharmacologically active NTP analog formed 
by most nucleoside analogs are limited by the first phosphorylation step. Furthermore, the 
salvage enzymes responsible for this phosphorylation step can be variably expressed based on 
cell type and activation state (133, 141).  
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In terms of the carbocyclic nucleoside analogs, neplanocin A was efficiently 
metabolized to the triphosphate level by the adenosine kinase in chinese hamster ovary cells and 
this metabolite was in part responsible for the observed toxicity (142). In contrast, another 
carbocyclic nucleoside analog, 3-deazaaristeromycin, seems not to be phosphorylated by L1210 
leukemia cells, which make it less cytotoxic than neplanocin A (143).  As shown in figure 1.7, 
the primary difference between two compounds is in that the former lacks a nitrogen atom (de-
aza) in the purine ring. Although DZNep possesses the similar deazapurine structure as 3-
deazaaristeromycin and less toxic than neplanocin (111), it is not devoid of possibility of the 
phorsphorylation of DZNep by nucleoside kinases in the cytoplasm. Of notice, by far, the 
pharmacological inhibition of both AdoHcy hydrolase and PRC2 complex has not been related 
to the nucleoside triphosphates (NTP) metabolite of DZNep. 
 
Figure 1.7 Chemical structures of 3 cyclopentenyl analogs of 3-deazaadenosine, 3-






























1.2.2.3 Catabolism of nucleoside analogs 
While many nucleoside analogs are not subject to significant catabolic transformation 
and a majority of the administered dose is recovered unchanged in the urine, some are 
extensively metabolized. Unlike many xenobiotics, cytochrome P450 enzymes have not been 
reported to degrade nucleoside analogs with the exception of zidovudine, which can be reduced 
nonspecifically by NADPH-cytochrome P450 reductase (144, 145). Many of the catabolic 
processes affecting nucleoside analogs are part of the natural purine and pyrimidine metabolic 
pathways. 
Deaminaton of the heterocyclic base can result in the degradation of nucleoside analogs 
to inactive or less active metabolites. One agent used in the therapy of human leukemia, 8-
chloroadenosine (8-Cl-A), is rapidly and extensively metabolized by adenosine deaminase 
(ADA) to a less active inosine analog, limiting its clinical efficacy (146), while a potent 
inhibitor of hepatitis C virus (HCV) in vitro, 2’-C-methyl-adenosine, had poor pharmacokinetic 
properties including a lack of oral bioavailability due to ADA. As a result, the investigators 
pursued an adenosine deaminase-resistant analog, 2’-C-methyl-7-deaza-adenosine, which shows 
high oral bioavailability and a long half-life in vivo (147).  Neplanocin A has been shown to be 
a substrate for adenosine deaminase (148) while 3-deazaaristeromycin is not subject to 
deamination by calf intestinal deaminase (143). Above two examples indicate the replacement 
of nitrogen atom with methylene group in the purine ring of the adenosine analogs render the 
agent the resistance to adenosine deaminase. In addition, the 2-halogenation in the purine ring 
has been the putative strategy in the production of adenosine deaminase-resistant agents such as 
fludarabine (FLU) and cladribine (CdA) (149). As the adenosine analog lacking 3-nitrogen in 
the purine moiety, DZNep may not be sensitive to the adenosine deaminase. 
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Another important metabolic pathway that affects some nucleoside analogs is removal 
of the base through depurination or depyrimidation (hydrolysis). Didanosine is extensively 
metabolized by a pathway including the enzyme purine nucleoside phosphorylase. This 
degradation pathway results in the observation of a first-pass effect, a short half-life in plasma, 
and the majority of the dose being recovered in the urine as metabolites (150). In addition to the 
deamination, 8-Cl-A is also rapidly hydrolyzed to 8-chloroadenine (8-Cl-Ad) by the purine  
nucleoside phosphorylases (PNPase) (146), both of which result in the rapid elimination of 8-
Cl-A in vivo. In contrast, due to the absence of the natural N-glycosidic bond, these 
carbanucleosides possess greater metabolic stability due to their inertness towards the 
hydrolytic activity (depurination or depyrimidation) of the PNPase. Therefore, DZNep is 
unlikely to be affected by the phosphorylases. 
Besides, other catabolism may occur in the carbocyclic nucleoside analogs. The 
carbocyclic anti-HIV nucleoside analog abacavir undergoes extensive catabolism resulting in 
only 1.2 % of the dose being recovered as the parent abacavir in urine (151). Two catabolic 
pathways are involved including oxidation by alcohol dehydrogenase or conjugation by UDP-
glucuronosyltransferase.  
In R.A. Coulombe’ report (152), the time-related disappearance of parent DZNep and 
appearance of major labelled DZNep metabolites in mouse plasma were shown in the HPLC- 
in-line radiochemical detection chromatogram. DZNep appeared to be rapidly metabolized in 
mice administered with a single intravenous dose of DZNep (0.1 mg/kg), which was considered 
to attribute to its rapid elimination and poor distribution in vivo. However, no further work was 
done to identify the content and structure of the conversion products of parent DZNep and 
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investigate the excretion properties of parent DZNep or its metabolites in animals. Thus, the 
further study of the metabolism and excretion of DZNep in vivo would be one of the 
assignments of this project. 
 
1.2.3 Toxicity 
As mimics of fundamental building blocks of life, nucleoside analogs have the potential 
to cause toxicity. The mitochondrion is one site in which nucleoside analogs can induce toxic 
side effects resulting in haematological toxicity (anemia and neutropenia), lipodystrophy, 
peripheral neuropathy, pancreatitis, and lactic acidosis (153). Mitochondrial toxicity may arise 
(i) because mitochondria contain their own nucleoside kinases including deoxyguanosine kinase, 
thymidine kinase 2, and the adenylate kinase 2 and 3 (154) capable of the compartmentalized 
phosphorylation of nucleoside analogs (155); (ii) due to the presence of transport systems that 
can exchange nucleoside between the cytoplasm and mitochondria with the potential to 
concentrate toxic nucleoside analogs (156); and (iii) due to the differential sensitivity to 
inhibition by nucleoside analogs of mitochrondrial DNA polymerase gamma relative to nuclear 
DNA polymerases (157). Incorporation by the mitochondrial DNA polymerase gamma is not 
the only mechanism for mitochondrial toxicity. For example, numerous studies have indicated 
that nucleoside analogues tend to interfere in the synthesis of essential proteins via depleting 
mitochondrial DNA and disrupt the electron respiratory chain (158, 159). This leads to the 
decreased ATP synthesis and causes electron leakage, resulting the generation of reactive 
oxygen species (ROS). ROS eventually damage the mitochondria and cause cell death. 
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The formation of toxic metabolites contributes to the adverse events observed with some 
nucleoside analogs. For example, catabolic degradation of zidovudine to the more toxic 
compound 3’-amino-3’-deoxythymidine has been suggested as a potential mode of erythroid 
progenitor cell toxicity resulting in the observation of anemia in patients (160).  Due to lack of 
the 3-deaza modification in the adenine moiety, the conversion of neplanocin A to the S-
adenosylmethionine-like metabolite (NepMet) and triphosphate of neplanocin A are associated 
with the cytotoxic effects observed with this drug (111, 119). Because DZNep is neither 
phosphorylated nor converted to the S-nucleosidylhomocysteine analogue, its cytotoxicity was 
significantly less than that of neplanocin A (119). 
The distribution of nucleoside analogs to cells and tissues can contribute to adverse 
events. The main toxicity associated with ribavirin therapy is anemia, facilitated by ribavirin’s 
distribution to erythrocytes (161, 162). Further studies have shown that the accumulation of 
ribavirin metabolites into red blood cells is likely due to active influx transport by the hENT1 
and phosphorylation by IMP phosphotransferase (163, 164). The accumulation of acyclic 
nucleotide phosphonates in renal proximal tubules due to their efficient transport by the organic 
anion transporter (165), depending on their respective intrinsic cytotoxicity, result in varying 
incidence of renal adverse events. The acute toxicity study indicated that inoculating single dose 
of up to 10 mg/kg DZNep in healthy adult mice did not result in hepatic injury or renal 
impairment, compared to mock-treated over 2 weeks (117). In addition, at a single intravenous 
dose of DZNep (0.1 mg/kg), the distribution of DZNep into mouse tissues was not extensive 
(152), which could in part explain the low hepatic and renal toxicity induced by DZNep. 
However, no erythrocyte partitioning of DZNep has been reported in animals. Thus, at present, 
 29
the relationship between haematological toxicity and erythrocyte partitioning could not be 
further discussed. 
1.2.4 Analytical methodology 
Numerous assays have been described for the determination of enodogenous or 
anticancer nucleoside analogs in different matrices such as cellular cultures, tissue, blood 
plasma, and peripheral blood mononuclear cells. The determination of these compounds is 
challenging due to the presence of numberous endogenous interferences and enzymes involved 
in the purines and pyimidines metabolism in complex matrices and the high polarity of the 
molecules due to the phosphate moiety or hydroxyl moiety.  
The sample preparation is probably the major critical step for the determination of 
endogenous nucleoside and nucleoside analogs in biological samples. There is no consensus 
and the method preparation depended in part on the detection mode and sample matrix. 
Generally, a precipitation step constituted the single phase common to all methods described. 
Then, a solvent or a solid phase treatments were associated to extract nucleoside or to clean the 
supernatant obtained after protein precipitation. For protein precipitation, the use of perchloric 
acid (PCA) and trichloroacetic acid (TCA) was less frequently due to its poor compatibility 
with detection by Mass spectrometry (MS) (166, 167). Protein precipitation was also described 
using pure methanol, acetonitrile or a methanol/water mixtutre with different proportions. The 
organic solvent such as hexane or chloroform to eliminate lipids was added after the protein 
precipitation based on liquid-liquid extraction approach (167). In addition, SPE was often 
described to effectively remove excess salts, lipids and other component added in the 
precipitation step. A solid phase extraction (SPE) technique using Bond Elute phenylboronic 
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acid (PBA)-SPE cartridges (Varian, Palo Alto, CA) specifically for the purification of 
compounds containing vicinal hydroxyl (diol) groups, was evaluated to improve extraction 
efficiency, reduce endogenous interference, and minimize the matrix effect of nucelosdie 
analogs in biosamples (168). As shown in Figure 1.8, the principle is that the molecules with 
vicinal hydroxyl (diol) groups, such as ribavirin or cyclopentenyl cytosine (169, 170), 
specifically bind to PBA in a neutral or alkaline medium. Once these compounds are retained, 
other components could be washed off. Then, the covalent bond is broken when the medium pH 
is lowered followed by the elution of these compounds.  
 
Figure 1.8 A chemical reaction involved in the product of the reversible nucleoside analogs 
(NA) -PBA complex through dehydration. 
 
Nucleosides are compounds with two different regions: a negative charged phosphate 
group for the phosphated nucleoside metabolites and the ribose basic group, less polar (171, 
172). Unlike nucleoside triphosphates highly polar, some monophosphate nucleosides and 
nucleoside analogs can be retained on reversed phase (RP)–HPLC column (173). Of notice, the 
ion-pair (IP) and anion exchange (AE) chromatography are in principle the most suitable 
methods for the determination of nucleoside metabolites and nucleoside analogs (174, 175). 
However AE chromatography suffered from a poor compatibility with MS because the elution 
of charged compounds caused ion suppression and contamination in the ionisation source (176). 
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In contrast, IP chromatography is considered as the appropriate chromatographic method in 
term of compatibility with the MS detection for analysis of negative charged compounds 
(phosphated nucleotide metabolites) (176). The separation is based on the formation of ion pairs 
between the negatively phosphated nucleotide metabolite and the positively  charged ion-
pairing reagents such as dimethylhexylamine (DMHA) or triethylamine (TEA) (175, 177). The 
stationary phase is a conventional apolar phase C18 or C8. However, for the positive charged or 
neutral nucleoside analogs such as ribavirin or DZNep, based on above discussion, IP 
chromatography would not a good choice. Instead, a hydrophilic interaction chromatography 
(HILIC) column, a powerful tool in bioanalysis of numerous polar compounds coupled with 
MS/MS detection (178), was employed. Hydrophilic interaction between the compound and the 
silica stationary phase is the driving force for on-column retention of basic compounds in acidic 
mobile phase and acidic compouns in neutral mobile phase. Increasing water content in the 
mobile phase would decrease retention. Because of the low aqueous/high organic mobile phase 
and the favourable solution chemistry for electrospray ionization mode that ensures the ionized 
form of analytes in solution, sensitive LC-MS/MS detection is therefore possible (179). 
Recently, HILIC column has been extensively employed in the separation and quantification of 
numerous nucleoside analogs and endogenous nucleosides in biosamples (180-182). 
Although UV detection mode was used to analyze ribonucleoside monophosphates in 
biological matrix, this detection mode lacked of sensitivity and specificity. The fluorescence 
detection mode greatly improved the sensitivity for adenosine analogs analysis. However, this 
detection mode required derivatization of the analytes. In contrast, LC coupled with MS 
detection has been, since the last decade, the most widely used analytical tool for endogenous 
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nucleoside or nucleoside analogs analysis. Due to the high sensitivity a triple quadruple mass 
spectrometer or ion trap mass spectrometer in multiple reaction monitoring mode (MRM) was 
required for detection of low concentration of cellular endogenous nucleosides. For example, 
LC-MS/MS device lowered the limit of detection by a factor of 100 compared to the UV 
detection mode and improved significantly the specificity. Besides, although some of 
compounds co-elute, it was possible to distinctly quantify them due to the separation via the m/z 
ratio.  
In previous study, the low limit of quantification (LLOQ) of the radiolabeling DZNep in 
mice was in the picomolar range using in-line radiochemical flow detection (152). However, the 
inherent costs and safety issues of radiolabeling technique make this assay impractical and 
unfeasible during the early drug discovery and optimization processes. Additionally, the 
pharmacokinetic and disposition properties of intact DZNep could not be distinguished only by 
a radioassay method. To specifically quantify non-radioactive DZNep in rat biological fluids, a 
sensitive liquid chromatography coupled with electrospray ionization/tandem mass 
spectrometry (LC-ESI-MS/MS) method was thus employed in this study. 
1.2.5 Preclinical pharmacokinetics in animals 
Compound with favourable pharmacokinetics is more likely to be efficacious and safe. 
Therefore, the preclinical pharmacokinetic evaluation should be comprehensive enough to 
ensure that compounds do not fail in the clinic.  
Due to the similar physical and chemical properties of nucleoside analogs including 
DZNep, they share some common disposition characteristics (Table 1.3), including low plasma 
protein binding, high renal clearance, low biliary clearance. The reason that the plasma protein 
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binding of nucleoside analogs is low is because the inherent hydrophilicity poorly induce any 
drug-to-protein forces (183). As described in section 1.2.2.3, most nucleoside analogs are not 
sensitive to cytochrome P450 enzymes, i.e. the in vivo hepatic plasma clearance (CLH) is not the 
major clearance mechanism. Nucleoside analogs show a high urinary excretion, suggesting they 
undergo a net secretion in the renal tubule as well as negligible reabsorption. This could be 
explained by the excretion rate equations, (1 - FR) x (rate of filtration + rate of secretion), where 
FR is the fraction reabsorbed from the lumen (184). The low plasma protein binding of 
nucleoside analogs is favourable to their filtration and secretion whereas the high hydrophilicity 
is unfavourable to its reabsorption. In addition, the poor fecal excretion of nucleoside analogs 
might be due to their relatively small molecular weight (around 300 dalton) because extensive 
biliary excretion to occur, molecules should possess a large molecular weight (MW, 400 to 500 
dalton) (185). 
Nucleoside analogs plasma pharmacokinetics can be described by a two or three 
exponential decay model (Table 1.3). These phases correspond to a rapid distribution phase 
from the plasma to the tissues and a terminal phase of elimination of parent compound or 
metabolites primarily from the kidney. The elimination of nucleoside analogs in vivo is 
dependent on the drug metabolism, tissue protein binding of parent compound or metabolites, 
renal excretion rate, dose and species. The short elimination half life of 8-Cl-A is primarily 
caused by its rapid and extensive biotransformation into two main metabolites, 8-chloroadenine 
(8-Cl-Ad) and 8-cloroinosine (8-Cl-I) in rat blood plasma or tissue (146); whereas the rapid 
renal excretion rate is the possible reason for rapid elimination of levovirin because levovirin is 
not readily metabolized in vivo (186). It has been reported that ribavirin readily entered red 
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blood cell (RBC) and converted to phosphorylated derivatives, including ribavirin triphosphate 
(RTP). Due to the lack of dephosphorylation enzymes in RBC, the high levels of 
phosphorylated ribavirin accumulated intracellularly (187). This not only brings about severe 
haemolytic anemia but also slow down the elimination of ribavirin (t1/2,β, 9.9 h) in vivo through 
the formation of a ribavirin depot in vivo. The apparent volume of distribution at steady state 
(Vss) of some nucleoside analogs such as ribavirin and 8-Cl-A was considerably greater than 
total tissue water (0.79 ± 0.012 L/kg) in animal (188), suggesting these nucleoside analogs are 
tissue-bound to a significant extent. However, intravenous DZNep and levovirin appear not to 
be extensively distributed in tissues. Since nucleoside analogs are hydrophilic compounds, 
nucleoside transporters (NTs) may play an important role in their distribution in tissues.  
The DZNep plasma concentration-time profile has was best described by a two-
compartment model in mice given a single intravenous dose of DZNep (0.1 mg/kg); the rapid 
disappearance from the systemic circulation (t1/2, β, 12.8 min), and the wide distribution into 
tissues the Vss value of DZNep, 3.1 L/kg, was greater than the total tissue water in mice (0.73 












Table 1.3 Pharmacokinetic, excretion, and metabolism parameters of several nucleoside analogs 
Purine Pyrimidine 
Nucleoside analogs 8-chloroadenosine DZNep Ribavirin levovirin 
Reference (146, 189) (152) (161, 190, 191) (186) 
Species rat mouse rat rat 
Dosage forms bolus i.v. bolus i.v. bolus i.v. bolus i.v. 
Dose (mg/kg) 100 0.1 30 30 
Plasma Protein binding 37% 17% 10% N.A. 
Compartments 2 2 3 2 
Elimination half life (h) 0.31 0.21  9.9 1.47 
CL (L/kg/h) 5.5 1.6 2.6 0.5 
Vss (L/kg) 3.2 0.5 11.4 0.8 
Urine 0.83% for parent; 39.9% for 8-Cl-I N.A. 87.7% radioactivity  88.6% parent
Feces U.D. N.A. 1.41% 2.08% 
Metabolite 8-Cl-Ad; 8-Cl-I N.A. phophorylated forms N.M. 
U.D.,undetectable; N.M., not extensively metabolized; N.A., not available; 8-Cl-Ad, 8-
chloroadenine;  8-Cl-I, 8-cloroinosine; DZNep, 3-deazaneplanocin A; CL, clearance; Vss, steady 
state distribution volume 
 
1.2.6 Liposome formulation encapsulating nucleoside analogues in 
cancer therapy  
Generally, nucleoside analogs are not naturally specific to tumor cells; hence they 
accumulate not only in tumors but also in healthy tissues. Furthermore, most nucleoside analogs 
have only short half-lives in the systemic circulation due to rapid enzymatic degradation or 
renal excretion; as a consequence, high doses have to be given for efficient tumor treatment, 
leading to severe side effects. The ideal scenario would be to sequester the drug in a package 
that would have minimal interactions with healthy cells, and to release drug at the appropriate 
time from the sequestering carrier at the tumor site. Several drug delivery systems, namely 
liposomes, microparticles, nanoparticles, polymeric micelles, dendrimers, hydrogels, polyplex 
nanogels and cyclodextrin inclusion complexes (192), have been introduced in order to facilitate 
effective chemotherapy and to overcome some of the above limitatons of nucleoside analogs. 
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Here, the existing mechanisms by which the liposome formulation encapsulates nucleoside 
analogs are extensively discussed.  
Liposomes are self-assembling vesicles with an inner aqueous compartment surrounded 
by a lipid bilayer. Lipophilic and amphiphilic drugs can be incorporated into the liposomal 
bilayers, whereas hydrophilic drugs can be incorporated into the inner aqueous compartment. 
Thus, the systemic environment does not recognize the free drug. It recognizes only the 
liposomes and the drug pharmacokinetics are replaced by the pharmacokinetic behaviour of the 
liposomes. Liposomal formulations aim to reduce the toxic side effects of cytotoxic drugs 
without hampering their efficacy. This can be achieved by a selective drug accumulation in 
tumour tissues by means of active targeting (coating liposomes with antibodies or ligands in 
order to specifically recognize epitopes or receptors of malignant cells), or by passive targeting 
due to the enhanced permeability and retention (EPR) effect of sterically stabilized liposomes, 
due to differences in the vasculature between tumours and healthy organs or tissues (192, 193). 
There are two challenges in preparation and application of liposome formulation 
containing nucleoside analogs. Firstly, the half life of liposomes is generally influenced by their 
stability in serum and their uptake by RES cells (194). Much research work has tried to 
overcome the instability of liposomes in serum by optimizing their formulation. It was found 
that the addition of cholesterol in quantities of 35 – 50% mol of the cytarabine loaded liposomal 
formulation stabilized membranes by reducing membrane fluidity and enhanced the 
encapsulation efficiency of cytarabineloaded liposomes (195). More importantly, components 
that sterically stabilize liposomes, such as PEG-phosphatidylethanolamine (Stealth components), 
lower the recognition and uptake by the RES by increasing the liposome hydrodynamic 
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circumference. When gemcitabine was encapsulated in pegylated liposomes (Stealth liposomes), 
a significant antitumour effect was observed using lower drug concentrations and after an 
earlier exposure time (196). 
Secondly, as most of nucleoside analogs are polar (amphipathic at minimum) and water 
soluble, it is very difficult using presently available technologies to stably encapsulate these 
water-soluble low molecular weight drugs into conventional liposomes: these molecules diffuse 
rapidly through liposome bilayers. Thus, shortly after their preparation, rapid diffusion of the 
drug out of the liposomes occurs, limiting the shelf life and, therefore, the clinical use of 
conventional liposomes. Recently, two approaches have been explored to sequester the 
nucleoside analogs in liposomal vesicles. The multivesicular liposomes (DepoFoam) drug 
delivery system was developed to permit sustained release of water-soluble drugs, capable of 
delivering drugs for a few days (197). The limitation of this formulation is the diameter of each 
particle is around 30 µm.  Apparently, this size is much bigger than the preferred size of 
approximate 100 nm for a nano drug carrier, which ensures it extravasate through fenestrated 
endothelium of tumor vessels (193). In addition, vesicular phospholipid gels (VPGs) are 
suitable for entrapping water-soluble substances with high encapsulation efficiency through 
densely packing liposome and thus enhancing ratio of aqueous volume inside the vesicles 
compared with the surrounding aqueous volume (198). However, the rapid leakage of 
nucleoside analogs would still occur, as the dilution of this formulation is necessary before 
injection. In conclusion, the truly effective methods require the interaction between nucleoside 
analogs and inner water phase, resulting in the encapsulation of these compounds without 
compromising the particle size or abnormally enhancing lipid materials.  
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A method for loading a therapeutic compound having a cis dio moiety into preformed 
liposomes using boronic acid compound has been reported by Samuel Zalipsky et al. (199). In 
the case of ionisable hydrophilic or amphipathic drugs, appropriate drug-loading efficiency can 
be achieved by loading the drug into liposomes against a transmembrane ion gradient (200). 
This loading method, generally referred to as remote loading, typically involves a drug having 
an ionisable amine group such as DZNep (pKa = 6.22). However, drugs suitable for loading by 
remote loading procedures must be sufficiently lipophilic to pass through the liposome lipid 
bilayer during the loading process. Based on the chemical equation shown in the Figure 1.8, a 
nucleoside analog-PBA complex may come out at the basic and neutral solution, which is likely 
to decrease the hydrophilicity of nucleoside analog and thus facilitate the transportation of 
nucleoside analog inside the liposome. This method would be tested in attempt to encapsulate 




Epigenetic inactivation of gene expression is one of important events in cancer 
development. Pharmacological reversal of such events has therapeutic potential in cancer 
treatment by inducing apoptosis. The epigenetic events consist primarily of histone methylation 
and deacetylation as well as DNA methylation. The current epigenetic drugs are against only 
two events, histone deacetylation and DNA methylation by histone deacetylase (HDAC) 
inhibitors (e.g. Vorinostat and Trichostatin A, TSA) and DNA methyltransferase (DNMT) 
inhibitor (5-aza-2’-deoxycytidine, AZA), respectively. Recently, DZNep has been found to 
inhibit the tri-methylated histone H3 at lysine 27 (H3K27me3) by depleting enhancer of zeste 
homolog 2 (EZH2) protein and preferentially induce apoptosis in cancer cells without affecting 
normal cells. To our knowledge, by far, it is the only EZH2 inhibitor. Firstly, EZH2 in 
combination with HDAC and DNMT generates a self-reinforcing, self-perpetuating cycle of 
epigenetic events that lead to long-term genes silence (49). Secondly, based on the semi-
heterochromatic state theory, when only using the HDAC inhibitor and DNMT inhibitor, it is 
unlikely to transfer abnormally silenced genes to the fully euchromatic state (70, 201). 
Therefore, the working hypothesis in the molecular pharmacological section is that the use of 
DZNep in combination with TSA and AZA is able to characterize the interaction of EZH2 with 
other epigenetic events and to identify a comprehensive set of genes abnormally regulated by 
EZH2 alone or combined with other epigenetic mechanisms in breast cancer cells.  
Cotreatment of DZNep with HDAC inhibitors (TSA and panobinostat) has recently been 
shown a strong synergy in cell death of human colorectal, multiple myeloma (MM), and acute 
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myeloid leukemia (AML) cells (63, 65, 202). However, little research has been carried out so 
far to study whether such a strong synergistic effect also occurs on breast cancer cells. Although 
FBXO32, a tumor suppressor gene, is responsible for the DZNep-related apoptosis of breast 
cancer cells (64), it is unlikely to be the modulator for the breast cancer cell death induced by 
the cotreatment of DZNep and HDAC inhibitor because FBXO32 belongs to the D pattern, 
which is regulated only by EZH2 but not HDACs (Chapter 2, Section 2.3.2). Therefore, it is 
hypothesized that DZNep in combination with a HDAC inhibitor is capable of inducing 
synergistic breast cancer cell death. Furthermore, it is worthwhile to identify the key genes, 
which is responsible for DZNep plus HDAC inhibitors-induced breast cancer cell death. 
In addition to serving as an epigenetic tool to probe the interaction between epigenetic 
events, DZNep is worthy of further exploration on its potential clinical effectiveness. The 
preclinical safety evaluation is necessary for a drug candidate to identify an initial safe dose, 
potential target organs for toxicity, and safety parameters for clinical monitoring. However, 
there is very little information available regarding the toxicity of DZNep in vivo. Therefore, it is 
hypothesized that the measurement of the median lethal dose (LD50) and no observable adverse 
effect level/dose (NOAEL) using single dose acute toxicity test are helpful in the selection of 
starting doses for the preclinical PK studies of DZNep and identification of target organs for 
toxicity in healthy Sprague Dawley (SD) rats.  
 Except for an in-line radiochemical flow detection (152), there are hardly any routine 
assay methods available for quantification of DZNep in biological samples. Liquid 
chromatography coupled with electrospray ionization/tandem mass spectrometry (LC-ESI-
MS/MS) detection has been, since the last decade, the most widely used analytical tool for 
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endogenous nucleoside or nucleoside analogs analysise due to its high sensitivity (179). 
Therefore, it is hypothesized that a LC-ESI-MS/MS method would be suitable for quantification 
of DZNep in rat biosamples.  
Up to date, the pharmacokinetics of DZNep has been reported in mice (152) but not in 
other animals, besides no detailed tissue distribution and excretion profiles of DZNep are 
available, which may compromise the comprehensive understanding of DZNep PK properties. 
In addition, the inherent costs and radiation safety issues associated with the use of 
radiolabeling compound make such a radiochemical assay method impractical and unfeasible 
during the early drug discovery and optimization processes. Therefore, it is worthwhile to 
investigate the pharmacokinetic, tissue distribution, plasma protein binding, erythrocyte 
partitioning and excretion properties of DZNep in the rats using the LC-MS/MS method. 
Due to the undesirable pharmacokinetic (Chapter 7) and toxic (Chapter 4) properties of 
DZNep in rats, an ideal strategy is to sequester DZNep in a package such as the peyglated 
liposomes, which has minimal interactions with healthy cells, and to release drug at an 
appropriate time from the sequestering carrier at tumor site. Since DZNep has a protonable 
moiety ideal for remote-loading technique and a cis-diol group suitable for the formation of a 
lipophilic phenylboronic acid (PBA)-DZNep complex (199), it is thus hypothesized that the 
encapsulation of DZNep in the pegylated unilamellar liposomes is feasible using the remote-
loading technique with the aid of PBA, and that this formulation is capable of prolonging the 
retention of DZNep in the systemic circulation of SD rats as compared to the free DZNep. 
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1.4 Objectives  
The main aim of this study is to characterize the relationship of EZH2 with other 
epigenetic events by the pharmacological disruption using the EZH2 inhibitor, DZNep, in 
combination with the other two epigenetic compounds (TSA and AZA) in breast cancer cells 
and to perform the preclinical study of DZNep in SD female rats. The specific objectives of this 
research works are as follows: 
1) To characterize the interaction of EZH2 with other epigenetic events and to identify a 
comprehensive set of genes abnormally regulated by EZH2 alone or combined with other 
epigenetic mechanisms in breast cancer cells by employing DZNep, and its combinations 
with other epigenetic drugs, AZA or/and TSA (Chapter 2). 
 
2) To explore the potential synergistic effect on the cell death by the combination of DZNep 
and TSA in breast cancer cells and find genes, associated with DZNep and TSA-induced 
breast cancer cell death using the correlation analysis between cell death and differential 
gene activation (Chapter 3). 
 
3) To identify median lethal dose (LD50), no observable adverse effect level/dose (NOAEL), 
and potential target organs for toxicity using acute toxicity method in SD rats (Chapter 4). 
 
4) To develop and validate a sensitive, selective and reliable HPLC-MS/MS assay method 
for the quantification of DZNep in rat biosamples (rat plasma, tissue, urine and feces 
samples) (Chapter 5). 
 
5) To characterize the pharmacokinetics, tissue distribution, and excretion  properties of 
DZNep in SD rats and to estimate rat plasma protein binding and erythrocyte partitioning 
of DZNep and their relation with the disposition properties (Chapter 6). 
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6) To improve pharmacokinetic characteristics of DZNep in vivo through developing a 
pegylated unilamellar liposomal formulation (Chapter 7). 
 
 
1.5 Significance of the Project 
The results of this study may contribute to a better understanding of epigenetic cross-
talk between EZH2-H3K27me3 and the other epigenetic events (DNA methylation and histone 
deacetylation) in gene silencing, which has imminent implications in epigenetic cancer therapy. 
This study would also provide a comprehensive set of genes regulated by EZH2 alone or in 
combination with other epigenetic mechanisms in breast cancer, which may be further 
investigated as the anticancer biomarkers. As the only antitumor agent through the inhibition of 
EZH2 protein, the preclinical study of DZNep may pave the way for its potential clinical 
application. On the other hand, it may provide the basis for extending the observation of the 
epigenetic antitumor mechanism from in vitro to in vivo.  
 44
 
CHAPTER 2  
Combinatorial pharmacological approaches target 


















                                                           1                       
1 Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q: Combinatorial pharmacologic 





Abnormal epigenetic changes, including both DNA hypermethylation and histone 
modifications have been implicated in cancer development (2, 203-205). Among various forms 
of histone modifications, histone acetylation and methylation are of particular interest owing to 
their established roles in gene regulation (14, 15). Although histone acetylation is generally 
associated with active gene expression, histone lysine methylation can be associated with either 
gene repression or activation (27). Specifically, methylation of histone H3 at lysine 4 (H3K4) is 
an active histone mark, while methylation of H3 at lysine 27 (H3K27) and lysine 9 (H3K9) are 
repressive ones (27, 28). These modifications are often mediated through the Trithorax (TrxG) 
and Polycomb (PcG) protein complexes (29, 206). Among PcG proteins, PRC2 is of particular 
importance in cancer since its key component EZH2 is often deregulated in human cancers  (28, 
36-38, 45) . EZH2 is a histone methyltransferase specific for histone H3K27 trimethylation 
(H3K27me3) (34, 43, 207). The role of EZH2-mediated gene silencing has been implicated in 
regulating cancer cell proliferation, invasion and metastasis (36, 44-46). Moreover, increasing 
number of EZH2 or H3K27me3 target genes linked to important cancer pathways have been 
recently identified (60, 63, 208, 209). With continued efforts to identify EZH2 targets, it is 
expected that additional roles of EZH2 in carcinogenesis could be revealed. 
Increasing evidences indicate that various silencing events are often interconnected and 
act in a coordinated manner (49, 210). It has been known that DNA methylation and methyl-
CpG binding proteins are associated with histone deacetylation (211). In addition, EZH2 
requires histone deacetylase (HDAC) for its gene silencing activity (45); it also recruits DNA 
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methyltransferase (DNMT) to certain gene promoters to directly control DNA methylation (58). 
Therefore, a comprehensive unmasking of genes inactivated by the coordinated actions in 
cancer cells is highly required.   
Since epigenetic modifications are reversible, they make attractive targets for 
therapeutic interventions. Genes silenced by DNA methylation in cancer can be reactivated by 
DNMT inhibitors such as 5-Aza-2’-deoxycytidine (AZA) (212, 213), or be synergistic with 
HDAC inhibitor, such as Trichostatin A (71) which can facilitate the gene activation through 
reversing the repressed chromatin (214). In addition to the potential clinical use of these two 
classes of compounds, they are also widely used as research tools to identify genes silenced in 
cancer (55). The combination of these agents is also used to understand the epigenetic cross-talk 
between the regulatory components in gene silencing. Recent studies indicate that silenced 
tumor genes reactivated by DNMT inhibitors even with the aid of HDAC inhibitors do not 
return to an euchromatic chromatin state due to the retention of repressive histone marks, such 
as H3K27me3 (70, 215). These results highlight the need for perturbation of multiple epigenetic 
components for stable and complete gene reactivation.  It has been previously shown that 3-
Deazaneplanocin A (DZNep), a potent S-adenosylhomocysteine hydrolase (SAHH) inhibitor 
(111, 216-219), inhibits global levels of histone methylations. In particular, DZNep can 
effectively deplete the oncogenic PRC2 components EZH2, SUZ12 and EED, as well as the 
associated H3K27me3, resulting in reactivation of PRC2 repressed target genes (64, 114). 
Moreover, it is synergistic with HDAC inhibitor to reprogram histone modifications, leading to 
robust gene reactivation (63). Given the frequent deregulation of EZH2 in human cancer, it was 
thus hypothesized that the unique effects of DZNep on histone modifications make its use in 
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combination with other chromatin remodeling agents an attractive approach for gene 
reactivation in cancer.  
Here, DZNep, and its combinations with other epigenetic drugs such as AZA or/and 
TSA have been employed to characterize the various epigenetic events in breast cancer cells. 
Coupled with genetic depletion of EZH2, a comprehensive set of genes regulated by EZH2 have 
been identified in breast cancer through various epigenetic mechanisms. It was further showed 
that EZH2 regulates a broad cohort of genes implicated in immunity and inflammation network, 
revealing a yet undisclosed link between EZH2 and cancer immunity. The data in this study 
indicate the cooperative nature of multiple epigenetic mechanisms in gene repression, which has 
imminent implications in epigenetic cancer therapy.   
 
2.2 Materials and Methods 
2.2.1 Cells and drug treatments  
Cell lines used in this study were all obtained from the American Type Culture 
Collection (ATCC). The breast cancer MCF-7, SK-BR-3, BT474 cells and non-cancerous 
human mammary epithelial MCF10A cells were maintained in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 
5000 U/ml penicillin/streptomycin (DMEM complete medium) and maintained at 37 OC with 
5% CO2. AZA (Sigma) and DZNep (National Cancer Institute of USA) was dissolved in sterile 
phosphate buffered saline (PBS, Invitrogen). TSA (Sigma) was dissolved in ethanol. Cells were 
seeded the day before the drug treatment. Then, cells were treated with 2.5 μM DZNep for 72 h, 
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5μM AZA for 72 h, and 100 nM TSA for the last 24 h within the 72-h treatment, alone or in 
various combinations (7 treatment conditions). For AZA treatment, the medium was added with 
freshly prepared AZA for every 24 h. The concentration of solvent (ethanol or PBS, < 0.1% of 
total medium volume) did not alter the growth and survival of the cells. For the time course test 
of H3K9/14ac, MCF-7 cells were treated with 2.5μM DZNep for 72 h and 5 μM TSA, alone or 
both. TSA was added into medium 48 h after the onset of the experiment. At 1, 3, 6, 12, 24 h 
after TSA dosing, cells were harvested for the western blot analysis. 
2.2.2 RNA interference 
The siRNA targeting EZH2 (sequence: 5’-GACUCUGAAUGCAGUUGCU-3’) and 
non-targeting control were purchased from 1st BASE Pte Ltd. MCF-7 and SK-BR-3 cells were 
seeded in DMEM complete medium without penicillin/streptomycin the day before the 
experiment in six-well plates. For the cells in each well (10 cm2), 5 μL of 20 μM siRNA 
duplexes was diluted in 100 μL of DMEM medium (without serum, L- glutamine and 
antibiotics). 4 μl Lipofectamine 2000 (Invitrogen) was diluted in 100 μl DMEM medium and 
incubated for 5 min at room temperature. Then, the diluted siRNA and Lipofectamine 2000 
were mixed and incubated at room temperature for 20 min to allow complexes to form. Then, 
800 μl of DMEM medium and 200 μl of siRNA/Lipofectamine 2000 complexes were loaded 
into the cells. After 4-6 h of incubation in 37 OC, the medium containing siRNA/Lipofectamine 
complexes was replaced with the complete DMEM medium for further incubation. The further 
drug treatments containing TSA and AZA or TSA alone in MCF-7 and SK-BR-3 cells were in 
the same way as described in Chapter 2, section 2.1.1. 
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2.2.3 Immunoblot analysis 
Cells (10 cm2) were collected and lysed in 200 μL RIPA buffer as described previously 
(220). The RIPA buffer (Invitrogen) contained protease inhibitors, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin, and 1 mM sodium fluoride. 
To release histones from chromatin, cell lysate was further sonicated for 15 sec using a XL2000 
Microson Ultrasonic Processor (Misonix). The cell lysate was then centrifuged with the 10,000 
X g for 15 min at 4 OC. Protein concentration in the cell lysate supernatant was quantified by 
the Bio-Rad protein assay using bovine serum albumin (BSA) as the standard. The lysate equal 
to 50 μg of total protein was electrophoresed on a 10% Tris/Glycine SDS – Polyacrylamide 
(PAGE) gel (30% acrylamide mix, 1.5 M Tris buffer (pH 8.8), 10% SDS solution, 10% 
ammonium persulfate (APS) and N, N, N', N'-tetramethylethylenediamine (TEMED)). Then, 
the protein in SDS-PAGE gel was transferred onto a polyvinylidene difluoride (PVDF) 
membrane (Millipore). The membrane was incubated in a 5% milk/Tris-buffered saline + 
Tween 20 (TBST) blocking solution for 1 h and then probed at room temperature for 1 h with 
the antibody. The membrane was washed with TBST solution and incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody (Abcam) at room 
temperature for 1 h. The membrane was washed again in TBST solution, and bands were 
visualized by treating the membranes with enhanced-chemoluminesence western blotting 
detection reagent (Amersham Life Science, UK) and exposing to Kodak autoradiograph film in 
a dark room. EZH2 (AC22), EED (07-368), SUZ12 (07-379), H3K9me3 (07-442), H3K27me3 
(07-449), H3K9/K14ac (06-599) and H3K4me3 (05-745) were purchased from Upstate 
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Biotechnology; H4K20me3 (ab9053) was from Abcam; Histone H3 (9715) and actin (4967) 
was from Cell Signaling; DNMT1 (60B1220.1) and DNMT3B (52A1018) were from Alexis 
Biochemicals. 
2.2.4 Total RNA isolation 
Total mRNA was isolated from cells using Trizol (Invitrogen) and purified with the 
RNAeasy Mini Kit (Qiagen). In brief, cell pellets (10 cm2) were lysed using 1mL Trizol. Then, 
1 mL of cell lysate was mixed with 0.2 mL chloroform. After centrifugation at 12,000 rpm for 
10 min, 0.5 mL of aqueous phase was collected for mRNA extraction using the RNeasy column. 
Purified mRNA was eluted with 30 μL of RNase/DNase free water and stored at -80 OC. All 
RNA isolation procedures were carried out in an area dedicated to RNA work using 
RNase/DNase free water and RNase free glass- and plastic-ware. Quantification of total mRNA 
was carried out using NanoDrop ND-1000 (Thermo Scientific, USA) spectrophotometer.  
2.2.5 Microarray analysis 
Reverse transcription was performed using the Ambion Illumina Total Prep RNA 
amplification kit (Ambion). Briefly, 1 μL of total RNA (100 ng) was mixed with 10 μL of 
distilled H2O (dH2O) and 9 μL reverse transcription mixture (2 μL 10X reverse transcriptase 
buffer; 4 μL deoxynucleoside triphosphate [dNTP] mix; 1 μL T7 Oligo(dT) primer, 1 μL RNase 
inhibitor; and 1 μL ArrayScriptTM reverse transcriptase), followed by incubation at 42 OC for 2 h. 
Then, 80 μL second strand master mix (63 μL dH2O, 10 μL 10X second strand buffer, 4 μL 
dNTP mix, 2 μL DNA polymerase, 1 μL RNase H) was added to the each sample, followed by 
incuation at 16 OC for 2h. cDNA transcripts were captured using magnetic beads followed by 
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washing twice with 150 μL cDNA buffer and elution using 20 μL dH2O. 17.5μL of cDNA 
sample was mixed with the 7.5 μL IVT Master Mix (2.5 μL Biotin-NTP Mix, 2.5 μL T7 10X 
reaction buffer, 2.5 μL T7 enzyme mix), followed by incubation at 37 OC for 12 h. Then, the 
labeled cDNA was purified with magnetic beads and eluted with 100 μL dH2O again. 40 μL 
labeled cDNA sample was then added to the Illumina Human RefSeq-8 v1 BeadChip (Illumina). 
Hybridization proceeded at 55 OC for 16 - 20 h. Then, the BeadChip was washed using Illumina 
Wash E1 buffer, twice. The BeadChip was further blocked for 5 min in 1% casein-PBS buffer. 
BeadChip signal was developed by 10-min incubation in 0.5 mL of 1 μg/mL streptavidin-Cy3 
solution. The BeadChip was washed in Wash E1 buffer again. Each BeadChip was then dried 
with the air. The BeadChip was imaged using the BeadArray Reader (Illumina) to measure 
fluorescence intensity. The intensity of the signal corresponds to the quantity of the respective 
mRNA in the original sample. The raw intensity of Illumina Human RefSeq-8 v1 BeadChip 
was scanned and extracted using BeadStudio (Illumina) with background subtraction. Data 
clustering and differential analysis were carried out with GeneSpring GX program, 7.3. (Silicon 
Genetics). The differentially expressed genes between any pair groups were defined as a greater 
than 3-fold change in the mean gene expression between 2 groups and converted to ‘expression 
ratio’ by dividing each value by the mean signal value of that gene in the control group. Three 
separate experiments were implemented to enhance the reliability of the gene-expression data. 
The genes were grouped according to their functional characteristics through the Gene 
Ontology database. Genes were clustered and displayed using average linkage clustering. The 
microarray data have been submitted to the GEO public database (accession number 
GSE17589). 
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2.2.6 RT-PCR and quantitative real-time PCR 
One microgram of total RNA from each sample was subjected to PCR using One Step 
RT-PCR kit (Clontech) according to the manufacturer’s protocol. The assay was carried out in a 
25 μL reaction mixture (2 μL of total RNA, 0.5μL Oligo(dT) primer, 12.5 μL thermostabilizing 
reagent, 2.5 μL 10 X one step buffer, 0.25 uL RNase inhibitor, 5 μL of GC-melt, 0.5 μL of PCR 
primer mix, 0.5 μL of RT-TITANIUM Taq Enzyme Mix, 0.75 μL dH2O) using a PTC 200 
Thermal cycler (MJ Research Inc., USA). The cycling conditions were as follows: reverse-
transcription at 50 OC for 1 h, inactivation of reverse transcriptase and activation of Hot star Taq 
DNA polymerase at 94 OC for 5 min, 32 cycles for GAGE2 and 29 cycles for GAPDH at 94 OC 
for 30 sec (denaturation), 60 OC for 30 sec (annealing), and 68 OC for 1 min (extension) with a 
final extension at 68 OC for 10 min. The PCR product with 10 X loading buffer (Sigma) was 
separated on a 2% agarose gel containing ethidium bromide and photographed under ultraviolet 
light. The primer sequences and the key parameters used are included in the Table S1.  
Quantitative Real-time PCR (qRT-PCR) was performed on a PRISM 7900 Sequence 
Detection System (Applied Biosystems) using Taqman probes (Applied Biosystems). Briefly, 
the expression level of 12 genes (KRT17, AKRIC4, FBXO32, CEBPD, CCL20, SERPINB5, 
SOX15, IGFBP3, RGS2, KRT7, ATOH8, and TGFBI) was determined using Taqman qRT-PCR 
gene expression Assay on Demand primers/probes with housekeeping gene 18S ribosomal 
RNA as an endogenous control. Each sample was run on the PRISM 7900 Sequence Detection 
System according to default parameters, with three replicate assays for each gene. For each 
assay, the average 18S cycle threshold (Ct) value in the TaqMan qPCR assay was subtracted 
from the Ct of gene of interest to obtain a △Ct, target value (Ct, target – Ct, 18S). The calculation of △
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△Ct involved subtraction of △Ct for the controls from the △Ct value for the drug treatments 
(△Ct ,target, drug -△Ct ,target, control). 2-△△Ct was the relative expression of the target gene exposed to 
drug treatments compared to control. 
2.2.7 DNA methylation analysis 
Genomic DNA was isolated from MCF-7, SK-BR-3, BT-474 and MCF10A cells using 
QIAamp DNA Blood Mini Kit (QIAGEN) according to the manufacturer’s protocol.  In brief, 
200 μL of cell pellets in PBS was treated using 200 μL QIAamp lysis buffer and 20 μL 
proteinase K at 56 °C for 10 min during the lysis procedure. Then, 200 μL of 100% ethanol was 
added to the sample, which was transferred to spin columns for DNA purification. After 
washing using QIAamp washing buffer twice, genomic DNA was eluted using 200 μL dH2O.  
DNA methylation status at the CpG islands was determined by methylation-specific 
PCR (MSP) analysis and Bisulfite genomic sequencing (BGS) after bisulfited modification 
(221). Genomic DNA extracted from MCF-7, SK-BR-3, BT-474 and MCF10A cells was 
treated with sodium bisulfite using the EZ DNA Methylation-Gold Kit (ZYMO) according to 
the manufacturer’s protocol. Briefly, 20 μL of DNA sample was diluted in 130 uL of the CT 
conversion reagent solution and further treated in a thermal cycler as following procedure: 98 
oC for 10 min, 64 oC for 2.5 hours, 4 oC up to 20 hours. Bisulfite-treated DNA was then purified 
using a Zymo-Spin ICTM column and eluted with dH2O.  
The bisulfite-treated DNA was amplified with either a methylation-specific (M) or an 
unmethylation-specific (U) primer set for MSP or a GAGE2 primer set for BGS (Table S1). The 
assay was carried out in a 10 μL reaction mixture (1 μL of template DNA, 1 μL of PCR primer 
mix, 5 μL of HotStarTaq Master Mix, 0.5 μL of 25 mM MgCl2, 2.5 μL dH2O) using a 
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Thermal cycler. The cycling conditions were as follows: activation of Hot star Taq DNA 
polymerase at 95 OC for 15 min, denaturation of DNA duplexes at 94 OC for 30 sec, extension 
at 68 OC for 1 min, a final extension at 68 OC for 10 min. The cycle number and annealing 
temperature for each gene are included in the Table S1.  
For MSP, the PCR product with 10 X loading buffer (Sigma) was separated on a 2% 
agarose gel containing ethidium bromide and photographed under ultraviolet light.  
For BGS, the PCR product was separated on a 2% agarose gel. Then, a segment of gel 
containing the bisulfite-treated DNA of interest was excise. The DNA in the agarose gel was 
extracted and purified using GIAquick Gel Extraction Kit (QIAGEN) according to the 
manufacturer’s protocol. In brief, 3 volume of Buffer QG was applied to dissolve gel at 50 OC 
for 10 min. The DNA in the dissolved gel was purified using QIAquick column and eluted with 
50 μL of dH2O. DNA of interest was produced through TA cloing using TOP Cloing kit 
(Invitrogen) for genomic sequencing test. 6 μL of TOPO cloning reaction (4 μL of fresh PCR, 1 
μL of TOPO vector and 1 μL of dH2O) was mixed with a vial of TOP10 E. coli cells and then 
incubated on ice for 20 min. The E. coli cells were heat-shocked for 30 sec in 42 OC. The E. coli 
cells were added into 250 μL of Super Optimal Broth (S.O.C) medium (Invitrogen) and shaken 
at 37 OC at 200 rpm for 2 h. The E.coli cells were spread on the Lysogeny Borth (LB) plate 
(Invitrogen) containing 40 μL of 40 mg/mL X-gal and 40 μL of 100 mM Isopropyl-β-D-thio-
galactoside (IPTG) and incubated at 37 OC overnight. 10 white or light blue colonies were 
picked out and added into 2 mL of LB medium containing 10 μM ampicillin followed by 
vigorous shaking at 37 OC at 300 rpm overnight. The E.coli cells were harvested by 
centrifugation at 1,000 rpm for 15 min at 4 OC. DNA-TOPO vector of interest in E.coli was 
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extracted and purified using QIAprep Spin Miniprep Kit (QIGEN) according to the 
manufacturer’s protocol. In brief, cell pellets in 250 μL buffer P1 were mixed with 250 μL 
buffer P2 and incubated for less than 5 min for cell lysis. The DNA-TOPO vector of interest 
was purified using QIAprep spin column and eluted with 50 μL dH2O. The vector containing 
interested DNA was analyzed using genomic sequencing at 1 st Base Pte Ltd. The amount of 
methylcytosine in each CpG dinucleotide was determined by comparing the peak height of the 
cytosine signal to the combined peak height of the cytosine and thymine signals. 
2.2.8 Chromatin Immunoprecipitation (ChIP) assays 
ChIP asays were performed as described previously (222). Briefly, chromatin proteins 
of interest were cross-linked to DNA by addition of formaldehyde directly to the culture 
medium to a final concentration of 1%. After 10 min incubation at room temperature, the cells 
in 75 cm2 flask were washed and scraped off in 10 mL of ice-cold PBS containing 1 X protease 
inhibitor cocktail (Roche Molecular Biochemicals). After centrifugation at 2000 X g, cell 
pellets were resuspended in 0.5 mL SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-
HCl pH 8.1, 1 X protease inhibitor cocktail) for 10 min on ice. The resulting lysate was 
subjected to sonication to reduce the size of DNA to 300-1000 bp. The sample was centrifuged 
to remove cell debris and diluted 6-fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-
100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCl, 1X protease inhibitor cocktail). 
The chromatin solution was pre-cleared with 100 μL of a mixture of salmon sperm DNA-
protein A agarose slurry (Upstate Biotechnology) to reduce non-specific background. After the 
pre-clearing, the solution was centrifuged at 200 X g for 1 min and the supernatant was 
collected. 0.5 mL of chromatin solution was kept aside as the input sample. 25 μg of antibodies 
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were added to 2.5 mL of chromatin solution and incubated overnight at 4 OC with agitation. 
Then, resulting immune complexes were collected by addition of 100 μL of salmon sperm 
DNA-protein A agarose slurry (beads) and incubated at 4 OC with agitation for 2 h. The beads 
were washed several times with the 50 mM Tris.HCl buffer (pH 8.1), and the attached immune 
complexes were eluted with 100 μL buffer containing 1% SDS and 50 mM Tris.HCl (pH 8.1). 
Cross-links were reversed by the incubation in the Thermomixer (Eppendorf) at 65 OC for 4 h 
with 850 rpm shaking. 100 μL of samples was then treated with 1.6 μL of RNase A at 37 OC for 
1 h and 20 μL proteinase K at 42 OC for 2 h. DNA fragment solution was purified by QIAquick 
PCR Purification Kit (QIGEN) according to the manufacturer’s protocol. In brief, 50 μL of 
DNA fragment solution was mixed with 250 μL of Buffer PB and loaded on the QIAquick spin 
column for further purification. Then, DNA fragment was eluted using 30-50 μL of dH2O. 
Quantification of total DNA in the elution was carried out using NanoDrop ND-1000 (Thermo 
Scientific, USA) spectrophotometer. The immunoprecipitated DNA was quantitated by qRT-
PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) on a PRISM 7900 
Sequence Detection System (Applied Biosystems). Briefly, the assay was carried out in a 10 μL 
PCR reaction mixture (1 μL of 10 ng/mL template DNA, 1 μL of PCR primer mix, 5 μL of 
Power SYBR Green PCR Master Mix (2X), 3 μL dH2O) using PRISM 7900 Sequence 
Detection System according to default parameters. Approximately 5 kb genomic region have 
been scanned surrounding the transcription start site (TSS) of GAGE2, KRT17, TNF and CCL2 
in MCF-7 cells and characterized the histone modification profiles in these regions. Primer set 
was chosen to amplify approximately 100-200 bp around the indicated region. The following 
antibodies were used in the ChIP study: H3K27me3 (07-449), H3K9/14ac (06-599) and 
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H3K4me3 (05-745) were purchased from Upstate Biotechnology; H3K9me3 (ab8898-100) was 
from Abcam and EZH2 (39103) from Active motif. The enrichments of these histone marks 
were quantitated relative to the input amount to obtain △Ct values. To compare the two pools 
of DNA materials, a further normalization of the △Ct values were against a region with low 
background enrichment. The sequences of the PCR primers are shown in Table S1. Values were 
calculated as the average from two independent experiments. The value which is less than 2 is 
classified as the baseline.  
2.2.9 Statistical analysis 
All data were shown as means ± standard deviation (SD). Statistical analysis was 
performed using SPSS 10.0 (SPSS Inc., USA). Comparisons between two groups were made 
using Student’s independent-samples t-test and with more than two groups, one-way analysis of 
variance (ANOVA) was performed followed by the Tukey tests used for post hoc multiple 
comparisons between individual groups. The statistical significance level was set to be p < 0.05. 
 
2.3 Results 
2.3.1 The effects of DZNep in combination with other epigenetic drugs 
on histone modifications  
As shown in the Figure 2.1 A, in MCF-7 cells, DZNep alone or in combination with 
AZA or/and TSA (DZNep-related treatment) resulted in remarkable reduction of PRC2 
components SUZ12, EZH2, EED, and associated H3K27me3 but had not effect on H3K9me3 
and H3K9/14 acetylation (H3K9/14ac); it also had no effect on DNMT1 and DNMT3b (Figure 
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2.1A). Of significant notice, DZNep and TSA combination induced a robust increase in 
H3K9/14ac, which was nearly undetectable in cells treated with TSA alone, indicating a strong 
synergistic effect of DZNep and TSA on histone acetylation. By contrast, DZNep and AZA 
combination did not give rise to the same effect. DZNep also inhibited H3K4me3; but this 
inhibition was reversed by its combination with TSA. On the other hand, AZA depleted 
DNMTs effectively, but had little effect on the above histone modifications. Thus, treatment of 
MCF-7 cells with DZNep and TSA induced marked changes in histone modifications: it 
reduced the repressive histone mark H3K27me3 but increased or at least maintained active 
marks H3K9/14ac and H3K4me3 (Figure 2.1 A).  
Figure 2.1B illustrates the time course of H3K9/14ac induced by TSA in the presence or 
absence of DZNep. TSA alone induced strong acetylation as early as 1h, which gradually 




Figure 2.1 Changes of histone modifications in response to different drug treatments. (A) 
Western blot results show the changes of PRC2 proteins, DNMTs and indicated histone 
modifications in MCF-7 cells after treatment with 2.5 µM DZNep (D) for 72 h, 5 µM AZA (A) 
for 72 h, 100 nM TSA (T) for the last 24 h in 72-h treatment, alone or in various combinations.  
C stands for the untreated MCF-7 cells. β-Actin was used as a loading control. (B) Western blot 
results show the changes of H3K9/14ac at indicated time points (1, 3, 6, 12 and 24 h) after 100 
nM TSA dosing in MCF-7 cells. MCF-7 cells were treated with 2.5μM DZNep for 72 h and 5 
μM TSA, alone or both. TSA was added into medium 48 h after the onset of the experiment. 
 
2.3.2 Differential gene expression response patterns to various drug 
combination treatments  
As shown in Figure 2.2A, 657 DNA methylation-related genes were identified that were 
upregulated by AZA alone (using 3-fold cut off, p<0.05) through performing microarray 
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analysis using Illumina BeadArray system. 372 DZNep-related genes were also found 
upregulated by DZNep alone or in combination with other agents (using 3-fold cut off, p<0.05). 
Comparing the two gene lists by Venn diagram revealed an overlap of only 64 genes, which 
could be reactivated simultaneously by DZNep and AZA. Of 372 DZNep-related genes are 
those strongly upregulated by DZNep alone (n=181) or in synergy with TSA (n=177) (Figure 
2.2A). Two sets of genes were divided according to whether gene expression (normalized) 
induced by DZNep plus TSA is greater than two-fold of that of DZNep alone. Among 372 
DZNep-related genes, 64 genes also showed induction by AZA treatment. Of these 64 genes, 28 
genes were mainly upregulated by DZNep and 22 by DZNep plus TSA. The remaining 14 
genes showed response to AZA-related treatment but not to DZNep or DZNep plus TSA. 
Moreover, the triple combination led to a strong synergistic induction of these 14 genes (Figure 
2.2B). Gene cluster analysis further presents three patterns of 372 DZNep-related genes (Figure 
2.2B). The first cluster (Cluster I, D+T pattern, n=177) in general shows a robust response to 
DZNep plus TSA treatment (34.8-fold induction) compared to any single treatment (Figure 
2.2C). This combination treatment (D+T) resulted in a 34.8-fold gene induction in average, 
compared to 1.7-fold by AZA, 1.9-fold by TSA, and 4.7-fold by DZNep alone. By contrast, 
other combination treatments, such as DZNep plus AZA (D+A) or AZA plus TSA (A+T) failed 
to give such an effect (Figure 2.2B). Many cytokine and chemokine genes such as TNF, CCL2 
are present in this cluster (Figure 2.2C). The second cluster (Cluster II, D pattern, n=181) 
appears to be sensitive to DZNep treatment alone (24.0-fold induction) and further combination 
with other agents did not yield further induction (Figure 2.2C).  
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The third cluster (Cluster III, D+T+A pattern, n=14) represents a small gene set that 
were responsive to AZA (18-fold induction), but not to DZNep, TSA or DZNep plus TSA 
(Figure 2.2C). In addition, combination of AZA with TSA and DZNep further enhanced their 
expression (80.2-fold). Included in this cluster were members of a family of genes encoding 
GAGE- and MAGE- type tumor antigens. qRT-PCR analysis of 12 genes selected to represent 
each cluster validated the Illumina microarray data (Figure S1). 
 
Figure 2.2 Distinct gene expression response profiles to different drug treatments. (A) The left 
Venn diagram shows 657 and 372 genes in MCF-7 cells that were upregulated for threefold or 
greater by AZA alone and DZNep-related treatments, respectively, with 64 genes showing the 
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overlap between the two groups. The right panel Venn diagram shows the breakdown of 372 
DZNep-related genes, including 181 genes induced by DZNep alone; 64 genes induced by both 
AZA and DZNep, and 177 genes induced by combination of DZNep with TSA. (B) 
Hierarchical clustering showing the expression profiles of 372 DZNep-related genes in three 
distinct patterns: DZNep plus TSA sensitive (Cluster Ⅰ, D + T pattern), DZNep sensitive 
(Cluster Ⅱ, D pattern) and triple combination sensitive (Cluster Ⅲ, D + T + A pattern). Shown 
on the right side are the averaged response patterns of each cluster following the indicated drug 
treatments. (C) Expression patterns of selected genes representing each cluster (mean ± SD of 
triplicate measurement). TNF and CCL2 (D+T pattern), KRT17 and FBXO32 (D pattern), 
GAGE2 and GAGE7B (D+T+A pattern).  
 
 
2.3.3 Chromatin modifications of selected gene loci reflecting 
associated drug response 
GAGE2, TNF and CCL2 represent gene cluster III and I that are regulated by 
coordinated actions of histone modifications, while KRT17 represents gene cluster II that is 
repressed only by histone methylation. The methylation-specific PCR (MSP) analysis revealed 
methylated promoter of GAGE2, whereas KRT17, TNF and CCL2 promoters were largely free 
of DNA methylation in MCF-7 cells (Figure 2.3A).  
ChIP results detected abundant EZH2 and repressive marks H3K27me3 enrichment in a 
200bp to 800bp region downstream of the TSS of GAGE2, KRT17, TNF and CCL2 while no 
repressive marks H3K9me3 in untreated MCF-7 cells (Figure 2.3B). On the other hand, the 
activating histone mark H3K9/14ac was found to be weakly enriched in TNF, CCL2 and 
GAGE2, though more in KRT17. Of notice, the activating mark H3K4me3 was detected near 
the GAGE2 TSS in MCF-7 cells. 
As shown in Figure 2.3C, in MCF-7 cells, treatment with AZA moderately increased the 
unmethylated cytosines at GAGE2 locus as compared to the control. Furthermore, the triple 
treatment significantly alleviated the promoter methylation of GAGE2 in MCF-7 cells. 
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ChIP analysis of drug-treated samples indicated that H3K27me3 at TNF, CCL2 and 
KRT17 (cluster and II genes) was markedly reduced by DZNep with or without TSA (Figure Ⅰ
2.3D). In contrast, H3K4me3 and H3K9/14ac were only induced in cells treated with DZNep 
plus TSA at TNF or CCL2. Furthermore, with respect to cluster  genes (Ⅲ GAGE2), ChIP 
analysis showed that although DZNep or DZNep plus TSA could effectively alleviate 
H3K27me3, an induction of H3K4me3 or H3K9/14ac was only found in cells treated with the 
triple combination.  
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Figure 2.3 Chromatin modifications in TNF, CCL2, KRT17 and GAGE2.  (A) Genomic DNA 
fragments covering the -2.5 kb to +2.5 kb region for TNF, CCL2, KRT17 and GAGE2 relative to 
the transcription start site (TSS) for PCR analysis are indicated with numbers. The hatched bar 
below the line indicate CpG islands. M represents the examined PCR regions for methylation 
analysis. Methylation specific PCR (MSP) analysis of TNF, CCL2, KRT17 and GAGE2 
promoters in MCF-7 cells indicates hypermethylated GAGE2 and largely unmethylated TNF, 
CCL2 and KRT17. (B) EZH2 and histone marks (H3K27me3, H3K4me3, H3K9/14ac and 
H3K9me3) at the each gene locus in MCF-7 cells. ChIP assays were performed using antibodies 
against the indicated histone modifications and analyzed by qRT-PCR. The values represent the 
normalized enrichments against the background region. The relative enrichments (bound/input) 
(mean ± SD of duplicate measurement) encompassing the indicated regions are shown for each 
 65
histone mark at each gene locus. The value which is less than 2 is classified as the baseline 
(shown with dashed lines). (C) MSP analysis of GAGE2 promoter in MCF-7 after the indicated 
drug treatments. (D) ChIP analysis indicates the changes of histone marks (H3K27me3, 
H3K4me3 and H3K9/14ac) at four gene loci in MCF-7 cells after indicated drug treatments. 
The data represent mean ± SD of two independent experiments. * p < 0.05. The numbers along 
the x-axis indicate the ChIP-PCR positions as in (A). 
 
2.3.4 Mechanistic heterogeneity of epigenetic regulation of tumor 
antigen GAGEs in breast cancer 
Screening our Illumina gene expression database of breast cancer cell lines repository 
(accession number GSE17589) revealed, while GAGEs showed a silenced expression in MCF-7 
cells with values from -7 to 10.3 (Figure 2.4A), they were basally expressed in SK-BR-3 cells 
(344.0 to 450.1) and highly in BT-474 cells (15706.7 to 22883.3). The bisulfite genomic 
sequencing analysis (BGS) indicated that GAGE2 promoter was unmethylated in both SK-BR-3 
cells and BT-474 cells, as opposed to methylated GAGE2 in MCF-7 cells (Figure 2.4B). ChIP 
analysis indicated that H3K27me3 was highly enriched in SK-BR-3 cells, less enriched in 
MCF-7, and in lowest level in BT-474 cells (Figure 2.4C). Interestingly, H3K27me3 was found 
basally enriched in a less methylated region (50bp to 200bp downstream of the TSS) of GAGE2 
(Figure 2.4B and C). H3K4me3, on the other hand, was highly enriched in BT-474 cells, 
modestly in SK-BR-3 cells and low in MCF-7 cells. In addition, GAGE2 in SK-BR-3 cells, 
whose expression was basally detected (Figure 2.4A), displays a bivalent chromatin as it carries 
both H3K27me3 and H3K4me3 (Figure 2.4C). In contrast, GAGE2 in MCF-7 cells, whose 
expression was scarcely detected (Figure 2.4A), is marked with both DNA methylation and a 
bivalent histone modification (Figure 2.4B and C). In addition, H3K9me3 was not enriched in 
GAGE2 in all the three cell lines. 
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DZNep plus TSA treatment resulted in a strong synergistic induction of GAGEs in SK-
BR-3 cells (Figure 2.4D), while MCF-7 cells carrying promoter methylated GAGE2 showed 
little response to the above combination treatment. In BT-474 cells, GAGEs were already highly 
expressed and only showed modest response to DZNep plus TSA treatment (Figure 2.4D). As 
shown in Figure 2.4E, DZNep plus TSA treatment of SK-BR-3 cells resulted in a dramatic 
decrease in H3K27me3, but concomitantly increases in H3K4me3 and H3K9/14ac, whereas 
neither TSA nor DZNep alone increased H3K4me3.  
The triple drug combination (D+T+A) treatment did not induce GAGE2 in non-
cancerous human mammary epithelial MCF10A cells (Figure 2.5A). In MCF10A cells, GAGE2 
promoter was also hypermethylated (Figure 2.5B), with no detectable H3K27me3 (Figure 2.5C). 
Instead, a strong H3K9me3 was detected.  
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Figure 2.4 Distinct epigenetic regulation of tumor antigen GAGEs in various breast cancer cells. 
(A) The table shows the different gene expression levels of GAGE family members in three 
representative breast cancer cell lines: MCF-7, SK-BR-3 and BT-474 cells. Shown are the raw 
expression values in Illumina Beadarray. (B) The bisulfite genomic sequencing (BGS) analysis 
of methylation status of GAGE2 promoter in MCF-7, SK-BR-3 and BT-474 cells. Open circles 
represent unmethylated CpGs; closed circles denote methylated CpGs. (C) ChIP analysis 
indicates the histone marks at GAGE2 locus in MCF-7, SK-BR-3 and BT-474 cells (mean ± SD 
of duplicate measurement). The value which is less than 2 is classified as the baseline. (D) Gene 
expression of GAGEs in MCF-7, SK-BR-3 and BT-474 cells in response to indicated drug 
treatments. (E) ChIP analysis indicates the changes of histone marks at GAGE2 locus in SK-




Figure 2.5 Triple combination treatment selectively reactivates GAGE2 in breast cancer MCF-7 
cells but not in non-cancerous MCF-10A cells. (A) GAGE2 response to indicated drug 
treatments in MCF-7 and MCF10A cells. (B) GAGE2 promoter is hypermethylated in MCF10A 
cells as determined by BGS analysis. (C) ChIP analysis of EZH2 enrichment and histone marks 
at GAGE2 locus in MCF10A cells. The value which is less than 2 is classified as the baseline. 
 
2.3.5 Functional determination of EZH2 as a crucial regulator of 
GAGE2 expression 
As shown in Figure 2.6A, both MCF-7 and SK-BR-3 cells treated with EZH2 siRNA 
displayed a marked decrease in EZH2 expression and a corresponding decrease in H3K27me3. 
Further treatment with AZA plus TSA in MCF-7 cells or TSA alone in SK-BR-3 cells resulted 
in remarkable increase in H3K9/14ac, compared to cells receiving the control siRNA. EZH2 
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knockdown, in combination with AZA plus TSA, induced strong re-expression of GAGE2 in 
MCF-7 cells (Figure 2.6B). Likewise, EZH2 knockdown in SK-BR-3 cells resulted in robust 
induction of GAGE2 in the presence of TSA.  
 
Figure 2.6 EZH2 is a crucial regulator of GAGE2 expression. (A) Western blotting analysis 
showing the changes of EZH2, H3K27me3, H3K9/14ac and H3K4me3 protein levels. MCF-7 
cells were treated with non-targeting control (NC) or EZH2 siRNA for 24 h, followed by 
treatment with TSA plus AZA for additional 24h. SK-BR-3 cells were treated with NC or EZH2 
siRNA for 24 h, followed by TSA treatment for additional 24h. (B) RT-PCR analysis of GAGE2 
mRNA levels in MCF-7 and SK-BR-3 cells treated as above. GAPDH served as a loading 
control. 
 
2.3.6 EZH2-H3K27me3 regulates the inflammation network which is 
activated by DZNep alone or in synergy with TSA in MCF-7 cells  
In MCF-7 cells, 96% of 372 DZNep-related genes are those induced by DZNep alone or 
in combination with TSA (Figure 2.2B). In addition, 340 genes were identified to be induced by 
 70
either EZH2 siRNA alone or in combination with TSA (3-fold cut off, p<0.05) using microarray 
analysis in MCF-7 cells. Further comparing them with the gene sets induced by DZNep alone or 
together with TSA gives rise to a common set of 213 genes, which represents EZH2-repressed 
gene targets that are reactivated by the DZNep-related treatments.  To identify EZH2-related 
gene response that may represent a cancer specific event, the above gene list was further 
compared with that in MCF10A cells treated by DZNep alone or in combination with TSA. 
This analysis resulted in the identification of a set of 148 genes that are strongly induced in 
MCF-7 cells by EZH2 siRNA or DZNep with or without TSA but not in MCF10A cells (Figure 
2.7A). Furthermore, this set of genes was also similarly induced in SK-BR-3 cells (Figure S2). 
Gene Ontology analysis revealed that the 148 gene set covers a broad range of 
functional categories (Figure 2.7B). Of significant notice, a set of 58 genes functioning in 
inflammation and immune response was remarkably enriched (39 %). This is significantly 
higher than the 11.9% (1,510) of inflammation-related genes out of all genes in the array 
(21,007) (p<0.01). These genes include cytokines and chemokines such as TNF, IL8, CCL2, 
CCL20, CXCL2, etc. ChIP-PCR analysis detected the enrichment of EZH2 and H3K27me3 in 
TNF and CCL2 in MCF-7 cells but not in MCF10A cells (Figure 2.7C). Moreover, the majority 
of 58 inflammation and immunoresponse genes were enriched with H3K27me3 in our in-house 
database (http://t2g.bii.a-star.edu.sg/cgi-bin/template/index.pl) containing the whole genome 




Figure 2.7 EZH2-repressed genes activated by DZNep alone or in synergy with TSA in cancer 
specific manner. (A) Gene cluster diagram showing the expression profiles of 148 genes that are 
induced by either EZH2 siRNA (E) or DZNep (D) with or without co-treatment with TSA (T) in 
MCF-7 but not in MCF10A cells. The fold induction under these conditions is shown at the 
right panel. (B) Gene Ontology analysis reveals that 58 (including TNF and CCL2) out of 148 
genes were remarkably enriched for their roles in immune response. (C) ChIP analysis indicates 
that EZH2 and H3K27me3 at TNF and CCL2 locus are highly enriched in MCF-7 cells but not 
in MCF10A cells. The value which is less than 2 is classified as the baseline. 
2.4 Discussion 
In this study, the pharmacological approaches, coupled with chromatin 
immunoprecipitation and gene knockdown by RNA interference, were applied to 
comprehensively investigate EZH2-related gene silencing events in breast cancer cells, and 
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demonstrated the diversity and complexity of epigenetic mechanisms involved in gene 
repression in cancer cells. 
DZNep is a potent inhibitor of S-adenosylhomocysteine  hydrolase (SAHH) (111, 216-
219). Inhibition of SAHH by DZNep increases the intracellular S-adenosylhomocysteine to S-
adenosylmethionine (SAH/ SAM) ratio, resulting in feedback inhibition of methylation in many 
cellular processes (223). Although DZNep appears to be a general methyl-donor inhibitor, 
DZNep has a minimal activity on genes silenced by DNA methylation (64, 114). Instead, it 
strongly induces genes whose silencing is associated with EZH2-H3K27me3 (63, 64). This 
feature makes DZNep as a powerful agent in probing epigenetic process. Therefore, it was 
postulated that DZNep in combination with other chromatin remodeling compounds (TSA and 
AZA) targeting distinct epigenetic processes would act in synergy to give rise to maximal gene 
reactivation.  
Firstly, the effects of such treatments on histone modifications and the associated 
chromatin modifying enzymes in MCF-7 cells were confirmed by the Western blotting (Figure 
2.1 A). It is especially intriguing that combination of DZNep and TSA induced a robust 
augment of histone H3K9/14ac (Figure 2.1 A), which is consistent with the report of Jiang et al. 
(63). Additionally, in the presence of DZNep, TSA-induced H3K9/14ac remained elevated 
within 24 h (Figure 2.1 B), indicating that DZNep treatment facilitates histone acetylation for a 
prolonged period of time. The results also indicate that combination of DZNep and TSA causes 
a global reprogramming of histone modifications. 
The microarray analysis identified only 64 genes (6.6%) was the overlap in total 965 
genes induced by AZA or DZNep-related treatment, indicating that the two silencing events 
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(DNA methylation and EZH2-H3K27me3) regulate distinct sets of genes (Figure 2.2A). This 
finding agrees with the recent genome wide analyses showing that most genes enriched at 
H3K27me3 are not targets of DNA methylation and vice versa (59, 60). As shown in the Figure 
2.2A, 372 DZNep-related genes were upregulated by DZNep alone or in combination with other 
agents. Since epigenetic events associated with AZA and TSA have been previously 
investigated in large numbers of literatures (53, 224, 225), 372 DZNep-related genes were 
chosen for exploring distinct models of epigenetic regulation involving histone methylations. 
Gene cluster analysis further presented three patterns of DZNep-related genes (Figure 2.2B). 
The first cluster (Cluster I, D+T pattern, n=177) showed a robust response to DZNep plus TSA 
treatment compared to any single treatment. Notably, many genes in this cluster are cytokines 
and chemokines such as TNF, IL8, CXCL2 that are implicated in a wide range of biological 
disorders, including tumorigenesis. The second cluster (Cluster II, D pattern, n=181) was 
sensitive to DZNep treatment alone and further combination with other agents did not yield 
further induction. Many of these genes, such as IGFBP3, KRT17 and FBXO32 (Figure 2.2C)., 
have been identified as PRC2 targets in our previous study (64). The third cluster (Cluster III, 
D+T+A pattern, n=14) represented a small gene set that are not responsive to DZNep or DZNep 
plus TSA treatment but were strong synerigistic induced by the triple combination. Included in 
this cluster are GAGE- and MAGE- type tumor antigens, which have been previously shown to 
be silenced by DNA hypermethylation (226, 227). Restored expression of these tumor antigens 
in cancer by DNA demethylating agent has been implicated in tumor immunotherapy (226, 227). 
In addition, combination treatment targeting multiple epigenetic processes is able to yield 
maximal induction of these tumor antigens. 
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ChIP coupled with qRT-PCR detected abundant EZH2 and H3K27me3 enrichment in a 
200bp to 800bp region downstream of the TSS of GAGE2, KRT17, TNF and CCL2 in MCF-7 
cells (Figure 2.3B). This result is consistent with the several recent genome-wide studies 
showing that a large portion of H3K27me3 is detected in the proximal downstream region of 
the TSS in both cancer and embryonic stem cells (209, 228, 229). Coupled with no H3K9me3 
mark being detected, these results suggest that the transcription of these four genes is primarily 
regulated under the EZH2-H3K27me3. The activating mark H3K4me3 was detected near the 
GAGE2 TSS in MCF-7 cells (Figure 2.3B), suggesting that the GAGE2 promoter is 
simultaneously modified by both repressive and activating histone methylation in these cells. 
Such bivalent histone states have been previously shown to correlate with genes transcribed at 
low levels (38, 228-230). Taken together, the high levels of repressive EZH2-H3K27me3 and 
low or basal levels of activating H3K4me3 at these genes are consistent with their repressed 
expression in MCF-7 cells, while H3K9/14ac might be responsible for the difference of gene 
expression response between cluster I and cluster II.    
ChIP analysis of drug-treated samples indicated that for Cluster I genes (such as TNF 
and CCL2) the inhibition of H3K27me3 alone is not sufficient for their full reactivation (Figure 
2.3D). In such case, perturbation of both H3K27me3 and HDAC seems to be required for an 
effective alleviation of their repression. In contrast, as for cluster II genes (KRT17), the 
inhibition of H3K27me3 by DZNep alone was sufficient for their reactivation and addition of 
TSA did not seem to further increase H3K4me3 and H3K9/14ac at KRT17. As for cluster Ⅲ 
genes (GAGE2), ChIP analysis showed that although DZNep or DZNep plus TSA could 
effectively alleviate H3K27me3, an induction of H3K4me3 or H3K9/14ac and thus the full 
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reactivation of GAGE2 were only found in cells treated with the triple combination. In addition, 
the demethylation of GAGE2 promoter was moderately induced by only AZA treatment and 
synergistically increased with the aid of DZNep and TSA (Figure 2.3C), suggesting that DNA 
methylation is dominant for the reactivation of GAGE2 in MCF-7 cells. Therefore, coupled with 
gene expression pattern of these three clusters, the collateral effects of inhibition of H3K27me3 
and increase in H3K4me3/H3K9/14ac seem to be required for an efficient induction of affected 
target gene expression. Collectively, three distinct expression response patterns induced by 
different treatment conditions reflect three models of epigenetic mechanisms involving histone 
modifications and DNA methylation, which are summarized using a schematic diagram (Figure 
2.8).  
 
Figure 2.8 Schematic representation of three models of epigenetic mechanisms reflected by 
different treatment conditions. Genes in cluster I are silenced by coordinated and synergistic 
actions of EZH2-H3K27me3 and HDAC, which can be reactivated by EZH2 inhibitor (DZNep) 
and HDAC inhibitor (TSA). Cluster II genes are inhibited only under EZH2-H3K27me3 and 
thus their restoration just need DZNep. Cluster III genes are simultanesouly suppressed by the 
DNA methylation and histone modification, which could be reactivated by the triple 
treatemment of three agents.    
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Given breast cancer is characterized by its cellular heterogeneity, three distinct 
expression response patterns observed in MCF-7 cells, have been extended to one representative 
gene, GAGE2, in other breast cancer cell lines. GAGEs including GAGE2 are generally 
expressed in three different levels: silenced, low (or basally), and highly expressed, in MCF-7, 
SK-BR-3 and BT-474 cells, respectively. In terms of GAGE2 in SK-BR-3 cells, its basally 
expression in untreated cells was synergistically induced by DZNep plus TSA (Figure 2.4D). 
Additionally, GAGE2 promoter was unmethylated and enriched with H3K27me3 in untreated 
SK-BR-3 cells (Figure 2.4B and Figure 2.4C) while increased in the accumulation of 
H3K9/14ac and H3K4me3 in SK-BR-3 cells cotreated by DZNep and TSA (Figure 2.4E). 
Therefore, GAGE2 in SK-BR-3 cells, whose expression is simultaneously regulated by 
H3K27me3 and HDAC but not the DNA methylation, belongs to the Cluster I, D+T pattern. In 
contrast, in BT-474 cells, GAGE2 was already highly expressed and thus showed modest 
response to DZNep plus TSA treatment (Figure 2.4B). In addition, GAGE2 promoter was 
neither methylated nor enriched with H3K27me3 but highly with the activating mark H3K4me3 
in untreated BT-474 cells (Figure 2.4B and Figure 2.4C). Therefore, GAGE2 presents a fully 
expressed status in BT-474 cells. As shown in the section 2.3.3, GAGE2 belongs to the Cluster 
Ⅲ, D+T+A pattern in MCF-7 cells. Interesting, although both DNA methylation and 
H3K27me3 are detected at GAGE2 in MCF-7 cells, H3K27me3 was found to be weakly 
enriched in a less methylated region of DNA (Figure 2.4B and C) and thus also contributes to 
gene repression. Our data provide the explanation why a small set of genes could be controlled 
by DNA methylation and EZH2 when two epigenetic events in principle target different set of 
genes in cancer cells (59, 60). 
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Members of GAGE family are cancer antigens whose expression are restricted to 
immunoprivileged normal tissues and different types of cancers, which make them attractive 
candidates for cancer-specific immunotherapy (231-233). As one of cancer antigens, members 
of GAGE family are expressed in a wide variety of malignancies but generally not in normal 
tissues (234); a feature that warrants the development of GAGE-targeted cancer immunotherapy. 
Indeed, it was found that GAGEs were silenced in non-cancerous human mammary epithelial 
cell line MCF10A (Figure 2.5A), but showed varied expression levels in different breast cancer 
cell lines (Figure 2.4A). This result is consistent with a recent report showing different GAGE 
protein expression levels owing to the cellular heterogeneity in malignancies (231). The data 
suggest that lack of GAGE expression in a subset of cancer cells within GAGE-positive tumors 
may result in failure of the development of GAGE-targeted cancer therapy. The distinct 
epigenetic mechanism involved in the silencing of GAGE2 in different breast cancer cell lines 
suggests that different pharmacological approaches are required for its reactivation. For 
example, GAGE2 silencing in MCF-7 cells is associated with both DNA methylation and 
histone methylation, and a triple combination treatment is required for a maximal reactivation 
(Figure 2.2C). Thus, our combinatory pharmacologic approaches targeting different epigenetic 
components would translate all GAGE-negative cancer cells to GAGE-positive cancer cells. 
One concern for such a treatment is that it might also lead to the GAGE2 induction in normal 
cells. However, the triple drug combination (D+T+A) treatment did not induce GAGE2 in 
MCF10A cells (Figure 2.5A). A repressive mark H3K9me3, which was detected around the 
GAGE2 promoter in MCF10A (Figure 2.5C), may contribute to the resistance of GAGE2 to the 
DZNep-related treatment.  Importantly, since breast cancer cells but not breast normal cells 
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showed reactivation of GAGEs by DZNep-related combination treatment, the enrichment of 
H3K27me3 at GAGE2 locus is cancer-specific event thus possibly avoiding DZNep-related 
side-effect on normal cells. Our data may also provide the explanation why Cheng et al did not 
see GAGE gene re-expression in some cancer cells treated with DNA methylation inhibitor 
Zebularine, since in these cells it can not alter cancer specific histone modification (227). It was 
hypothesize that the overall activation of GAGE family by our approach may have implications 
in clinical immunotherapy for breast cancer.  
EZH2 knockdown gave rise to a similar effect as DZNep on GAGE2 expression in 
MCF-7 and SK-BR-3 cells, alone or in combination with other epigenetic drugs (Figure 2.6 B). 
These results confirm a crucial role of EZH2 in repressing GAGE2 in breast cancer cells, either 
through coordination with both histone deacetylation and DNA methylation in MCF-7 cells or 
histone deacetylation only in SK-BR-3 cells.  
Using the gene knockdown by EZH2 RNA interference, coupled with the 
pharmacological approaches, a cohort of 148 genes repressed by EZH2 and reactivated by 
DZNep or DZNep plus TSA treatment were uncovered in a potential cancer-specific manner 
(Figure 2.7A). Furthermore, a set of 58 genes functioning in inflammation and immune 
response was identified using gene ontology analysis. The data also suggest a potential role of 
EZH2 in the regulation of immune response in breast cancer cells. These genes include 
cytokines and chemokines such as TNF, IL8, CCL2, CCL20, CXCL2, etc. TNF encodes a 
pleiotropic cytokine TNF-α, whose production can trigger a variety of cellular responses, 
ranging from inflammatory cytokine production, cell proliferation, to paradoxically, cell death 
(235). As one of the major mediators of the inflammatory response, IL8 and other cytokines 
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could mediate either tumor promoting or anti-tumor effects (236-239). These results raise the 
question of whether this effect may be detrimental to the efficacy of EZH2-targeted strategy or 
in fact provide an additional benefit. Accumulating literatures have highlighted the dilemmatic 
roles of inflammation and immunity network in cancer development, driving cancer progression 
or inhibiting tumor growth (236, 240-242). Contrary to the traditional view of chronic 
inflammation promoting cancer progression, recent evidences show that immune mediators 
such as IL8, CXCR2 (its associated ligands) have roles in implementing oncogene-induced 
senescence (OIS) in cancer cells in autocrine and cell-autonomous fashion, which is believed to 
be a first-line defense against potentially dangerous mutations (243-245). In addition, the local 
production of chemokines such as CCL2, CXCL2 can attract tumor-infiltrating leukocytes to 
inhibit tumor growth in some instances (246, 247). Thus, depending on the context, specific 
cytokines and chemokines elicit anti- or pro-tumorigenetic effect, thereby affecting cancer 
immunity. In fact, 58 EZH2-repressed immunoresponse genes were reactivated by our 
pharmacological approach in a cell-autonomous fashion, closely resembling what occurs with 
OIS. It is therefore speculated that EZH2 inhibition-mediated activation of human tumor-
associated antigens (GAGEs) and other immune mediators might provide a protective host 
response to malignancy indirectly through the activation of innate immunity. However, a further 
study to validate this hypothesis using appropriate animal models is required. Hence, the 
development of clinical trials with EZH2-targeted therapeutic agents should proceed with 
caution and be mindful of the impact on other signaling cascades that may promote or 
antagonize its anti-tumor effect.  
 80
In summary, this study provides a comprehensive view of epigenetic 
mechanisms involving EZH2-mediated gene repression. The coordinated actions of 
EZH2 with other epigenetic components highlight the mechanistic heterogeneity, either 
among different genes in single cell line or the same genes in different cell contexts. In 
addition to yielding novel insights into epigenetic regulation, our study suggests that the 
best hope for epigenetic therapy may lie in the development of combinatory approach 




CHAPTER 3  
TNF: a modulator for the breast cancer cell death 




Cotreatment of DZNep with HDAC inhibitors (TSA and panobinostat) not only serves 
as the epigenetic probe to identify the interaction between EZH2 and HDAC in the modulation 
of gene transcription, but has also recently been shown strong synergy in cell death of human 
colorectal, multiple myeloma (MM), and acute myeloid leukaemia (AML) cells (63, 65, 202). 
However, no research has been carried out so far to study whether combination of DZNep and 
HDAC inhibitors would induce strong synergy in cell death of breast cancer cells. 
As a promising combination epigenetic therapy strategy, the EZH2 and HDAC-co-
targeted genes, especially for the cell death-related genes, have been extensively studied via 
perturbation by DZNep and HDAC inhibitors. Any novel findings in these genes would enrich 
our knowledge of survival of cancer cells under the control of EZH2 and HDAC together and 
also present new cancer related biomarkers, which could be reversed by epigenetic agents. It 
has been found that DZNep alone just induced apoptosis through a tumor suppressor, FBXO32, 
in breast cancer cells, using the correlation analysis method between cell death and differential 
gene activation (64). As FBXO32 belongs to the D pattern in three distinct models (Chapter 2, 
Section 2.3.2), i.e. this gene is regulated only by EZH2, it is unlikely that DZNep combined 
with HDAC inhibitor could exert a synergistic effect on the reactivation of this gene in breast 
cancer cells. Therefore, it is reasonable to search for the unknown D+T pattern of genes, which 
is associated with the possible synergistic cell death induced by the cotreatment of  DZNep and 
TSA in breast cancer cells.  
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As mentioned previously (Chapter 2, Section 2.3.6), a set of 58 EZH2-repressed and 
cancer specific genes is considered to implement oncogene-induced senescence (OIS) in cancer 
cells in autocrine and cell-autonomous fashion.  Of notice, most of these genes such as TNF, 
IL8, CCL2, CCL20, CXCL2, etc., which could be reactivated by the cotreatment of DZNep and 
TSA, belong to the D+T pattern. 
In this study, we aimed to explore the potential synergistic effect on the cell death by 
the combination of DZNep and TSA in breast cancer cells and find key genes, the high 
expression of which was associated with DZNep and TSA-induced breast cancer cell death, 
from the 58 verified EZH2-repressed and cancer specific gene list using the correlation analysis 
method between cell death and differential gene activation.  
 
3.2 Materials and Methods 
3.2.1 Cells and Drug treatment 
Breast cell lines used in this study were all obtained from the American Type Culture 
Collection (ATCC), including MCF-7, BT474, MDA-MB361, MDA-MB468, SK-BR-3, 
MCF10A, BT549, MDA-MB231, MDA-MB436, and MDA-MB415 cells. The detailed 
procedure of cell culture was in the same way as described previously in Chapter 2, section 
2.2.1. Prior to drug treatment, cells were firstly seeded for 24 h. Then, cells were treated with 
2.5 μM DZNep for 72 h and 100 nM TSA for the last 24 h within the 72-h treatment, alone or 
both (3 treatment conditions).  
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3.2.2 Flow cytometric analysis 
After drug treatments, cells were harvested by centrifugation at 2000 X g at 10 OC for 5 
min, washed in 1 mL PBS (pH 7.4) twice, and fixed in 5 mL of 70% ice-cold ethanol for more 
than 1 hour. After centrifugation at 2000 X g for 5 min, the cell pellets were washed using 1 mL 
of PBS twice. Then the pellets were re-suspended in 100 μL of 100 μg/mL RNase A (Sigma) 
and 400 μL of 50 μg/mL propidium iodide solution (Sigma). Stained cells were incubated for at 
least 30 min at room temperature in the dark. Stained cells were then analyzed for DNA content 
in a Becton Dickinson FACSCalibur (Franklin Lakes, NJ). 488-nm laser line and 620-nm red 
fluorescence were used for excitation and measurement, respectively. 10,000 cells per sample 
were counted for analysis in each gated region. The percentage of cell death nuclei was 
measured by analysis of the broad hypodiploid (sub-G1) peak in the DNA histogram after 
elimination of residual debris. The data obtained using the sub-G1 peak in the flow cytometric 
analysis was just approximate estimate of the percentage of cell death.   
3.2.3 Microarray analysis 
Gene expression in MCF-7, BT474, SK-BR-3, MCF10A, BT549 and MB231 cells treated 
by DZNep and TSA, alone or both, was measured by the microarray analysis as described 
previously in Chapter 2, section 2.2.5. Gene expression data was stored in the in-house Illumina 
database (http://t2g.bii.a-star.edu.sg/cgi-bin/template/index.pl). The correlation between cellular 
TNF mRNA level and the cell death in breast cells exposed to DZNep plus TSA treatment was 




RT-PCR for TNF was carried out in the same way as described in Chapter 2, section 2.2.6. 
The PCR primer pair for TNF was 5’-CGAGTCTGGGCAGGTCTA-3’ (forward) and 5’-
GTGGTGGTCTTGTTGCTTAA-3’ (reverse). The cycle number for TNF was 30 and the 
annealing temperature 58 OC. 
 
3.3 Results 
3.3.1 The cell death in MCF10A and other 9 breast cancer cell lines  
As shown in Figure 3.1, in all the cell lines, DZNep plus TSA led to the mild to strong 
induction of cell death compared to single treatment by DZNep and TSA in the range between 
1.32-18.04 fold. Similar to MCF-7 cells, BT474, MDA-MB361, MDA-MB468, SK-BR-3 cells 
were highly susceptible to the cotreatment of DZNep and TSA with cell death rate ranged 
within 47.57-86.83%. In contrast, MCF10A, BT549, MDA-MB231, MDA-MB436, MDA-
MB415 cells were relatively resistant to combined treatment with cell death rate ranged within 
6.34-29.19% (Figure 3.1). Considering the cell growth status and sensitivity to drug treatment, 
the MCF-7, BT474 and SK-BR-3 cells were chosen as the sensitive group while the MCF10A, 
BT549 and MB231 cells as the resistant group.  
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Figure 3.1 The percentage of cell death (mean ± SD, n = 3) in 9 breast cancer cell line and 
MCF10A treated with 2.5 µM DZNep for 72 h and 100 nM TSA for the last 24 h in 72-h 
treatment, alone or both. CTRL stands for the untreated cells. The percentage of cell death was 
measured by analysis of the broad hypodiploid (sub-G1) peak in the DNA histogram after the 
cells was stained with propidium iodide. 
3.3.2 TNF is associated with the different cell death pattern in two 
kinds of cell lines  
As shown in Figure 3.2A, TNF expression level (Illumina raw data) in MCF-7, BT474 
and SK-BR-3 cells exposed to DZNep plus TSA treatment appeared to be much superior to that 
in untreated cells, whereas minimal induction by the same combined treatment was observed in 
MCF10A, BT549 and MB231 cells. To confirm these array data of TNF in the above six chosen 
cells, semi-quantitative PCR was employed and similar result was obtained (Figure 3.2B). 
Additionally, as shown in Figure 3.2C, using the correlation analysis method between cell death 
and differential gene activation, the TNF expression level (Ilumina) exposed to DZNep plus 
TSA was in a good linear relationship with the cell death status in these cell lines (r2 = 0.9085).  
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Figure 3.3 shows that only the differential expression of TNF gene accords with cell death 
pattern of sensitive cell lines and resistant cell lines cotreated with DZNep plus TSA in the 
representative TNF family members and TNF receptor family members: TNF, TNFRSF1A, 
TNFSF10, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFSF6, TNFRSF6, 




Figure 3.2 (A) TNF expression (raw data) after 6 breast cells untreated or treated with 2.5 µM 
DZNep for 72 h and 100 nM TSA for the last 24 h within 72-h treatment (DZNep plus TSA). 
(B) Semi-quantitative PCR for TNF gene expression after 6 breast cell lines untreated or treated 
with DZNep plus TSA. (C) Relationship between cell death and TNF reactivation following 

































































Figure 3.3 Gene expression of TNF family members in 6 breast cell lines administered with 
DZNep plus TSA. 
 
3.4 Discussion 
This study examined the potentially synergistic effect of cotreatment of DZNep plus TSA 
on the cell death of breast cancer cells and the key genes involving the DZNep plus TSA-
induced breast cancer cell death. The cell death analysis revealed that there exists sensitive and 
resistant cell death response in MCF10A and other 9 breast cancer cell lines exposed to 
combined treatment of DZNep and TSA (Figure 3.1). Interestingly, such combination treatment 
induced a similar breast cell line sorting as the previous finding of Tan et al. (64) that BT549, 
MCF10A and MB231 are resistant, while SK-BR-3, MB468 and MCF-7 are sensitive to 
DZNep treatment alone. Together with the observation that no breast cancer cells were sensitive 
to TSA alone treatment (Figure 3.1), this suggests that DZNep is the dominant agent 
responsible for cell death induction while TSA robustly coordinates with DZNep to cause death 
in the sensitive breast cancer cells.  
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Due to a good linear relationship (r2 = 0.9085) between cell death and high mRNA level 
of TNF in two kinds of breast cell lines exposed to DZNep plus TSA treatment (Figure 3.2C), 
the reactivation of TNF, one cell death gene, may play a role in modulating the DZNep plus 
TSA-induced cell death in the breast cancer cells. In the previous study (68), coupled with the 
EZH2 siRNA perturbation and ChIP-PCR analysis, it has been verified that EZH2-H3K27me3 
was enriched in TNF locus in MCF-7 cells (sensitive) but not in MCF10A cells (resistant). This 
explains why two kinds of cells appeared distinct sensitivity to DZNep related treatment. In 
addition, for TNF (see D+T pattern, Chapter 2, section 2.3.3) in MCF-7 cells, it has been 
confirmed that the inhibition of EZH2-H3K27me3 alone is not sufficient for its full reactivation. 
In contrast, perturbation of both H3K27me3 and HDAC seems to be required for an effective 
alleviation of its repression. Therefore, combined treatment with DZNep and TSA might induce 
synergistic TNF expression in sensitive breast cancer cells. Collectively, it is reasonable to 
consider the role of TNF in negatively regulating cell survival may be jointly regulated by the 
EZH2 and HDAC, and be pharmacologically reversed by combined treatment of DZNep and 
TSA.  
Tumor necrosis factor (TNF) was first identified in 1984 as a cytokine with anti-tumor 
effects in vitro and in vivo (248). Extensive research since then has shown that there are at least 
18 distinct members of the TNF super family and they exhibit 15–25% amino acid sequence 
homology with each other. These family members bind to distinct receptors, which are 
homologous in their extracellular domain. Various members of the TNF super family are able to 
mediate either proliferation, survival, or apoptosis of cells (249). Thus, due to the strong 
connection between the TNF family members and cell death, the gene expression (Illumina 
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normalized data) of the representative TNF family members and TNF receptor family members 
co-induced by DZNep and TSA was analyzed. Only the differential expression of TNF gene 
accords with cell death pattern of sensitive cell lines and resistant cell lines cotreated with 
DZNep plus TSA (Figure 3.3). This differential expression suggests that the role of TNF is 
unique in DZNep plus TSA-induced cell death. However, in the future study, the function 
analysis is still required for further validating the role of TNF in modulating DZNep plus TSA-
induced breast cancer cell death by showing that the TNF signalling pathway could be blocked 
by gene knockdown by TNF siRNA or TNFR1 neutralization. 
In summary, based on varied sensitivity to combined treatment of DZNep and TSA, 
MCF10A and other 9 breast cancer cells can be divided into two groups, sensitive and resistant 
breast cells. More importantly, TNF, a cell death gene, is associated with the DZNep plus TSA 
induced synergistic cell death in the sensitive breast cancer cells due to the co-suppression by 
EZH2 and HDAC 
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CHAPTER 4  
Acute toxicity study of DZNep in rats: assessment of 
the median lethal dose (LD50) and the no-observed-




DZNep, a nucleoside analog, which can reverse PRC2 and histone methylation-
mediated gene silencing and effectively induce cancer cell death, may open the therapeutic 
potential of inhibiting this epigenetic regulator (64). In addition to serving as an epigenetic tool 
to probe the interaction between epigenetic events, numerous scientific reports have stressed the 
significance of the further study on the potential clinical effectiveness of DZNep (63, 114, 250). 
As the specific antitumor function of DZNep in vitro, which was firstly reported by our 
collaborator (Yu Qiang) (64), it would be our prime interests to explore further on its potential 
application in preclinical studies. The preclinical study of DZNep may pave the way for the 
potential clinical application of DZNep alone or in combination with other HDAC inhibitors. 
On the other hand, it may provide the basis for extrapolating the epigenetic antitumor 
mechanism from in vitro to in vivo. 
The preclinical safety evaluation for a drug candidate is required: (1) to identify an 
initial safe dose and subsequent dose escalation schemes in humans; (2) to identify potential 
target organs for toxicity and for the study of whether such toxicity is reversible; and (3) to 
identify safety parameters for clinical monitoring. The previous acute toxicity study indicated 
that inoculating a single dose of up to 10 mg/kg DZNep in healthy adult mice did not result in 
weight loss, behavioral change or other visible signs of toxicity over 2 weeks (117). Also, no 
evidence of hepatic injury or renal impairment, as compared to the mock-treated mice, was 
identified (117). However, by far, no study has been carried out to identify the median lethal 
dose (LD50) of this compound in animals. 
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At present, in order to identify the median lethal dose (LD50), an acute toxicity study 
was thus performed on DZNep intravenously administered to Sprague Dawley (SD) rats using 
the up-and-down method (UDP). The UDP method was conducted according to the guideline 
for up-and-down procedure published by the Organisation for Economic Cooperation and 
Development (OECD, 2001) (251). The UDP method is a staircase design in which the stimulus 
level for the next subject is based on the response of the previous subject. LD50 values are only 
estimated, after completing the data base that consists of various clinical signs, and are to be 
interpreted as ‘50% severe toxic dose’. The advantage of this method is that it can provide the 
best estimate of threshold level (LD50) with a minimum number of animals by concentrating 
tests near LD50 and thus avoid tests far from this threshold. However, the shortcoming of this 
method also exists in that it is not adequate for estimating a dose-response of mortality or signs 
of toxicity. 
 LD50 is a general constant that indicates how toxic a substance is, which is far higher 
than the practical doses in the preclinical study of the compound. In contrast, no observable 
adverse effect level/dose (NOAEL) is more helpful in the selection of starting doses for the 
preclinical pharmacokinetics and disposition studies and antitumor activity studies of a drug. 
LD50 value and other related information obtained during carrying out UDP method would 
provide the maximum value for further investigation of NOAEL and the clue in relevant to 
target organs of toxicity. The primary objective of this study was to identify the LD50 and 
NOAEL of DZNep using acute toxicity method in SD rats.  
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4.2 Materials and methods 
4.2.1 Materials and Animals 
3-deazaneplanocin A (DZNep, purity > 99%) was purchased from OKeanos Tech. 
Co.(Beijing, China). The female Sprague Dawley (SD) rats were provided by Laboratory 
Animal Center (National University of Singapore, Singapore), and housed in a temperature 
controlled room (25OC) with a 12-h light-dark cycle. The research protocol was approved in 
advance by the Animal Ethics Committee of National University of Singapore. Of notice, since 
breast cancer cells have been used in the investigation of the pharmacological effects of DZNep 
in vitro and will be used to establish the animal model for pharmacodynamic exploration of 
DZNep in vivo, all the animals employed in this dissertation are female.  
4.2.2 LD50 detection using the up-and-down procedure (UDP) 
The female SD rats were intravenously injected via the tail vein, one at a time. The first 
animal was given DZNep (20 mg/mL in 5% glucose solution) at the dose of 20 mg/kg, the best 
estimate of the LD50 (117). If the first animal was alive at the end of 24 h, the next animal 
would be given a higher dose. If the first animal died, then the next animal would receive a 
lower dose. The dose for the next animal was changed, either increased or decreased, by a factor 
of around 1.3. The dosing options were repeated until 4 reversals occurred in any 5 consecutive 
animals tested. The LD50 and 95% confidence interval (CI) for the LD50 was calculated using 
AOT425 statistical program (Version 1.0, OECD). Additionally, for each drug-treated rat, 
another rat would receive 5% glucose solution serving as the control. The animals were 
observed for clinical signs of toxicity during the 14-day observation period; symptoms and 
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lethality were recorded every day. The animals would be euthanized promptly if they were 
experiencing unrelieved pain or distress prior to the defined experimental endpoint. During this 
entire period, the animals were weighed daily. At the end, the surviving animals were sacrificed 
by carbon dioxide asphyxiation, dissected, and also examined for macroscopically visible 
changes. Only females were used because of being slightly more sensitive than the males(252). 
4.2.3 No observable adverse effect level (NOAEL) for DZNep solution 
Based on the LD50 value obtained previously, an acute toxicity study was then carried 
out to determine the NOAEL level for a preliminary PK study on DZNep in rats. In total, 20 
female SD rats were divided into 4 groups of five each. Three groups were intravenously 
administered 20, 15, 10 mg/kg body weight DZNep solution by the tail vein, respectively. The 
remaining group was given 5% glucose solution as the control group. Then, the NOAEL of free 
DZNep was determined, depending on the following endpoint parameters obtained.  
4.2.4 Clinical signs and weight changes 
Four groups of SD rats after dosing were observed for clinical signs of toxicity during 
the 14-day observation period; symptoms and lethality were recorded every day and the animals 
were weighed daily. Animals found dead were dissected as soon as possible. Then the relative 
weight gain was calculated as the daily weight change (the body weight recorded daily – the 
pretreated weight) divided by the pretreated weight, which was plotted against time (day) to 
better evaluate the acute toxicity effect of DZNep on the change in body weight in rats.  
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4.2.4.1 Hematological investigations and clinical chemistry  
On the second day and the last day postdose, hematological and clinical chemistry 
examinations were performed on all animals without withdrawal of food. Different blood 
parameters were then measured by using a biochemical autoanalyzer (Type 7170, Hitachi, 
Japan). The reference ranges were supplied by the NUS Vivarium at the Centre for Life Science. 
Hematological parameters evaluated were leukocyte counts (WBC), neutrophils (NEU), 
lymphocytes (LYM), monocytes (MONO), eosinophils (EOS), basophils (BASO), erythrocyte 
counts (RBC), haemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
red cell distributive width (RDW), platelet count, and mean platelet volume (MPV). 
The following clinical chemistry parameters were evaluated: albumin, alkaline 
phosphatise (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
bilirubin direct, bilirubin total, creatinine (Cr), total protein, and blood urea nitrogen (BUN). 
The results obtained from the drug-treated rats were compared to those from the control rats. 
4.2.4.2 Anatomic pathology: necropsy and macroscopic examination 
All animals, including those that died of toxication and those that survived the entire 
observation period, after exsanguination, were autopsied for observation of macroscopic change 
in their body organs. The heart, lung, liver, kidneys, and spleen of each rat were removed and 
weighed. Then the absolute organ weight was used to calculate the relative organ weight with 
respect to the total body weight to better evaluate the change in organ weight due to toxicity of 
DZNep. The results of the drug-treated rats were compared to those of the control rats.  
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4.2.5 Statistical analysis 
Statistical analysis was performed using SPSS 10.0 (SPSS Inc., USA). All data were 
shown as means ± standard deviation (SD). One-way analysis of variance (ANOVA) was 
performed in statistical comparisons of means for the relative organ weight, clinical chemistry 
parameter, and haematological parameter among three dose groups and one control group. The 
post hoc tests were used for comparison between individual groups. The significance level was 
set to be p< 0.05. A profile-likelihood-based computation procedure (AOT425 statistical 
program, Version 1.0, OECD) was used to obtain a 95% confidence interval for the LD50 using.  
 
4.3 Results  
4.3.1 LD50 detection using the up-and-down procedure (UDP) 
As shown in the Table 4.1, four out of eight rats employed in the UDP process died 
within 24 h. Out of four rats only one survived receiving a single dose of 26 mg/kg DZNep. The 
only rat receiving the highest dose of 32 mg/kg was dead. None of the rats receiving the lowest 
dose of 20 mg/kg died during the entire period of toxicity testing. The process was stopped 
when 4 reversals at a single dose of 26 mg/kg occurred in 5 consecutive rats tested between 20 
and 26 mg/kg dose. Acute intravenous toxicity testing of DZNep solution in SD rats, followed 
by a 14-day recovery period, yielded a median lethal dose of 26 mg/kg DZNep with the 95% 




Table 4. 1 LD50 estimation in SD rats using AOT425 Statistical Program (OECD Test Guideline 
425) 
 
Animal ID    Dose (mg/kg) Short-term Result Long-term Result 
1 20 O O 
2 26 O O 
3 32 X X 
4 26 X X 
5 20 O O 
6 26 X X 
7 20 O O 
8 26 X X 
  Stop dosing     
X = died, O = Survived. Statistical Estimate based on long term outcomes: estimated LD50 = 
26 mg/kg (The one dose with partial response). 95% confidence interval for the LD50 is 20.59 to 
28.5 mg/kg DZNep. 
 
Rats given various dose levels appeared somnolent and lethargic after acute dosing, but 
those given the lowest dose of DZNep rapidly recovered and appeared normal during the rest of 
the treatment period. Body weight development was disturbed in all surviving animals during 
the study period. The relative body weight values decreased to the study day 3, followed by an 
increase until the end of the study. Also, these surviving rats showed to have a relative small 
kidney compared to the control rats.  
 
4.3.2 NOAEL determination for DZNep solution in rats 
In UDP experiments, all the three rats intravenously administered with 20 mg/kg 
DZNep survived during the entire study period. But, this dose induced distinctly clinical signs 
of toxicity during 14-day observation and markedly macroscopically visible change. Thus, this 
dose size was chosen to administer to rats as the high dose group, followed by those receiving 
10 and 15 mg/kg DZNep as the low and medium dose groups. None of the rats showed any 
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visible signs of morbidity and all the animals survived during the experimental period. Four rats 
in the high dose group and one in the medium group appeared lethargic and low body posture 
and decreased in spontaneous motor activities but could be aroused by prodding within three 
days post-dose. Then, they recovered and appeared normal during the recovery period. In 
contrast, no acute clinical signs were observed at the low dose and control groups. 
The changes in relative body weight of rats treated with 5% glucose solution (control) 
and DZNep against time points are depicted in Figure 4.1. There was a progressive increase in 
weight of rats treated with 5% glucose solution in a time-dependent manner (the mean growth 
rate = 3.19% per day). Administration of 20 mg/kg DZNep not only markedly reduced the 
relative weight of the rats compared to the initial weight (-2.0 %, -4.9 % and -1.2 %) in the first 
three days post-treatment, but also suppressed the weight growth rate to 2.56% per day from the 
third day onwards postdose. In contrast, the 15 mg/kg DZNep dose just slowed down the body 
weight growth rate in the first two days and, then the growth rate subsequently returned to 
normal (3.18% per day). In total, the high dose severely compromised the weight growth (p < 
0.01), while 15 mg/kg dose level mildly weakened the weight growth (p < 0.05). Importantly, 
administration of DZNep at a dose of 10 mg/kg did not cause any appreciable change in the 
body weight and body weight growth rate (3.29% per day) when compared to the control.  
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Figure 4.1 Mean relative body weight gain-time profiles of SD rats for 14 days following i.v. 
injection of DZNep solution at the doses of 0 (control), 10, 15, 20 mg/kg. Each value represents 
mean ± SD (n = 5). The dotted line (0%) indicates no body weight gain compared with the 
initial body weight. The double and single asterisks represent significant difference from control 
at p < 0.01 and p < 0.05, respectively. 
 
The effect of DZNep on major organ weights is summarized in Table 4.2. The ratio of 
kidney weight to the body weight (expressed as gram per 100 gram body weight) was 
significantly decreased (p < 0.01), but no changes in other organ weight were found, in rats 
treated with 20 mg/kg of DZNep at 14th day postdose compared to the control rats. 
Additionally, no changes in all organ weight and organ size were detected in rats with the other 






Table 4. 2 Effect of DZNep in various dose levels on relative organ weights in the SD rats (n = 
5). 
Relative organ weight (g.100 gTissue weight) 
Dose (g.kg-1 BW) Heart  Liver Spleen Lung  Kidney 
control 0.30 ± 0.02 4.31 ± 0.21 0.24 ± 0.02 0.35 ± 0.03 0.79 ± 0.06 
10 0.28 ± 0.02 4.34 ± 0.25 0.23 ± 0.03 0.34 ± 0.05 0.77 ± 0.03 
15 0.28 ± 0.01 4.42 ± 0.19 0.23 ± 0.02 0.39 ± 0.04 0.73 ± 0.04 
20 0.29 ± 0.03 4.17 ± 0.15 0.23 ± 0.03 0.36 ± 0.03 0.62 ± 0.05**
** Significant difference from control at p < 0.01. 
 
The changes in serum clinical chemistry parameters of rats treated with DZNep at three 
doses on the second day and fourteenth day postdose are depicted in Table 4.3. Significant 
increases in serum BUN and Cr in rats treated with 20 mg/kg DZNep were observed compared 
to the control group at the 2nd day and 14th day post-treatment while these significant increases 
were found with 15 mg/kg DZNep only at the 2nd days. The increased BUN was out of the 
reference range while the increased Cr was still within the normal range. In contrast, no 
significant changes occurred in serum BUN and Cr at the dose of 10 mg/kg DZNep. Moreover, 
10 mg/kg DZNep intravenously administered dose was not found to induce any renal 
dysfunction in rats. In addition, other clinical chemistry parameters were within the reference 










Table 4.3 Effect of DZNep in various dose levels on clinical chemistry parameters in the SD 
rats (n = 5) 
 
Second day Item unit Ref. 
Range Control 10 mg.Kg-1 15 mg.Kg-1 20 mg.Kg-1 
ALP U/L 70-450 294.0 ± 26.9 314.3 ± 40.4 307.8 ± 44.4 310.7 ± 52.3 
AST U/L 20-100 80.4 ± 9.0 76.8 ± 8.3 70.4 ± 8.1 72.4 ± 5.9 
ALT U/L 10-80 48.9 ± 6.5 52.1 ± 7.2 46.9 ± 8.2 47.1 ± 6.8 
Total protein g/L 50-80 58.0 ± 4.4 62.7 ± 4.4 59.0 ± 7.8 57.4 ± 6.4 
Albumin g/L 30-50 36.9 ± 1.3 37.6 ± 1.2 38.4 ± 1.2 38.3 ± 0.8 
Bilirubin-D mg/dL 0-0.2 0.026 ± 0.006 0.038 ± 0.013 0.029 ± 0.016 0.041 ± 0.016 
Bilirubin-total mg/dL 0.2-0.5 0.26 ± 0.02 0.27 ± 0.02 0.27 ± 0.01 0.25 ± 0.02 
BUN mg/dL 10-21 18.68 ± 3.68 18.98 ± 1.17 24.90 ± 2.06 * 32.49 ± 3.38 **
Creatinine mg/dL 0.1-0.8 0.17 ± 0.03 0.18 ± 0.03 0.24 ± 0.05 * 0.30 ± 0.05 ** 
Fourteenth day Item unit Ref. 
Range Control 10 mg.Kg-1 15 mg.Kg-1 20 mg.Kg-1 
ALP U/L 70-450 301.3 ± 38.1 293.7 ± 40.3 278.5 ± 45.6 301.9 ± 38.9 
AST U/L 20-100 68.4 ± 6.3 73.4 ± 7.4 70.9 ± 10.7 75.4 ± 11.3 
ALT U/L 10-80 48.3 ± 5.5 48.7 ± 6.7 46.9 ± 9.4 55.4 ± 8.2 
Total protein g/L 50-80 62.2 ± 4.9 60.3 ± 4.8 61.5 ± 6.4 62.5 ± 6.3 
Albumin g/L 30-50 39.4 ± 1.6 38.9 ± 1.1 39.4 ± 0.8 39.9 ± 2.2 
Bilirubin-D mg/dL 0-0.2 0.037 ± 0.011 0.033 ± 0.013 0.034 ± 0.014 0.037 ± 0.010 
Bilirubin-total mg/dL 0.2-0.5 0.27 ± 0.03 0.27 ± 0.01 0.26 ± 0.03 0.26 ± 0.02 
BUN mg/dL 10-21 17.38 ± 1.43 18.30 ± 2.59 18.04 ± 4.00 24.88 ± 3.12 **
Creatinine mg/dL 0.1-0.8 0.20 ± 0.03 0.20 ± 0.03 0.19 ± 0.05 0.27 ± 0.04 * 
** Significant difference from control at p < 0.01. 
* Significant difference from control at p < 0.05. 
Ref. range: reference range supplied by the NUS Vivarium at the Centre for Life Science. 
 
The hematological parameters of rats treated with various doses of DZNep are shown in 
Table 4.4 to assess the possible blood side-effect as a function of the DZNep at a dose-
dependent manner. DZNep treatments in all the groups revealed insignificant changes in rat 








Table 4.4 Effect of DZNep in various dose levels on Hematological parameters in the SD rats 
(n = 5) 
 
Second day Item unit Ref. 
Range Control 10 mg.Kg-1 15 mg.Kg-1 20 mg.Kg-1 
WBC K/uL 3.10-16.10 5.37 ± 0.66 4.75 ± 0.71 5.27 ± 0.80 4.74 ± 0.99 
NEU K/uL 0-4.20 0.40 ± 0.09 0.44 ± 0.08 0.55 ± 0.10 0.62 ± 0.06 
LYM K/uL 2.20-12.0 4.95 ± 1.40 4.27 ± 1.72 5.06 ± 1.38 4.14 ± 1.61 
Mono K/uL 0-0.7 0.33 ± 0.10 0.43 ± 0.11 0.39 ± 0.09 0.35 ± 0.08 
EOS K/uL 0-0.5 0.19 ± 0.05 0.21 ± 0.06 0.15 ± 0.06 0.22 ± 0.09 
BASO K/uL 0-0.1 0.09 ± 0.03 0.09 ± 0.04 0.10 ± 0.03 0.08 ± 0.02 
RBC M/uL 6.39-8.90 6.89 ± 0.26 6.92 ± 0.29 6.66 ± 0.45 6.92 ± 0.62 
HGB g/dL 12.9-16.4 14.07 ± 0.74 13.78 ± 0.36 13.81 ± 0.59 14.49 ± 0.33
HCT % 31.2-50.8 39.98 ± 4.30 38.97 ± 2.84 40.45 ± 3.44 44.06 ± 3.95
MCV fL 52.4-69.1 60.17 ± 3.43 57.72 ± 3.91 58.79 ± 1.79 60.25 ± 2.55
MCH pg 16.5-22.1 21.28 ± 0.39 20.73 ± 0.80 20.93 ± 0.67 21.14 ± 1.18
MCHC g/dL 29.6-34.1 33.00 ± 0.48 33.18 ± 0.65 33.13 ± 0.67 32.87 ± 0.85
RDW % 0-99.9 14.19 ± 0.70 14.36 ± 0.55 14.71 ± 0.65 14.14 ± 0.60
platelet count K/uL 595-1424 902 ± 94 922 ± 49 945 ± 87 970 ± 90 
MPV fL 0-99.9 5.72 ± 0.38 5.89 ± 0.57 5.36 ± 0.63 5.53 ± 0.51 
Fourteenth day Item unit Ref. 
Range Control 10 mg.Kg-1 15 mg.Kg-1 20 mg.Kg-1 
WBC K/uL 3.10-16.10 5.90 ± 1.04 5.51 ± 1.47 5.67 ± 1.07 5.68 ± 1.01 
NEU K/uL 0-4.20 0.41 ± 0.04 0.43 ± 0.07 0.36 ± 0.02 0.59 ± 0.11 
LYM K/uL 2.20-12.0 5.33 ± 1.80 5.15 ± 1.23 5.98 ± 1.54 6.16 ± 2.00 
Mono K/uL 0-0.7 0.31 ± 0.08 0.34 ± 0.07 0.37 ± 0.08 0.37 ± 0.07 
EOS K/uL 0-0.5 0.20 ± 0.06 0.18 ± 0.04 0.19 ± 0.06 0.28 ± 0.07 
BASO K/uL 0-0.1 0.09 ± 0.03 0.09 ± 0.01 0.10 ± 0.02 0.10 ± 0.03 
RBC M/uL 6.39-8.90 7.16 ± 0.41 7.49 ± 0.46 7.35 ± 0.19 7.20 ± 0.44 
HGB g/dL 12.9-16.4 14.53 ± 0.62 14.16 ± 0.37 14.58 ± 0.66 14.03 ± 0.75
HCT % 31.2-50.8 42.45 ± 3.99 40.10 ± 6.41 41.04 ± 1.63 39.11 ± 4.04
MCV fL 52.4-69.1 58.90 ± 2.48 59.53 ± 4.07 58.06 ± 2.02 60.50 ± 1.78
MCH pg 16.5-22.1 20.62 ± 0.53 20.91 ± 0.59 20.85 ± 0.39 20.25 ± 1.55
MCHC g/dL 29.6-34.1 32.97 ± 0.23 33.45 ± 0.98 33.13 ± 0.83 32.63 ± 1.59
RDW % 0-99.9 14.36 ± 0.93 14.82 ± 0.86 15.05 ± 0.77 14.76 ± 1.07
platelet count K/uL 595-1424 964 ± 63 939 ± 45 1002 ± 107 974 ± 74 
MPV fL 0-99.9 5.64 ± 0.45 5.91 ± 0.58 5.51 ± 0.36 5.97 ± 0.48 
Treatment with DZNep at the above doses showed no significant difference.  
Ref. range: reference range supplied by the NUS Vivarium at the Centre for Life Science. 
 
4.4 Discussion 
Identification of the LD50 and NOAEL of DZNep using acute toxicity method would aid 
in the selection of starting doses for the preliminary pharmcokinetics and disposition studies 
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and antitumor activity studies of DZNep in SD rats. Acute toxicity studies also provide 
information relevant to target organs of toxicity (253). 
As a animal-saving method, the UDP method has been widely used in the acute toxicity 
of intravenous administration in animals (254, 255). Thus, the acute toxicity of DZNep was 
examined in rats administered intravenously within 2 weeks. The median lethal dose (LD50), 
using the UDP method, was found to be around 26 mg/kg with the 95% confidence interval 
from 20.59 to 28.5 mg/kg DZNep (Table 4.1). This result demonstrates that DZNep is 
considerably toxic to rats, which may result in the low therapeutic index of this compound in 
the potential clinical application. However, because small numbers of animals are used in the 
UDP method, the actual level of confidence interval for the LD50 is generally not exact (256). 
A dose-dependent body weight loss was found in the rats intravenously administered 
with DZNep (Figure 4.1). Administration of 20 mg/kg DZNep remarkably compromised the 
weight growth rates of rats (2.56% per day) and even decreased the actual weight of the rats in 
the first three days, whereas 10 mg/kg DZNep did not lead to any appreciable change in the 
body weight and body weight growth rate (3.29% per day) when compared to the control. 
Generally, the weight loss caused by high doses in rats may be due to enhanced catabolism, loss 
of body fluid due to gastrointestinal toxicity, and reduction in food and water intake at different 
time points. Together with the toxic symptoms such as fatigue and loss of appetite, a fairly well 
known damaging-mitochondria effect of nucleoside analogues may be the reason. Numerous 
studies have indicated that nucleoside analogues tend to interfere in the synthesis of essential 
proteins via depleting mitochondrial DNA and disrupt the electron respiratory chain (158, 159). 
Thus, the fatigue symptoms of the tested animals may be due to the decreased ATP synthesis. 
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Significant increases in serum BUN and Cr in rats were associated with 20 mg/kg 
DZNep dose but not with 10 mg/kg DZNep dose (Table 4.3). Detectable changes in the serum 
levels of BUN and Cr were reported when a significant kidney function was lost (257). 
Together with the macroscopically visible decrease of kidney size at the dose higher than 20 
mg/kg and the decreased relative kidney weight in a dose-dependent manner (Table 4.2), it was 
concluded that DZNep caused nephrotoxicity and renal atrophy in rats in a dose-dependent 
manner in a 14-day observation period. In addition, the nephrotoxicity caused by DZNep in rats 
may not be related to the immunological reactions, which are generally not dose-dependent and 
do not occur until after a certain period of time (258). Of notice, it is consistent with the 
previous in vitro finding that a number of genes in inflammation and immunity network are not 
sensitive to the DZNep related treatment in the normal cells as their expression is not regulated 
by EZH2 (Chapter 2, section 2.3.6). However, the underlying mechanism of DZNep-induced 
nephrotoxicity remains obscure and needs to be further examined through investigation of 
microscopical renal changes and intracellular structural changes by histopathological techniques 
and electron-microscopy in a future study. In addition, DZNep treatments in the dose range of 
this study had insignificant effect on the hematological system of rats (Figure 4.4). This result 
was contrary to the observation with the ribavirin, another nucleoside analog, which was found 
to induce severe anemia, facilitated by being enriched and phosphorylated in the erythrocytes in 
rats (30 mg/kg body weight) or monkeys (10 mg/kg body weight) after intravenous 
administration (161, 163, 164). Therefore, the minimal toxicity of DZNep in the haematological 
system of rat may attribute to the low distribution of drug in erythrocytes and bone marrow or 
the relative resistance of drug to the nucleoside phosphotransferases.  
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Based on the various endpoints obtained, including body weight change, organ weight 
change, clinical signs, hematological parameters and clinical chemistry parameters, 
administration of DZNep to SD rats at a dose as high as 10 mg/kg body weight did not cause 
any obvious signs of toxicity or mortality. Therefore, a no-observable-adverse-effect-level 
(NOAEL) of DZNep was concluded to be 10 mg/kg body weight, the highest single safe dose 
tested in SD rats with intravenous bolus injection.  
In summary, DZNep caused nephrotoxicity and renal atrophy in rats in a dose-
dependent manner, but had no apparent effect on the hematological system of rats. The 
median lethal dose (LD50) was around 26 mg/kg DZNep. A NOAEL of DZNep was 
determined to be 10 mg/kg body weight, based on various toxicity endpoints. The 
present finding provides valuable information regarding initial safe dose and target 
organs for toxicity, which serves as a firm basis for further investigation of DZNep in 
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3-deazaneplanocin A (DZNep), a cyclopentanyl analog of 3-deazaadenosine that was 
first synthesized by Glazer et al. (259), has broad and potent antiviral activity (117, 218). 
Recently, DZNep appears to be a unique chromatin remodelling (epigenetic) compound that can 
deplete the cellular EZH2 proteins, which is abnormally overexpressed in varied metastatic 
cancer (44, 45) and inhibit the associated histone methylation (63, 64, 68). In turn, it can 
effectively reverse EZH2 and histone methylation-mediated gene silencing and induces cancer 
cell death but not in corresponding normal cells with normal EZH2 expression. Hence, DZNep 
may hopefully open the therapeutic potential via inhibiting this epigenetic regulator. By far, 
DZNep has not been extensively investigated using animal models. Thus, a sensitive and 
reliable assay is needed for quantifying DZNep in animal biosamples.  
In previous study, the Lower Limit of Quantification (LLOQ) of the radiolabeling 
DZNep in mice was in the picomolar range using in-line radiochemical flow detection (152). 
However, the inherent costs and safety issues of radiolabeling technique make this assay 
impractical and unfeasible during the early drug discovery and optimization processes. 
Additionally, the pharmacokinetic and disposition properties of intact DZNep could not be 
distinguished only by a radioassay method. To specifically quantify non-radioactive DZNep in 
rat biological fluids, a sensitive liquid chromatography coupled with electrospray 
ionization/tandem mass spectrometry (LC-ESI-MS/MS) method has been employed in this 
study. In addition, the protein precipitation (PPT) for the extraction of DZNep from plasma and 
tissue samples was reported (152). Although PPT is a quick and simple technique, it fails to 
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sufficiently remove enough endogenous interference in the biosamples, which could cause 
variability in analyte signal intensity in a mass spectrometer (260). Here, a solid phase 
extraction (SPE) technique using Bond Elute phenylboronic acid (PBA)-SPE cartridges (Varian, 
Palo Alto, CA) specifically for the purification of compounds containing vicinal hydroxyl 
groups, was evaluated to reduce endogenous interference, and minimize the matrix effect of 
DZNep in rat biosamples. To achieve good retention and minimize peak tailing of DZNep, a 
hydrophilic interaction chromatography (HILIC) column, a powerful tool in bioanalysis of 
numerous polar compounds coupled with MS/MS detection (178), was applied. The purpose of 
the present work was to develop and validate a sensitive, selective and reliable LC-MS/MS 
method for the quantification of DZNep in rat biosamples.  
 
5.2 Materials and methods 
5.2.1 Chemical reagents and animals 
3-deazaneplanocin A (DZNep, purity > 99%) was purchased from OKeanos Tech. Co. 
(Beijing, China). Tubercidin (purity >99%) was from Sigma (St. Louis, MO, USA). HPLC 
grade acetonitrile was obtained from TEDIA (Fairfield, USA). Deionized water was purified 
using a Milli-Q system (Millipore, Milford, MA, USA). All other chemicals and solvents used 
were obtained from standard vendors, and were of the highest quality available. The Sprague 
Dawley (SD) rats were supplied by Laboratory Animal Center (National University of 
Singapore, Singapore), and housed in temperature controlled room (25OC) with a 12-h light-
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dark cycle. The study was approved by the Animal Ethics Committee of National University of 
Singapore. 
5.2.2 Instrument 
A LC-MS/MS system used was composed of a series 1200 HPLC instrument (Agilent 
Technologies, Palo Alto, CA, USA) with a Q TrapTM 3200 hybrid triple quadrupole linear ion 
trap mass spectrometer (Applied Biosystems/MDS Sciex, Concord, Ontario, Canada). Data 
processing was performed with AnalystTM 1.4.2 software package (Applied Biosystems). 
5.2.3 Chromatographic conditions 
The elution of DZNep in reversed-phase (RP) HPLC was previously performed using an 
isocratic mobile phase with very low organic solvent (4% acetonitrile) (152). Thus, several RP 
HPLC columns including Zorbax Eclipse XDB column-C8, C18, phenyl, CN, Zorbax SB-Aq 
and a Hydrophilic interaction chromatography column (2.1 X 50 mm, Zorbax HILIC plus, 
Agilent) were screened for the analysis of DZNep. All RP columns used were of 3 X 50 mm 
dimension with 5 µm particle size. The mobile phase consisted of 10% solvent A (H2O, 0.1% 
formic acid) and 90% solvent B (acetonitrile, 0.1% formic acid) at a flow rate of 0.3 mL/min. 
10 µl of DZNep standard solution was injected onto each column with isocratic elution. The 
capacity factors (k’) of DZNep on the columns was calculated according to the equation: K’ =  
(tr - tm)/tm, where tr is the time required for analyte to elute from a column; tm is the time 
required for the mobile phase to travel the entire length of the column.  
Finally, the chromatographic separations of DZNep were performed on a Hydrophilic 
interaction chromatography column (2.1 X 50 mm, Zorbax HILIC plus, Agilent) with a Silica 
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Security Guard Cartridge (3.0 X 4 mm, Phenomenex). The mobile phase was made up of 
solvent A (H2O, 0.1% formic acid) and B (acetonitrile, 0.1% formic acid) at a flow rate of 0.3 
mL/min, according to the elution programs listed in Table 5.1 for the separation of all 
biosamples. The chromatographic run time of each sample was 12 min. The temperatures of 
column and autosampler were both maintained at ambient temperature (25 OC). A 10 µl full 
loop sample injection was used.  
Table 5.1  LC program for chromatographic separation for all biological samples 
Time (min) Solvent A (%) Solvent B (%) 
0.00 9.0 91.0 
0.10 9.0 91.0 
0.11 20.0 80.0 
5.00 20.0 80.0 
5.01 9.0 91.0 
12.00 9.0 91.0 
12.01 pump stop  
Solvent A (%) represented the proportion of aqueous phase (H2O, 0.1% formic acid); Solvent B 
(%) represented the proportion of organic phase (acetonitrile, 0.1% formic acid). The flow rate 
was 0.3 mL/min. 
5.2.4 Mass spectrometric conditions 
The mass spectrometer was operated using ESI source in the positive ion detection. In 
order to optimize all the MS parameters, standard solutions (1 µg/mL) of the analyte and IS 
were infused into the mass spectrometer at a flow-rate of 10 µL/min using a Harvard model 22 
syringe pump (Harvard Apparatus, South Natick, MA). The optimized instrument parameters 
for monitoring DZNep and tubercidin were as follows: source temperature (TEM), 400OC; 
turbo spray voltage (IS), 4500 V; curtain gas (CUR), 10; Nebulising gas (GS1), 30; 
turboionspray gas (GS3), 30; collision gas (CAD), medium; declustering potential (DP), 50 V 
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(DZNep) and 41 V (tubercidin); entrance potential (EP), 7 V (DZNep) and 8.5 V (tubercidin); 
collision energy (CE): 29 eV (DZNep) and 27 eV (tubercidin);  collision cell exit potential 
(CXP), 4 V (both). Quantification was performed using the multiple reaction monitoring (MRM) 
mode with the following transitions: m/z 263.3/135.1 for DZNep, and m/z 267.2/135.0 for 
tubercidin (IS), respectively, with a dwell time of 200 ms. Representative product ion mass 
spectra of these compounds are shown in Figure 5.1. The mass spectrometer was operated at 
unit mass resolution for both Q1 and Q3 quadrupoles. 
5.2.5 Preparation of calibration standards and quality control (QC) 
samples 
Calibration standards at final concentrations of 20, 50, 200, 800, 2000, 8000, 10000 
ng/mL of DZNep were prepared by spiking an appropriate quantity of the intermediate DZNep 
solution in blank plasma, urine and feces samples, while 20, 50, 100, 500, 1000, 5000 ng/mL of 
DZNep in blank tissue samples. The limit of quantification (LLOQ) QC  , low QC, medium QC, 
high QC were prepared at 20, 30, 500, 7500ng/mL of DZNep in rat plasma, urine and feces 
samples, while at 20, 30, 300, 3000 ng/mL in tissue samples. In addition, the dilution QC 
samples were prepared at 40000 ng/mL of DZNep with fivefold dilution for plasma and tenfold 
dilution for urine. All standards and QC samples were spiked with 100 ng/mLof IS and then 
stored at 4 oC before analysis.  
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5.2.6 Sample preparation 
200 µL of rat blood samples in heparinized 1.5 mL microtubes were centrifuged for 10 
min at 2000 x g at 10 OC to separate plasma samples. Tissue samples (heart, liver, spleen, lung, 
kidney, stomach, adipose, muscle, brain) harvested from sacrificed rats were rinsed with ice-
cold 0.9 % NaCl saline and then gently blotted with absorbent paper. The tested tissues and 
feces were firstly minced or crushed to pieces in ice bath. Then 0.2 g tissues and feces were 
added with 1 mL deionized water and crushed by a Diax 900 homogenizer (Heidolph, 
Germany). IS working solution was added to aliquots of 100 μL of biosamples (plasma, urine, 
and homogenized feces and tissues) to obtain the final concentration of 100 ng/mL. Then, the 
biosamples were mixed with 1 mL of 0.2 M ammonium acetate buffer (pH 9.0). The Bond Elute 
PBA-SPE cartridges (Varian, Palo Alto, CA) were preconditioned by consecutive washing with 
1 mL methanol, 1 mL 0.1 M formic acid, and 1 mL 0.2 M ammonium acetate buffer (pH 9.0). 
The biosample mixtures were loaded into the column. Then, the columns were washed thrice 
with 1 mL 0.2 M ammonium acetate buffer (pH 9.0). Samples were eluted with 1.5 mL 0.1 M 
formic acid and freeze-dried overnight using a lyophilizer (Labconco, Kansas City, MO). 
Following this, the freeze-dried residues were reconstituted in 100 μL reconstitution solution 
(80% solvent B plus 20% solvent A), and 10µL was injected onto column for analysis. 
5.2.7 Method validation 
The method validations for rat biological samples (plasma, urine, feces and tissue) were 
carried out in a similar way as follows. 
The selectivity of the method was evaluated by comparing the chromatograms of five 
blank samples with the corresponding spiked samples at the LLOQ level. The peak areas of 
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endogenous compounds co-eluting with DZNep should be less than 20% of the peak area of the 
LLOQ standard. 
The calibration curves were fitted by a weighted (1/y2) least squares linear regression 
method through the measurement of the peak-area ratio of the DZNep to IS. The coefficient of 
determination (r2) greater than 0.99 was set for acceptable linearity of calibration curves. The 
accuracy and precision at the LOQ for each biosample were required within 20% of the nominal 
concentration and less than 20.0 % RSD (n=5), respectively. 
Matrix effect was evaluated at low, medium and high QC concentrations as shown in 
Section 2.5. Two groups of samples (n=5) were prepared: (A) DZNep dissolved in the 
reconstitution solution; (B) DZNep spiked after extraction of blank biosamples (post-extraction). 
Matrix effect was calculated as the percentage ratio of the response of B to A. The same 
evaluation was performed for IS at the concentration of 100 ng/mL in each biological sample. 
Additionally, to further pinpoint the location of the interference that causes matrix effects, the 
post-column infusion was performed by continuous infusion of DZNep (100 ng/mL, in the 
reconstitution solution) at a flow rate of 10µl/min using a Harvard syringe pump and single 
injection of the reconstitution solution and blank biosample extracts on the column. Then, the 
eluent from the HPLC column and the flow from the infusion pump were combined with a zero-
dead-volume ‘T’ union and introduced into the source of the mass spectrometer. Injection of the 
reconstitution solution generated the ‘baseline’ profile. Any deviation from the ‘baseline’ 
caused by injecting the blank biosample extracts indicated the existence of matrix effects. The 
‘valleys’ in the resulting chromatograms indicate the retention windows of signal suppression, 
while the ‘peak’ means signal enhance. 
 116
 The extraction recovery of DZNep at three concentration levels (low, medium and high) 
in biosamples using the SPE procedure was evaluated by comparing two groups of control 
samples: (B) DZNep spiked after extraction of blank biosamples (post-extraction); (C) DZNep 
spiked to normally prepared blank biosamples (pre-extraction). Extraction recovery was 
calculated as the percentage ratio of the response of C to B. The extraction recovery of the IS at 
the concentration of 100 ng/mL was determined in a similar way. 
To evaluate the precision and accuracy of the method, Intra-day accuracy and precision 
of five replicates of QC samples at the each concentration level was analyzed within the same 
day. Inter-day accuracy and precision evaluated at the same QC samples was carried out on 
three consecutive days. Accuracy was calculated as the percentage ratio of the mean of the 
measured concentration to the spiked concentration. Precision was expressed by relative 
standard deviation (RSD) of the measured concentrations. The accuracy and precision were 
required within 15% of the nominal concentrations and less than 15 % RSD, respectively. Five 
replicates of plasma and urine dilution QC samples were measured after a fivefold dilution with 
blank plasma and tenfold dilution with blank urine, respectively, to assess the dilution integrity. 
An extracted blank sample was placed after the upper limit of quantitation (ULOQ) standard to 
determine the carry-over of the LC-MS/MS system. 
The stability tests were designed to cover the anticipated conditions that clinical samples 
may experience. The stability of DZNep in rat biosample (n=5) was evaluated at three 
concentration levels (low, medium and high). The analytes were considered stable when the 
accuracy was within 15% of the spiked concentration and the precision was below 15%. For 
freeze-thaw stability, QC samples were stored at -20OC for 24 h and thawed unassisted at room 
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temperature. When completely thawed, the samples were refrozen at -20OC for over 24 h. The 
freeze-thaw cycles were repeated two more times in 4 weeks, and then QC samples were 
extracted and analyzed on the third cycle. Short-term temperature stability was assessed by 
analyzing QC samples, which were kept at ambient temperature (25OC) for 12 h before sample 
preparation. The post-preparative stability of QC samples was analyzed by re-injecting QC 
sample prepared under autosampler condition (25OC) 5 times in 24 h.  
 
5.3 Results  
5.3.1 Optimization of the mass spectrometric conditions 
Figure 1 shows the MS/MS spectra of both DZNep and IS. Mass spectrometer analysis 
was set up in the multiple reaction monitoring (MRM) mode in positive polarity. The MRM 
transition of m/z 263.3/ 135.1 and m/z 267.2/ 135.0 were selected for DZNep and IS, 
respectively. The other MS parameters were optimized to enhance the sensitivity of two 
compounds as shown in section 2.4. 
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Figure 5.1 Representative product ion mass spectra and chemical structure of DZNep (A) and 
tubercidin (B), respectively. For mass spectrometer conditions, see section 5.2.4. 
 
5.3.2 Optimization of the chromatographic conditions 
The capacity factors (k’) of DZNep on the RP columns including Zorbax Eclipse XDB 
column- C8, C18, phenyl and CN and Zorbax SB-Aq, were less than 1 at a mobile phase of 
90% solvent B (Table 5.2).Using the same conditions as described in Section 2.3, an adequate 
retention, 7.5 ± 0.2 min (k’ = 11.93) was obtained in the Zorbax HILIC plus column.  
 119
Table 5.2 The capacity factors (k’) of DZNep on the columns (n = 3) 
 
Column k' 
Eclipse XDB column- C8 0.60 ± 0.08 
Eclipse XDB column- C18 0.41 ± 0.08 
Eclipse XDB column- phenyl 0.92 ± 0.14 
Eclipse XDB column- CN 0.60  ± 0.08 
Zorbax SB-Aq 0.64 ± 0.14 
Zorbax HILIC plus 11.93 ± 0.20 
 
The retention time of tubercidin (4.5 ± 0.3 min) was closer to that of DZNep 
(6.1 ± 0.3 min) compared to ribavirin (4.1 ± 0.3 min) using the optimized gradient 
elution condition (Table 5.1). Thus, tubercidin, a nucleoside analogue structurally 
similar to DZNep, was chosen as the IS. Using a gradient elution as specified in Table 
5.1, appropriate peak shape and minimal matrix effects for DZNep and IS were 
achieved on the HILIC column (Figure 5.2C and D). It took seven minutes to re-
equilibrate the mobile phase to initial level and remove the potential remaining 
endogenous component after SPE preparation. Thus, the total HPLC analysis time was 
12 min.  
5.3.3 Optimization of sample preparation conditions 
The extraction of DZNep from rat biosamples was performed using the Bond Elut PBA 
SPE columns. The extraction recovery was around 80% and the matrix effect was around 90% 
(Table 5.4).  
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5.3.4 Method evaluation 
5.3.4.1 Selectivity and calibration model 
Injection of blank rat biosamples from 6 different sources to evaluate the selectivity, 
showed no interference signals presented at the location of DZNep and IS peaks (Figure 5.2 A - 
B and Figure S3 and S4). Furthermore, as shown in Figure 5.2C and Figure S5, the elution time 
for DZNep and IS in rat biosamples found 6.1 ± 0.3 min and 4.5 ± 0.3 min, respectively. As 
shown in Table 5.3, the r2 values were found greater than 0.99 in all biosamples. The back-
calculation results for all calibration standards showed less than 10% RSD and were within 15% 
of the nominal concentration (data not shown). As for 20 ng/mL DZNep samples, the RSD was 
lower than 20% (7.4 to 19.4%) and the accuracy was within 20% of the nominal values (Table 
5.3). Measurements of the lower concentration at 15 ng/mL resulted more often in outliers. 
Therefore, the LLOQ of DZNep in this method was set at 20 ng/mL.   
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Figure 5.2 Mass chromatograms of DZNep and tubercidin in plasma (left column) and kidney 
(right column) samples under MRM mode: (A) Mass chromatograms of DZNep in blank 
plasma and kidney samples (m/z, 263.3 / 135.1); (B) Mass chromatograms of IS in blank plasma 
and kidney samples (m/z, 267.2 / 135.0); (C) LLOQ Plasma and kidney samples spiked with 
DZNep at 20 ng/mL and IS at 100 ng/mL; (D) a plasma sample and a kidney sample obtained at 
1h after an intravenous dose of 5 mg/kg DZNep administered in a rat. 
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Table 5.3 The coefficient of determination (r2) of calibration curves for DZNep concentration in 
rat biosamples and precision and accuracy of LLOQ samples (n = 5) 
 
LLOQ (20 ng/mL) 
Biosamples r2 Accuracy (%) Precision (%) 
Plasma 0.9996 97.7-118.2 7.4 
Urine 0.9981 82.1-105.7 9.8 
Feces 0.9982 81.7-116.3 11.8 
Heart 0.9991 91.5-114.7 13.4 
Liver 0.9999 89.7-114.5 16.1 
Spleen 0.9986 89.2-114.9 11.8 
Lung 0.9986 81.3-111.1 14.2 
Kidney 0.9997 81.1-113.0 19.4 
Stomach 0.9992 94.8-111.5 13.8 
Adipose 0.9994 80.3-113.8 15.1 
Muscle 0.9996 86.9-115.4 15.2 
Brain 0.9983 83.4-106.2 10.6 
 
5.3.4.2 Matrix effect and Recovery 
Evaluation of the mean peak areas of DZNep in the reconstitution solution compared to 
those of the biosample extracts showed matrix effects in all the biosamples ranging within 84.8 
– 94.7% at various QC biosamples (Table 5.4). For the 100 ng/mL of IS, similar matrix effects 
were found ranging from 85.4 to 93.0% (Table 5.4). Figure 5.3A - C represents the overlaid 
infusion chromatograms for DZNep from injections of representative blank biosamples (plasma, 
urine and kidney) and reconstitution solution. Figure 5.3D is a similar overlaid infusion 
chromatogram for IS from the injection of blank plasma and reconstitution solution. Since a 
gradient elution was employed as described in Table 5.1, the analyte MS response was changed 
along with the mobile phase change: higher MS response in a mobile phase with higher 
acetonitrile content. With a mobile phase containing 80%, the analyte MS response was about 
1/3 of that obtained with a mobile phase containing 91% acetonitrile. Evidently, compared to 
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the profiles obtained by injecting the reconstitution solution, the minimal matrix suppression 
appeared around the elution time of DZNep (6.1 ± 0.3 min) and IS (4.5 ± 0.3 min) in the 
representative blank biosamples (Figure 5.3). The extraction recovery of DZNep ranged from 
71.6 – 85.8% while that of IS ranged from 76.2 – 84.8% at 100 ng/mL, at various QC samples 
of tested biofluids (Table 5.4).  
 
Figure 5.3 Matrix effect profiles by post-column infusion of DZNep (100 ng/mL) while 
injecting extracted matrix blanks: (A) plasma; (B) urine; (C) kidney. The matrix effect profile of 
tubercidin (100 ng/mL) in plasma (D). The black traces were baseline profile injected with the 






Table 5.4 Matrix effect and extraction recovery of DZNep and IS in rat biosamples (n = 5) 
Biosample Drug Drug Conc. (ng/mL) Recovery (%) Matrix Effect (%) 
Plasma DZNep 30 79.9 ± 4.7 91.3 ± 8.0 
500 83.6 ± 5.8 86.0 ± 5.9  
7500 79.7 ± 8.2 91.1 ± 4.6  
Tubercidin 100 82.0 ± 7.7 88.5 ± 4.9 
Urine DZNep 30 78.2 ± 4.3 93.3 ± 3.9 
500 76.3 ± 5.5 94.7 ± 4.6  
7500 83.7 ± 4.1 92.1 ± 3.3  
Tubercidin 100 80.2 ± 4.0 86.1 ± 2.8 
Feces DZNep 30 85.8 ± 5.2 89.9 ± 5.4 
500 81.3 ± 7.1 90.9 ± 5.2  
7500 81.8 ± 7.4 88.3 ± 5.2  
Tubercidin 100 80.5 ± 7.7 85.4 ± 6.3 
Heart DZNep 30 79.9 ± 5.7 90.4 ± 5.3 
300 74.1 ± 8.4 86.8 ± 5.7  
3000 71.6 ± 8.3 86.1 ± 6.9  
Tubercidin 100 79.4 ± 4.5 90.4 ± 4.7 
Liver DZNep 30 79.3 ± 6.8 93.2 ± 5.6 
300 81.9 ± 5.8 90.6 ± 6.6  
3000 78.6 ± 7.2 91.0 ± 7.1  
Tubercidin 100 81.7 ± 7.1 88.0 ± 7.2 
Spleen DZNep 30 77.3 ± 7.8 93.0 ± 7.1 
300 81.8 ± 7.0 91.8 ± 4.7  
3000 79.2 ± 4.7 91.1 ± 5.6  
Tubercidin 100 76.6 ± 5.4 89.4 ± 5.5 
Lung DZNep 30 81.7 ± 8.9 91.0 ± 6.3 
300 76.1 ± 7.0 91.5 ± 5.7  
3000 80.0 ± 7.7 90.6 ± 7.2  
Tubercidin 100 79.2 ± 6.1 89.6 ± 5.5 
Kidney DZNep 30 74.9 ± 8.9 88.7 ± 8.0 
300 75.5 ± 10.0 88.2 ± 7.8  
3000 78.7 ± 8.2 90.1 ± 7.5  
Tubercidin 100 83.9 ± 7.6 90.7 ± 7.9 
Stomach DZNep 30 82.2 ± 9.4 91.2 ± 7.0 
300 78.0 ± 8.4 86.6 ± 6.8  
3000 77.0 ± 8.2 90.3 ± 6.7  
Tubercidin 100 76.4 ± 8.5 89.3 ± 6.5 
Adipose DZNep 30 79.6 ± 9.5 90.3 ± 7.9 
300 73.1 ± 5.6 93.1 ± 5.9  
3000 78.2 ± 10.5 88.7 ± 7.3  
Tubercidin 100 76.2 ± 7.7 93.0 ± 6.5 
Muscle DZNep 30 81.2 ± 4.6 92.7 ± 8.0 
300 82.7 ± 8.6 90.9 ± 6.6  
3000 85.7 ± 8.1 86.3 ± 7.5  
Tubercidin 100 82.6 ± 8.4 87.6 ± 5.5 
Brain DZNep 30 84.1 ± 7.3 90.9 ± 4.5 
300 82.5 ± 9.0 92.2 ± 5.9  
3000 82.9 ± 8.3 84.8 ± 7.5  
Tubercidin 100 84.8 ± 9.6 89.9 ± 5.8 
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5.3.4.3 Precision and accuracy of the method 
The precision and accuracy data are summarized in Table 5.5. The intra-day precision 
and inter-day precision values, expressed as RSD, were less than 10% at various concentrations 
of QC samples. In addition, the intra-day accuracy data were all within 96.8–108.7% while the 
inter-day within 93.9 – 103.2%. The dilution integrity was determined by measuring dilution 
QC samples (only plasma and urine) after a 5-fold dilution with blank plasma and 10-fold 
dilution with blank urine. As shown in Table 5.5, both intra-day and inter-day accuracy values 
in rat plasma and urine dilution QC samples ranged from 94.9 to 104.4%, while the precision 
from 5.4 to 8.5%.  No carry-over effect of the LC-MS/MS system was observed in the 














Table 5.5  Accuracy and precision of the method for the analysis of DZNep in rat biosamples   
(n = 5) 
Intra-day (n=5) Inter-day (n=5)  Biosample DZNep conc. (ng/mL)
Accuracy (%) Precision (%) Accuracy (%) Precision (%)
Plasma 30 101.3 7.8 96.6 7.2 
500 98.3 5 97.5 4.3 
7500 101.9 3.3 95.9 4.2  
40000* 98.9 5.4 94.9 5.5 
Urine 30 105.1 6.9 93.7 5.5 
500 103.4 6.4 97 5.8 
7500 101.4 3 97.9 4  
40000** 104.4 8.5 98.7 7.3 
Feces 30 100.7 3.5 103.2 4.3 
500 104.3 5.1 98.4 5.8  
7500 101.6 1.4 96.1 2.8 
Heart 30 99.8 5.9 96.3 4 
300 96.8 4.2 94.2 4.8  
3000 98.1 2.3 95.5 6.9 
Liver 30 101.9 4.7 97.7 5.5 
300 104.9 2.3 95.9 4.2  
3000 108.7 5.6 98.6 5.5 
Spleen 30 104.4 3.5 96.7 3.9 
300 102.5 3.4 95.8 4  
3000 101.8 4.9 96 3.8 
Lung 30 104 1.9 95 6.8 
300 104.7 4.6 97.5 6.9  
3000 105.9 2.8 101.6 4.4 
Kidney 30 101.2 5.6 96.8 7.5 
300 97.7 3.2 96.2 6.4  
3000 101.3 5.1 98.3 6 
Stomach 30 97.9 4.4 93.9 5 
300 100.8 6 95 2.7  
3000 101.1 5.3 94.6 2.6 
Adipose 30 98.7 6.4 97.2 9.7 
300 102.8 5.1 98.2 5  
3000 102.4 5.2 95 7.7 
Muscle 30 101.1 5.2 97.5 3.4 
300 102 5.9 97.3 9.6  
3000 106.8 4.8 98.6 8.4 
Brain 30 101.3 6.3 96.4 2.8 
300 102.8 3.6 93.8 4.3  
3000 104.2 4.6 94.6 4.3 
*After 5 x dilution with blank rat plasma;  ** After 10 x dilution with blank rat urine 
5.3.4.4 Stability of DZNep in rat biosamples 
As shown in Table 5.6, three freeze-thaw cycles and ambient temperature storage of the 
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QC samples, appeared to have little effect on the stability, with accuracy ranging from 87.9 to 
95.3%. Of the spiked concentrations, the accuracy ranged from 95.5 to 105.8% for short-term 
stability while that ranged from 96.1 to 102.9% for post-preparative stability.  
Table 5.6 Stability of DZNep in rat biosamples (n = 5) 
Biosample DZNep Conc. (ng/mL) Freeze-thaw cycles (%) Short-term (%) Post-preparative (%)
Plasma 30 94.1 ± 5.8 103.2 ± 2.2 102.0 ± 5.4 
500 95.6 ± 4.2 101.2 ± 6.7 98.6 ± 2.7  
7500 93.5 ± 5.2 95.5 ± 4.0 98.6 ± 3.6 
Urine 30 91.7 ± 4.2 95.9 ± 3.5 98.5 ± 1.7 
500 93.1 ± 7.8 96.6 ± 2.7 97.3 ± 2.7  
7500 93.3 ± 4.0 98.4 ± 1.2 99.7 ± 2.4 
Feces 30 94.6 ± 3.3 102.2 ± 3.7 98.9 ± 3.6 
500 92.4 ± 3.8 102.0 ± 5.5 94.4 ± 5.2  
7500 95.4 ± 1.6 99.2 ± 3.0 97.2 ± 2.3 
Heart 30 89.0 ± 4.4 97.9 ± 4.9 101.9 ± 4.6 
300 93.7 ± 4.9 98.2 ± 6.0 98.7 ± 6.7  
3000 90.4 ± 6.1 97.0 ± 5.4 102.9 ± 8.8 
Liver 30 92.6 ± 6.0 97.8 ± 7.5 101.0 ± 6.2 
300 93.3 ± 6.8 100.6 ± 6.9 101.9 ± 5.7  
3000 92.8 ± 8.9 101.7 ± 5.8 99.6 ± 7.4 
Spleen 30 89.87 ± 4.1 102.5 ± 6.5 98.0 ± 6.0 
300 93.58 ± 6.6 97.3 ± 4.2 100.3 ± 7.0  
3000 89.96 ± 6.0 105.8 ± 7.9 101.5 ± 7.3 
Lung 30 89.8 ± 4.7 98.7 ± 6.0 99.7 ± 5.7 
300 90.3 ± 5.7 96.9 ± 4.1 97.4 ± 5.0  
3000 91.5 ± 4.5 98.6 ± 4.9 100.3 ± 6.7 
Kidney 30 94.9 ± 7.2 100.1 ± 6.1 98.6 ± 6.4 
300 92.4 ± 4.6 98.6 ± 4.9 100.3 ± 5.1  
3000 87.9 ± 5.0 98.4 ± 5.5 96.6 ± 5.2 
Stomach 30 92.0 ± 3.6 97.9 ± 5.4 98.2 ± 8.2 
300 91.9 ± 2.6 98.7 ± 3.7 96.4 ± 4.2  
3000 89.8 ± 5.3 96.6 ± 3.5 99.1 ± 4.7 
Adipose 30 92.7 ± 4.5 97.8 ± 5.1 98.7 ± 5.3 
300 88.8 ± 2.3 98.4 ± 5.6 100.3 ± 7.6  
3000 90.8 ± 2.5 96.9 ± 4.2 100.6 ± 3.8 
Muscle 30 92.0 ± 4.8 98.2 ± 5.9 98.0 ± 4.4 
300 91.0 ± 5.6 95.8 ± 5.9 97.9 ± 5.9  
3000 93.5 ± 3.5 97.2 ± 3.2 97.5 ± 5.3 
Brain 30 95.3 ± 5.2 97.6 ± 5.5 96.1 ± 0.6 
300 90.1 ± 4.7 98.6 ± 7.1 96.6 ± 6.0  







The chromatograms for quantification of DZNep in plasma, urine, feces and tissue 
samples in rats intravenously administered 5 mg/kg DZNep are demonstrated in Figure 5.2D 
and Figure S6.  
 
5.4 Discussion 
To develop and validate a sensitive, selective and reliable LC-MS/MS method for the 
quantification of DZNep in rat biosamples, a number of chromatographic and MS conditions, 
and sample preparation need to be studied. 
First of all, the chromatographic conditions were optimized. The capacity factors (k’) of 
DZNep on several RP columns were less than 1 (Table 5.2), suggesting that the RP column is 
an improper separation tool for DZNep, a highly hydrophilic compound with a low partition 
constant (LogKow = -0.71, pH 7.4). Instead, an adequate retention, 7.6 ± 0.3 min (k’ = 12.17) 
was obtained in the Zorbax HILIC column, which is typically used for the retention and 
separation of small, polar analytes (178). Because there is no stable isotope-labeled DZNep 
available commercially, ribavirin and tubercidin, two nucleoside analogs, were evaluated for 
potential use as the IS. Although both ribavirin and tubercidin worked well tracking DZNep in 
the solid phase extraction, the retention time of tubercidin (4.5 ± 0.3 min)  was closer to that of 
DZNep (6.1 ± 0.3 min) compared to ribavirin (4.1 ± 0.3 min) using the optimized gradient 
elution condition (Table 5.1). Together with the post-column infusion analysis (Figure 5.3), this 
result suggests the intensity variation caused by the gradient elution in tubercidin was less than 
that in ribavirin. Thus, tubercidin was chosen as the IS. 
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Then, sample preparation method was optimized. In the case of DZNep and tubercidin, 
their highly hydrophilic nature ensures that liquid-liquid extraction is not a viable option. 
Additionally, the insufficient cleanliness of the biosamples using PPT would result in 
significant matrix suppression and unsymmetrical peaks of DZNep in the chromatograms (260). 
The purification, using Bond Elut PBA SPE columns, was based on the principle that the 
molecules with vicinal hydroxyl (diol) groups, such as DZNep and tubercidin, specifically bind 
to PBA in a neutral or alkaline medium (168, 169, 261). Once these compounds are retained, 
other components could be washed off. Then, the covalent bond is broken when the medium pH 
is lowered followed by the elution of these compounds. In fact, the extraction and purification 
of DZNep from rat biosamples, using the Bond Elut PBA SPE cartridges, could effectively 
minimize the suppression effects (around 10%) and achieve the consistent, precise and 
reproducible extraction recovery (71.6-85.8%) (Table5.4). In addition, the post-column infusion 
of analytes into the mobile phase while injecting extracted blank matrix is a very useful tool to 
pinpoint the location of the interference that causes matrix effects (262). Compared to the 
profiles for the injection of the reconstitution solution, the minimal matrix suppression appeared 
around the elution time of DZNep (6.1 min) and IS (4.5 min) in the representative blank 
biosamples (Figure 5.3), which is consistent with the above conclusion regarding to the matrix 
effects (Table 5.4). Collectively, the precolumn SPE-solid phase extraction procedure used is 
effectively minimizing the matrix suppression by sufficiently cleaning up all the rat biosamples 
and achieving the acceptable extraction recovery.  
 The unique pair of ions with m/z 263.3 and135.1 for DZNep and m/z 267.2 and 135.0 
for the IS (Figure 5.1), respectively, constituted the parent/daughter ion pairs. By the multiple 
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reactions monitoring (MRM), the selection and quantification of compound-specific ion-pairs 
enabled a reduction in the interference by co-eluting substances and a considerable 
improvement in assay selectivity. In fact, no interference signals ,induced by endogenous 
compounds, were observed (Figure 5.2 A -B and Figure S3-4) at the location of DZNep (6.1 
min) and IS (4.5 min) peaks in the biosamples (Figure 5.2 C and Figure S5). The acceptable 
linearity was achieved as the r2 values of all biosamples were above 0.99 (Table 5.3). The 
LLOQ in the calibration curves of plasma, urine, feces and tissues was set as 20 ng/mL with 
appropriate precision (RSD < 20%) and accuracy with 20% of the nominal values (Table 5.3). 
The intra-bath and inter-batch precision values (RSD<10%) and their accuracy values (85 -
115%) were within the acceptable range in rat biosamples (Table 5.5). No apparent stability 
issues were observed in biosamples spiked with DZNep using three freeze-thaw cycles, short-
term, and post-preparative stability tests (Table 5.6). Thus, this LC-MS/MS method for 
quantification of DZNep in rat biosamples was confirmed to have relatively acceptable 
sensitivity, precision, accuracy, selectivity, recovery and stability. Furthermore, the proposed 
method was successfully applied in the characterization of DZNep in rat pharmacokinetics, 
excretion and tissue distribution (Chapter 6 and 7).  
It should be noted that the method here has two limitations. Firstly, effective as it is in 
purification of biosamples containing DZNep, the sample preparation process using Bond Elute 
PBA-SPE cartridges was time- and labor-consuming. Unfortunately, by far, there is no better 
clean-up strategy for this drug in rat samples if the detection method is the LC-MS/MS method. 
Secondly, it took twelve minutes to accomplish the elution of one biosample in the Zorbax 
HILIC column. Alternatively, the application of Acquity UPLCTM BEH HILIC UPLC column is 
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likely to significantly shorten the elution time as well as to improve the sensitivity, 
chromatographic resolution of DZNep in the animal biosamples.   
In summary, a sensitive, selective and reliable LC-MS/MS method using sample 
preparation by Bond Elute PBA-SPE cartridges and sample separation on the Zorbax HILIC 
plus column was developed for the quantification of DZNep in rat biosamples (plasma, urine, 
feces and tissue samples). Also, the assay was demonstrated to be highly ruggedly and 
successfully used for the routine analysis of varied biosamples to generate ADME parameters of 




CHAPTER 6  
Pharmacokinetics, Tissue Distribution and Excretion 





3-deazaneplanocin A (DZNep) has been shown to  specifically and effectively induce 
cancer cell death in vitro and hopefully become an antitumor agent for the clinical application 
(63, 64). Thus, the preclinical and clinical studies of pharmacokinetics/pharmacodynamics 
(PK/PD) characteristics of this compound in vivo are necessary. Based on the FDA’s regulation 
concerning the approval of new drugs or biological products via animal models (21 CFR 
314.600 & 21 CFR 601.90), the preliminary PK studies should be done in healthy animals to 
characterize the PK profile of the compound and to propose dosing regimens that provide 
comparable drug exposures in the animals.  
The pharmacokinetics of 3H-DZNep in mice following intravenous administration has 
been reported using HPLC with the in-line radiochemical detection by Coulombe et al. (152). 
The DZNep plasma concentration-time profile appeared to be best described by a two-
compartment model after a single intravenous dose of DZNep (0.1 mg/kg) administered in mice; 
the rapid disappearance from the systemic circulation (t1/2, β, 12.8 min), and the wide distribution 
into tissues （the Vss value of DZNep, 3.1 L/kg, was greater than the total tissue water in mice 
(0.73 L/kg) (263), were important disposition characteristics of DZNep in vivo. Obviously, 
DZNep would have an undesirable PK profile for further clinical application. No excretion 
profile of DZNep in mice was reported by Coulombe et al (152), which may compromise the 
comprehensive understanding of DZNep PK properties in vivo. In addition, the inherent costs 
and safety issues of radiolabeling technique make the assay impractical and unfeasible during 
the early drug discovery and optimization processes. Therefore, in our study, a new detection 
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method, LC-MS/MS was developed. Of notice, since breast cancer cells have been used to 
investigate the pharmacological effects of DZNep in vitro and to establish animal models 
bearing xenograft human breast cancer cells for pharmacodynamic exploration of DZNep in 
vivo, all the rats employed in this study were female.  
This study aimed to characterize the pharmacokinetics, tissue distribution, excretion 
properties of DZNep in female SD rats. In addition, rat plasma protein binding and erythrocyte 
partitioning of DZNep and their relation with the disposition properties were estimated. In 
conjunction with the DZNep-induced toxicity in SD rats in the Chapter 4, the relationship was 
explored between the DZNep concentrations in tissues and corresponding toxicity.  
 
6.2 Materials and methods 
6.2.1 Chemical reagents and animals 
3-deazaneplanocin A (DZNep, purity > 99%) was purchased from OKeanos Tech. Co. 
(Beijing, China). Tubercidin (purity >99%) was from Sigma (St. Louis, MO, USA). HPLC 
grade acetonitrile was obtained from TEDIA (Fairfield, USA). Deionized water was purified 
using a Milli-Q system (Millipore, Milford, MA, USA). All other chemicals and solvents used 
were obtained from standard vendors, and were of the highest quality available. The female 
Sprague Dawley (SD) rats were supplied by Laboratory Animal Center (National University of 
Singapore, Singapore), and housed in temperature controlled room (25OC) with a 12-h light-
dark cycle. The study was approved by the Animal Ethics Committee of National University of 
Singapore. 
 135
6.2.2 Pharmacokinetic investigation of DZNep in SD rats 
6.2.2.1 Pharmacokinetic experiments 
The right jugular veins of female SD rats were cannulated with the polyethylene cannula 
(PE 50, I.D. 0.58 mm, O.D. 0.965 mm, Becton Dickinson) for intravenous collection of rat 
blood, as described by Thrivikraman et al. (264). The rats were allowed to recover for one day 
prior to the dosing. Rats were randomized divided into three groups (each group consisting of 
six rats). Based on the established no observable adverse effect dose (NOAEL), 10 mg/kg (see 
Chapter 4), Three groups of rats received intravenous bolus 2 mg/mL DZNep in 5% glucose 
solution via the tail vein at the doses of 1, 5, 10 mg/kg body weight (BW), respectively. For all 
the rats, at 0, 0.016, 0.083, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 2, 3, 6, 9 h after dosing, 0.2 mL blood 
samples were collected via the jugular vein cannula in heparinised polypropylene tubes. The 
plasma was separated by centrifuging blood samples for 10 min at 2000 g and stored at -20OC 
until analysis using the established LC-MS/MS method as described in the chapter 5.  
6.2.2.2 Pharmacokinetics analysis 
As suggested by the presence of a large distribution nose of the log-transformed plasma 
concentration-time profiles of DZNep after intravenous injection, the disposition of DZNep 
would be described by at least two compartment model (Figure 6.1). The plasma 
pharmacokinetic parameters were assessed using compartmental analysis with WinNonLin 
5.0.1 (Pharsight, Mountain View, CA). Fittings of two (as a reduced model) or three (as a full 
model) compartment disposition model to DZNep data were performed by using Gauss-Newton 
(Levenberg and Hartley) algorithm as a minimization method with a weighting factor of 1, 1/C 
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or 1/C2. For model discrimination between the reduced and full models, weighted residual sum 
of squares (WRSS), Akaike information criterion (AIC), and the frequency of changing +/- 
signs were applied. AIC is defined as NobsLn (WRSS) + 2 Npar, where Nobs and Npar are the 
number of observations and parameters, respectively. The model associated with the smaller 
values of WRSS and AIC, the larger values of frequency of changing +/- signs, is better. 
Moreover, F-test was performed to assess whether the full model was statistically superior to 














where WRSS1 and WRSS2 are the objective function of the reduced and full models, while DF1 
and DF2 are the degree of freedom for the reduced and full models, respectively. If F is larger 
than Ftable (P = 0.05, F-table; △DF = ∣DF1-DF2∣= column and DF2 = row), it means that the 
full model is statistically better than the reduced model. 
The pharmacokinetic parameters describing the DZNep plasma concentration-time 
curve were estimated for each rat and expressed as the means ± standard deviation (SD). The 
peak plasma concentration (Cmax) after intravenous injection was calculated as Dose/Vc, where 
Vc is the volume of central compartment. The area under the plasma concentration-time curve 
(AUC0-t) and the area under the first moment curve (AUMC0-t) from time zero to the last 
measurable time (tlast) were calculated using the log-linear trapezoidal rule. AUC extrapolated to 
infinity (AUC0-∞) was calculated as follows: AUC0-∞ = AUC0-tlast + Clast/λz, where Clast is the last 
measured plasma concentration and λz  is the elimination rate constant calculated from the slope 
of the terminal log linear phase of the plasma concentration-time profile. The area under the first 
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moment curve from time zero to infinity (AUMC0-∞) was calculated as the sum of AUMC0-t and 
the extrapolated area, which was estimated as (tlast x Clast/λz + Clast/λz2). The mean residence time 
(MRT) for intravenous dose was determined as AUMC0-∞/ AUC0-∞. The plasma clearance for 
intravenous dose (CL) was calculated as dose/ AUC0-∞. The volume of distribution at steady 
state (Vss) was estimated as CL x MRT. The other parameters included the dose-normalized 
area under the concentration-time curve from time zero to infinity (AUC0-∞/dose), the dose-
normalized maximum plasma concentration (Cmax/dose), and the distribution and elimination 
half-lives. 
6.2.3 Plasma protein binding of DZNep solution in SD rats 
The binding of DZNep to rat plasma proteins was determined by ultrafiltration using  a 
Microcon centrifugal filter cartridge (Microcon YM-3, Millipore Cop., Bedford, MA, USA) 
with a molecular weight cutoff (MWCO) of 3000, as described by Li et al. (265). To confirm 
the quality of the rat blank plasma and cartridges, the total protein of the freshly collected blank 
plasma and ultrafiltrate of blank plasma treated with the cartridges from 5 rats was measured 
using a biochemical autoanalyzer (Type 7170, Hitachi, Japan). The nonspecific adsorption of 
DZNep to the Microcon filter device was examined within 50-5000 ng/mL DZNep in phosphate 
buffer (pH 7.4). The concentrations of DZNep in the pre- and post-centrifuged phosphate buffer 
were determined using the LC-MS/MS method as established previously (Chapter 5). For 
plasma protein binding studies, freshly collected rat blank plasma (0.5 mL) was spiked with 
known amount of DZNep to obtain final concentrations of 50, 100, 500, 1000 and 5000 ng/mL. 
Each concentration was in quintuplicate. The samples were thoroughly mixed and equilibrated 
at 37 °C in a shaking water bath for 1 h, after that each sample was transferred to a Microcon 
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centrifugal filter cartridge, and centrifuged (8300 x g,) at 37 °C for 15 min. About 150 µL of 
ultrafiltrate and pre-centrifuged plasma samples were stored at -20 OC until analysis. The 
unbound and total DZNep concentrations in two sets of samples were quantitated using the LC-
MS/MS method (see Chapter 5). 
The percent plasma protein binding was calculated as (1 – Cf /Ct) x 100, where Cf is the 
drug concentration in the ultrafiltrate of the plasma (i.e., the unbound drug concentration) and 
Ct is the total drug concentration spiked in the plasma. 
6.2.4 Erythrocyte partitioning of DZNep in SD rats 
Erythrocyte partitioning of DZNep in SD rats was determined as described by Li et al. 
(265). Briefly, the right jugular veins of 5 female SD rats were cannulated with the polyethylene 
cannula. DZNep solution (2 mg/mL in 5% glucose solution) was administered to these female 
SD rats by the tail vein at 5 mg/kg BW. Blood samples were drawn via the jugular vein cannula 
in heparinised polypropylene tubes at 0, 0.083, 0.25, 0.5, 1, 2, 3, 6 h after dosing. At each time 
point, two blood samples were drawn: one (0.2 mL) was used for determination of DZNep 
blood concentration (Cb), and the other one (0.2 mL) was centrifuged (2000 g, 10 min, 4OC) to 
separate plasma for measurement of DZNep plasma concentration (Cp). All blood and plasma 
samples were stored at -20 OC until analyzed. The plasma concentrations of DZNep were 
determined using the validated LC-MS/MS method for its determination in rat plasma (Chapter 
5). The whole blood concentrations of DZNep were measured using the validated LC-MS/MS 
method (Chapter 5) with modified sample pretreatment. Briefly, 0.2 mL of the blood sample 
was crushed by a Diax 900 homogenizer (Heidolph, Germany), followed by centrifugation (10 
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min at 2000 g, at 10 OC) to separate supernatant, which was then subject to the same assay 
procedure as rat plasma samples.  
The erythrocyte partitioning (ρ) of DZNep was measured by the ratio of DZNep 
concentration in blood cells (Cbc) to that unbound in plasma (Cu) and  expressed as ρ = (H – 1 + 
Cb/Cp)/(fu x H) (266), where H is the hematocrit, Cb is the blood concentration of drug, Cp is the 
plasma concentration of drug, and fu is the unbound fraction of drug in plasma (i.e., fu = Cf/Ct). 
The ratios of the unbound DZNep in the plasma (Au) to the total drug in blood (Ab), the DZNep 
in blood cell (Abc) to the total drug in blood, and the DZNep bound in the plasma protein (Apb) 
to the total drug in blood  were expressed as fu /{1 + ρfu[H/(1-H)]}, ρfu[H/(1-H)] /{1 + ρfu[H/(1-
H)]}, and (1-fu) /{1 + ρfu[H/(1-H)]}, respectively. The ratio of DZNep AUC in blood cells 
(AUCbc) to that in plasma (AUCp) was calculated as AUCbc/AUCp = ρ x fu (266).  
6.2.5 Distribution of DZNep in organs of rats 
25 female SD rats (5 animals for each time point) were intravenously injected with the 
DZNep solution (2 mg/mL in 5% glucose solution) through the tail vein at 5 mg/kg BW. The 
tested animals were slightly anaesthetized with enflurane and followed by the blood collection 
and exsanguination at 0.083, 0.5, 1, 6, 12 h after dosing. Immediately, the animal was perfused 
with 50 mL of ice-cold saline. Tissues (blood, heart, liver, spleen, lung, kidney, stomach, 
adipose, muscle, and brain) were harvested and kept immediately in an ice bath at the end of 
each collection interval followed by the treatment with the established preparation methods as 
described previously (Chapter 5, section 5.2.6). All the plasma and tissue samples were then 
stored at -20 OC until analysis. DZNep in plasma and tissues was quantitated using the LC-
MS/MS method as described previously (Chapter 5). 
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6.2.6 Excretion of DZNep in rat urine and feces 
Six rats were given intravenously 5 mg/kg dose of DZNep solution (2 mg/mL in 5 % 
glucose) via tail vein. After dosing, the rats were individually housed in metabolic cages. Urine 
and feces samples at 0-6, 6-12, 12-24, 24-48 and 48-72 h were collected. The volume for each 
urinary sample and the dry weight for each feces sample were recorded. Both urine and feces 
samples were treated using the preparation method as described previously (Chapter 5, section 
5.2.6) and then stored at -20OC until analysis. DZNep in urine and feces were quantitated by the 
validated LC-MS/MS method (Chapter 5). The renal clearance (Clr) was calculated by Ae/AUC, 
where Ae is the amount of unchanged drug in urine over 72 h postdose. 
6.2.7 Statistical analysis 
Statistical analysis was performed using SPSS 10.0 (SPSS Inc., USA). All data were 
shown as means ± standard deviation (SD). Comparisons between two groups were made using 
Student’s independent-samples t-test and with more than two groups, one-way analysis of 
variance (ANOVA) was performed followed by the Tukey tests used for the post hoc multiple 
comparisons between individual groups. The statistical significance level was set to be p < 0.05. 
 
6.3 Results 
6.3.1 Pharmacokinetic analysis of DZNep in rats at varying doses 
The concentration-time plots of DZNep in plasma after intravenous bolus injection at 
doses of 1, 5, and 10 mg/kg were shown in Figure 6.1. Mean DZNep plasma levels fell below 
the lower limit of quantification (LLOQ, Chapter 5, section 5.3.4) 3 h after a single dosing of 1 
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mg/kg of DZNep and 6 h after that of 5 and 10 mg/kg of DZNep. The plasma concentrations of 
DZNep during terminal phase were lower after one hour postdose of 1 and 5 mg/kg of DZNep 
while those after 2 hours postdose of 10 mg/kg of DZNep than the expected effective level (622 

































Figure 6.1 Plasma concentration of DZNep in SD rats after intravenous administration of 
DZNep solution (5% glucose solution) at dose of 1, 5, 10 mg/kg body weight. The mean plasma 
concentration of DZNep (ng/mL) is expressed as the mean ± SD (n = 6). The lower dotted line 
indicates the LLOQ (20 ng/mL) of LC-MS/MS method for quantifying DZNep in the rat plasma. 
The upper dotted line indicates the effective dose (655 ng/mL or 2.5 µM) which induced time-
dependent cell death and reactivation of EZH2 related repressed genes in various breast tumors. 
 
The drug appeared to follow a bi- or tri-exponential decline from the body. Thus, the 
time profiles of intravenous concentration data of DZNep were fitted to both 2 compartment 
disposition model (the reduced model) and 3 compartment disposition model (full model). The 
observed and model-predicted concentration-time profile for each individual rat is shown in 
Figure S7.  The reduced model displayed systemic deviation between observed and predicted 
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data as the model with the weighting factor of 1 and 1/C apparently missed several data points 
in the terminal phase while the reduced model with 1/C2 missed two or three data points in the 
intermediate phase. Remarkable improvements were seen in the data fittings by the full model. 
The representative residuals-time plots for the reduced and full models are shown in Figure S8. 
The residuals in the full model showed a more random scatter than those in the reduced model. 
The frequency of changing +/- signs counted from the residuals-time plots as well as other 
goodness-of-fit parameters (i.e., WRSS, AIC and frequency of changing +/- sign) are 
summarized in Table S2. For most individual rats, the full model generated a smaller WRSS 
and AIC and a larger frequency of changing +/- signs, compared to the reduced model. At the 
10 mg/kg dose group, there was a larger frequency of changing +/- signs in the full model with 
the weighting factors 1/C and 1/C2 as compared to that in the full model with 1 (Table S2). The 
full model with the weighting factor 1 was discarded. Model discrimination F-test demonstrated 
that the full model was statistically superior to the reduced model (p < 0.05) for 5/6, 5/6, and 
6/6 of the rats in groups with the weighting factor 1/C and 4/6, 5/6, and 4/6 in groups with 1/C2. 
As the full model with the weighting factor 1/C2 was comparable to that with 1/C, the latter was 
chosen as the model for fitting the plasma concentration-time data of DZNep in rats.  In light of 
the aforementioned information, the plasma concentration-time curve was best described by a 
full model (i.e., three-compartment disposition model) with the weighting factor 1/C. 
The estimates of pharmacokinetic parameters for DZNep are listed in Table 6.1. The 
rapid distribution half-lives (t1/2, α) ranged from 0.0058 to 0.0063 h and the slow distribution 
half-lives (t1/2, β) ranged from 0.078 to 0.13 h while the terminal half-lives (t1/2, γ) ranged from 
1.0 to 1.2 h. As shown in Table 6.1, no differences were noted in dose-normalized area under 
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the concentration-time curve from time zero to infinity (AUC 0-∞/dose, p = 0.45), dose-
normalized maximum concentration (Cmax/dose, p = 0.23), across the investigated dosage range 
(1 mg/kg to 10 mg/kg BW), indicating PK of DZNep is a dose-independent and linear in rat 
plasma after single dosing. Total clearance (CL) ranging within 1.8-1.9 L/h/kg and mean 
residence time (MRT) ranging within 0.80-0.96 h remained unaltered over the dose range ( p = 
0.40 and 0.053, respectively). The apparent volume of distribution at steady state (Vss), 
independent of the dose (p = 0.09), ranged within 1.5-1.7 L/kg. In terms of the 
intercompartmental distribution between the central and two peripheral compartments, in the 
dose range, CLD2 ranging within 2.1-2.9 L/h/kg was higher than CLD3 ranging within 0.88-1.55 
L/h/kg. As shown in Table 6.1, the fractional loss under the α, β, and γ phases (% AUCα, % 
AUCβ, and % AUCγ), ranged from 24.2 % to 31.5 %, 15.9 % to 23.4 %, and 45.1 % to 59.9 % 
across the investigated dosage range, respectively. Since pharmacokinetics of DZNep appears to 
be a dose-independent and linear in rat plasma after single dosing, the dose of 5 mg/kg DZNep 











Table 6.1 Pharmacokinetic parameters for DZNep after an intravenous bolus to SD rats (n = 6) 
Parameter Units 1 mg/kg 5 mg/kg 10 mg/kg p 
A µg/mL 18.2 ± 2.9 74.2 ± 12.1 178.0 ± 50.8 < 0.01 
B µg/mL 1.1 ± 0.3 3.2 ± 0.8 4.8 ± 1.2 < 0.01 
C µg/mL 0.14 ± 0.02 1.1 ± 0.2 1.9 ± 0.3 < 0.01 
α L/h 110.3 ± 8.4 112.3 ± 9.0 121.4 ± 16.1 0.25  
β L/h 9.1 ± 1.5 7.4 ± 1.8 5.3 ± 0.8 < 0.01 
γ L/h 0.61 ± 0.05 0.68 ± 0.04 0.62 ± 0.08 0.18  
K21 L/h 15.2 ± 2.7 12.4 ± 2.9 9.1 ± 1.4 < 0.01 
K31 L/h 0.72 ± 0.11 1.12 ± 0.16 0.94 ± 0.3 < 0.01 
K10 L/h 37.2 ± 4.5 28.9 ± 4.8 33.7 ± 8.7 < 0.05 
K12 L/h 39.4 ± 2.7 43.8 ± 6.9 48.9 ± 7.1 0.06  
K13 L/h 17.1 ± 5.1 23.7 ± 2.4 24.4 ± 12.5 0.25  
t1/2, k10 h 0.019 ± 0.002 0.024 ± 0.004 0.022 ± 0.006 0.11  
t1/2, α h 0.0063 ± 0.0005 0.0062 ± 0.0005 0.0058 ± 0.0007 0.29  
t1/2, β h 0.078 ± 0.013 0.099 ± 0.026 0.133 ± 0.022 < 0.01 
t1/2, γ h 1.2 ± 0.1 1.0 ± 0.1 1.1 ± 0.2 0.20  
AUC0-∞ h*µg/mL 0.52 ± 0.03 2.73 ± 0.25 5.49 ± 0.23 < 0.01 
AUC/Dose h*g/mL 0.52 ± 0.03 0.55 ± 0.05 0.55 ± 0.02 0.45  
Cmax µg/mL 19.5 ± 3.0 78.5 ± 11.7 184.7 ± 50.1 < 0.01 
Cmax/Dose g/mL 19.5 ± 3.0 15.7 ± 2.3 18.5 ± 5.0 0.23  
CL L/h/kg 1.92 ± 0.12 1.84 ± 0.16 1.83 ± 0.08 0.40  
CLD2 L/h/kg 2.06 ± 0.34 2.80± 0.29 2.85 ± 0.93 0.06  
CLD3 L/h/kg 0.88 ± 0.23 1.55 ± 0.34 1.29 ± 0.42 < 0.01 
AUMC h*h*µg/mL 0.43 ± 0.06 2.49 ± 0.23 5.3 ± 1.0 < 0.01 
MRT h 0.80 ± 0.09 0.91 ± 0.05 0.96 ± 0.15 0.053  
Vss mL/kg 1486.0 ± 159.4 1683.9 ± 196.3 1745.3 ± 230.6 0.09  
V1 mL/kg 52.4 ± 8.4 64.8 ± 9.3 57.8 ± 16.3 0.22  
V2 mL/kg 139.6 ± 40.0 236.3 ± 62.3 310.4 ± 82.9 < 0.01 
V3 mL/kg 1294.0 ± 147.4 1382.8 ± 208.1 1377.1 ± 188.3 0.65  
% AUCα  31.5 ± 2.9% 24.2 ± 2.5% 26.3 ± 4.5% < 0.01 
% AUCβ  23.4 ± 3.0% 15.9 ± 2.4% 17.0 ± 5.5% < 0.01 
% AUCγ  45.1 ± 4.6% 59.9 ± 4.0% 56.7 ± 5.2% < 0.01 
Data are expressed as mean ± SD. Abbreviations: A, B, C, intercepts with y axis of the equation; 
α, β, γ: macro-constants of the equation; K21, K31, K10, K12, K13, micro-constant from 
compartments 2 to 1, 3 to 1, 1 to output, 1 to 2, and 1 to 3, respectively; AUC0-∞, area under the 
curve from time zero to infinity; Cmax, maximum concentration; CL, clearance; Vss, steady state 
distribution volume;  MRT, mean residence time; CLD2, intercompartmental distribution 
between 1 and 2; CLD3, intercompartmental distribution between 1 and 3; V1, V2 and V3, the 
volume of the central, shall peripheral and deep peripheral compartment. % AUCα, % AUCβ, 
and % AUCγ, the fractional areas under the α, β, and γ phases, which could be calculated as 
A/α/AUC, B/β/AUC, and C/γ/AUC, respectively. 
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6.3.2 Plasma protein binding and Erythrocyte partitioning of DZNep 
in rats 
The extent of binding of DZNep to plasma proteins was evaluated by in vitro 
ultrafiltration method. The mean total protein of the blank plasma was 61.4 ± 4.8 g/L, which is 
within the normal range (Chapter 4, Table 4.3) while no apparent leakage of plasma protein was 
found as the total protein in ultrafiltrate was undetectable. The extent of nonspecific binding of 
DZNep to the Microcon cartridge was negligible (< 2%). About 18.5 ± 0.8% of DZNep were 
found to bind to rat plasma protein over the concentration range of 50-5000 ng/mL (Table 6.2).  
Table 6.2 Protein binding fraction in rat plasma spiked with various concentrations of DZNep 
(n = 5) 
Spiked DZNep concentration (ng/mL) Protein binding fraction in plasma (1-fu) 
50 17.2 ± 4.4% 
100 18.5 ± 2.8% 
500 19.1 ± 4.0% 
1000 18.5 ± 2.2% 
5000 19.2 ± 2.4% 
average 18.5 ± 0.8% 
p 0.886 
The percent plasma protein binding was calculated as (1 – Cf /Ct) x 100, where Cf is the drug 
concentration in the ultrafiltrate of the plasma (i.e., the unbound drug concentration) and Ct is 
the total drug concentration spiked in the plasma.  
 
By simultaneous determination of the plasma and blood concentrations of DZNep after a 
single intravenous dose of 5 mg/kg of DZNep in rats with their respective time as summarized 
in Table 6.3, the ratios of blood-to-plasma concentration ranged within 0.80-0.90, over the 
plasma concentration range of 44-3068 ng/mL achieved in vivo. Furthermore, the affinity of 
blood cells for drug (the ρ value) estimated was 0.78 ± 0.12 for DZNep in rat blood (Table 6.3), 
given that the mean rat blood hematocrit was 0.41 (Chapter 4, Table 4.4), and the protein 
binding fraction of DZNep (1-fu) in rat plasma was 18.5 % (Table 6.2). Furthermore, it was 
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estimated that of DZNep in rat blood as a whole, about 56 % in rat plasma existed as the free 
drug, whereas 32 % resided in the erythrocyte and and 13 % bound to the plasma protein (Table 
6.3). The ratio of DZNep AUC in blood cells to that in plasma was calculated as 0.64 (ρfu). 
Table 6.3 Erythrocyte partitioning (ρ) of DZNep in rat blood and the ratios of the unbound 
DZNep in the plasma, the DZNep amount in blood cell, and the DZNep bound in the plasma 
protein to the total drug amount in blood at different time points after intravenous 
administration of DZNep solution (5 mg/kg BW) to SD rats (n = 5) 
Time Cp Cb/Cp ρ Au/ Ab Abc/ Ab Apb/ Ab 
0.08  3068 ± 249 0.89 ± 0.06 0.90 ± 0.19 53 ±4 ％ 35 ± 5 ％ 12 ± 1 ％ 
0.25  1558 ± 162 0.90 ± 0.06 0.94 ± 0.18 52 ± 3 ％ 36 ± 4 ％ 12 ± 1 ％ 
0.50  886 ± 111 0.84 ± 0.05 0.74 ± 0.16 56 ± 4 ％ 31 ± 5 ％ 13 ± 1 ％ 
1.00  298 ± 47 0.85 ± 0.08 0.77 ± 0.24 56 ± 6 ％ 31 ± 7 ％ 13 ± 1 ％ 
3.00  159 ± 12 0.80 ± 0.09 0.64 ± 0.28 60 ± 7 ％ 27 ± 9 ％ 14 ± 2 ％ 
6.00  44 ± 9 0.83 ± 0.10 0.72 ± 0.29 57 ± 7 ％ 30 ± 9 ％ 13 ± 2 ％ 
Mean ± SD 0.78 ± 0.12 56 ± 3 ％ 32 ± 3 ％ 13 ± 1 ％ 
p 0.30  0.31  0.28  0.19  
The erythrocyte partitioning of the drug was expressed as ρ = (H – 1 + Cb/Cp)/(fu X H), where 
the hematocrit (H) is 0.41, Cb is the blood concentration of drug, Cp is the plasma concentration 
of drug, and the unbound fraction in plasma (fu) is 0.815. 
 
6.3.3 Distribution of DZNep in organs of rats 
Time courses of DZNep tissue distribution and tissue-to-plasma concentration ratios 
following an intravenous bolus dose of 5 mg/kg DZNep to rats are shown in Figure 6.2. DZNep 
was detectable almost in all tissues at 5 min, except for brain, with considerable accumulation, 
particularly in kidney (21.25 ± 2.12 µg/g) and most tissue-to-plasma concentration ratios were 
greater than 1 (e.g. 7.93 ± 0.79 in kidney). The accumulation of DZNep was greater in well-
perfused organs than that in poorly-perfused organs: kidney > spleen > heart = liver > lung > 
stomach = muscle > adipose > brain (Figure 6.2A). Despite initial high accumulation, DZNep 
rapidly declined over time in the well-perfused organs, e.g. from 21.25 µg/g at 5 min to 0.88 
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µg/g at 6 h with the elimination half-life of 1.5 h  in kidney (t1/2, kidney) (Figure 6.2A). By contrast, 
DZNep just feebly went down in the poorly-perfused organs, e.g. from 0.59 µg/g at 5 min to 
0.17 µg/g at 6 h with the elimination half-life of 3.2 h in adipose (t1/2, adipose). At 6 h postdose, 
thus, all the tissues dropped to a very low concentration level. By 12 h postdose, DZNep was 
undetectable in all the tissues. Of notice, the tissue-to-plasma concentration ratio of DZNep for 
most of the observed tissues peaked at about 0.5-1 h and then remained relatively stable or 
slightly declined over time (Figure 6.2B).  
 
Figure 6.2 (A) Concentration of DZNep in tissues and plasma (µg/g, Drug/body weight) and (B) 
Tissue-to-plasma concentration ratios at 0.083, 0.5, 1 and 6 h after a single intravenous 
administration of 5 mg/kg DZNep into SD rats (n = 5). The levels of DZNep are expressed as 
the mean ± SD.  
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6.3.4 Excretion of DZNep in rat urine and feces 
In SD rats given a single intravenous dose of 5mg/kg DZNep, 69.5 % of the unchanged 
drug was excreted in the urine within 6 h, and the majority of the dose (79.5 %) was eliminated 
via the urine by 12 h (Figure 6.3). By 72 h, 80.3 % of the unchanged DZNep administered had 
been recovered in the urine. In contrast, only 6.5 % of DZNep dosed were excreted in the feces 
by 72 h, which was not likely to be contaminated by the urine as the DZNep excreted in the 
feces was detectable after 12 h postdose when DZNep was already not present in urine. 
Furthermore, by comparing the cumulative amount of DZNep excreted in urine with plasma 
AUC0-∞ for DZNep (Table 6.1), the renal clearance (Clr) was estimated to be 1.5 L/h/kg. 
Overall, 86.8 % of unchanged DZNep appeared in urine and feces over 72 h.  
 
























Figure 6.3 Cumulative recovery of DZNep in urine and feces following a single intravenous 
administration of 5 mg/kg DZNep into SD rats (n = 6). The levels of DZNep recovered are 




The primary objective of the study was to investigate the disposition properties of 
DZNep in female SD rats. The disposition studies consisted of tissue distribution, plasma 
protein binding, erythrocyte partitioning, and excretion of DZNep in SD rats.  
DZNep plasma pharmacokinetics appeared to follow a three exponential disposition 
model, which was statistically superior to a two exponential disposition model (Figure S7 and 
S8 and Table S2). These three phases correspond to a rapid distribution phase from the plasma 
to the highly-perfused tissues (t1/2, α, 0.0058-0.0063 h), a second phase of slow distribution into 
poorly-perfused tissue from plasma (t1/2, β, 0.078-0.13 h) and a last phase of elimination 
primarily from the kidney (t1/2, γ, 1.0-1.2 h) (over 80% of unchanged DZNep recovered in the 
urine). The intravenous administration with the free DZNep up to 10 mg/kg (NOAEL, Chapter 
4) to SD rats fell rapidly below an effective plasma concentration (622 ng/mL) within 2 hours 
postdose (Figure 6.1), which might compromise the tumor accumulation of DZNep in vivo. 
Across the investigated dosage range (1, 5, and 10 mg/kg BW), similar AUC 0-∞/dose and 
Cmax/dose (Table 6.1) indicated that DZNep exhibited a dose-independent pharmacokinetics. 
The apparent volume of distribution at steady state (Vss) ranging within 1.5-1.7 L/kg  was 
considerably greater than the total tissue water (0.79 ± 0.01 L/kg BW) in SD rats (188), 
suggesting that DZNep was preferentially enriched in the rat tissues (Table 6.1), which was 
consistent with the results in the tissue distribution of DZNep in rats (Figure 6.2) and the Vss 
value of DZNep (3.1 L/kg) in mice calculated based on the reported data by Coulombe et al. 
(152). In addition, CLD3 was much small than CLD2 (Table 6.1), suggesting that the transfer of 
the drug from the deep tissue compartment to the central compartment is rate-determining. The 
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fractional loss under the γ phase was the greatest among three phases in the DZNep plasma 
concentration-time profile, indicating that this terminal phase was the elimination phase. 
By measuring DZNep retained in tissues against time points, DZNep was almost 
detectable in all the tissues at 5 min, except for brain, with considerable accumulation and 
tissue-to-plasma concentration ratios (Figure 6.2), suggesting that DZNep was rapidly and 
widely distributed throughout various tissues in rats whereas the polar drug was prevented from 
entering into the brain by the blood-brain barrier. In addition, DZNep was found to 
preferentially accumulate in well-perfused organs such as kidney compared to poorly-perfused 
organs such as adipose tissue (Figure 6.2A). Although DZNep is hydrophilic (LogKow, -1.09, 
Chapter 7, Table 7.2), it could still be widely distributed in majority of the tissues in SD rats, 
possibly via the nucleoside transporter proteins, which are specific for the transfer of naturally 
occurring nucleosides (267) as well as nucleoside analogs, such as ribavirin, tiazofurin (191, 
268), across the cell membranes. In addition, due to the higher transfer rate from the shallow 
peripheral to central compartment (CLD2 = 2.8 L/h/kg) than that from the deep peripheral to 
central compartment (CLD3 = 1.5 L/h) (Table 6.2), DZNep remarkably declined over time in the 
well-perfused organs (e.g. t1/2, kidney = 1.5 h) while just feebly went down in the poorly-perfused 
organs (e.g. t1/2, adipose = 3.2 h) (Figure 6.3A). The tissue-to-plasma concentration ratio of DZNep 
for most of the observed tissues peaked at about 0.5-1 h and then remained stable or slightly 
declined over time (Figure 6.2B), suggesting a fast pseudo-equilibration occurred for the 
DZNep distribution between the plasma and organs in rats. 
Plasma protein binding and erythrocyte partitioning of drug generally affect the free 
drug concentration available for target binding and, potentially, the pharmacological effect 
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(269). The plasma protein binding was 18.5 % (Table 6.2),which is in agreement with previous 
finding of low plasma protein binding of DZNep in mice (152). The reason for low plasma 
protein binding of DZNep was that  the inherent hydrophilicity and unionized form of DZNep 
at physiological pH (7.4) poorly induce any drug-to-protein interaction (183). Erythrocyte 
partitioning of some nucleoside analogues, such as ribavirin, is in close correlation with the 
haemolytic anaemia. In this study, AUC of DZNep in the erythrocyte was just 64 % of that in 
plasma in rats. In contrast, AUC of ribavirin in the erythrocyte was 33-fold higher than that in 
plasma in monkeys (161). As a result, the erythrocyte appears to be an important target of 
toxicity for ribavirin (162) but not for DZNep. As the erythrocytes are anuclear, they can not 
convert the phosphorylated ribavirin induced by the adenosine kinase back to unchanged form, 
which is readily accumulated inside the erythrocyte. Phosphorylated ribavirin can competitively 
inhibit energy utilization as it is structurally similar to ATP, which results in haemolytic 
anaemia (187). In contrast, due to having a similar structure as 3-deazaaristeromycin in that a 
methylene group replaces the nitrogen atom (de-aza) in the purine ring, which makes 3-
deazaaristeromycin metabolic resistance to the adenosine kinase (16), DZNep may have the 
metabolic stability against the adenosine kinase (143). Thus, the unchanged DZNep may be 
readily transported out of the erythrocytes. Therefore, unlike ribavirin, DZNep would not be 
preferentially accumulated in erythrocytes and hence haemolytic anaemia was negligible as 
shown previously in the above acute toxicity studies (Chapter 4, Table 4.4).  
By 72 h, DZNep showed a high cumulative urinary excretion (80.3 % of the unchanged 
DZNep) but a relatively low cumulative fecal excretion (6.5 % of the unchanged DZNep) in rats 
(Figure 6.3).  The renal clearance (Clr) of DZNep estimated to be 1.5 L/h/kg is much greater 
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than the product (0.42 to 0.47 L/h/kg) of the unbound fraction of DZNep in plasma (fu = 0.815, 
Table 6.2) and the normal glomerular filtration rate (GFR) of SD rats (0.51 to 0.58 L/h/kg) (270, 
271), indicating that DZNep underwent not only a renal filtration but also a net secretion in the 
renal tubule with negligible reabsorption. Actually, the low plasma protein binding (18.5%) is 
favourable to DZNep renal filtration and secretion whereas the high hydrophilicity of DZNep 
(LogKow, -1.09, Chapter 7, Table 7.2) is unfavourable to its renal reabsorption (265). Many 
nucleoside and nucleotides and their metabolites are eliminated by active tubular secretion 
including the nucleoside analogs acyclovir, zalcitabine, zidovudine, and entecavir (272-275) 
and acyclic nucleotide phosphonates cidofovir, adefovir, and tenofovir (276-278). In addition, 
the poor fecal excretion of DZNep might be due to its relatively small molecular weight (MW, 
262 dalton) because the extensive biliary excretion require molecules possess a large molecular 
weight (MW, 400 to 500 dalton) (279). In conjunction with the previous observation in the 
acute toxicity test of DZNep in SD rats, the toxic symptoms including the body weight loss and 
nephrotoxicity (Chapter 4, Figure 4.1 and Table 4.3) did not disappear along with the rapid 
excretion of DZNep from the rat body (Figure 6.3), indicating a delayed toxicity of DZNep in 
rats. In fact, according to the report by Tan et al. (64), the exposure of DZNep to intracellular 
organelles was within 2 hours postdose, whereas the onset of apoptotic response distinctly 
occurred two days later.  
The 86.80 % recovery of unchanged DZNep from urine and feces by 72 h indicated that 
the metabolism of DZNep played an insignificant role in the elimination of DZNep in rats. This 
phenomenon is likely attributed to the deazapurine and cyclopentenyl moiety of DZNep, which 
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endows DZNep with unique metabolic stability towards phosphorylases, deaminases and 
adenosine kinases (143, 280, 281).  
In summary, the disposition characteristics of DZNep was thoroughly investigated in the 
female SD rats in an attempt to examine whether further antitumor study of this compound in 
human tumor xenografts animals would be feasible. The present preclinical studies indicated 
that, following an intravenous bolus administration, DZNep had a dose-independent 
pharmacokinetic profile with a rapid clearance from the plasma and a short elimination half-life. 
DZNep also showed a low protein binding in plasma and low partitioning to erythrocyte, but 
had extensive tissue distribution, and predominant urine excretion. In addition, DZNep was not 
extensively metabolized in vivo. Overall, DZNep has an undesirable PK profile for further 
clinical application. At present, studies are ongoing to develop an appropriate nanoparticle 
formulation, with the aim to effectively prolong the retention of DZNep in the systemic 
circulation in the hope of enhancing the DZNep’s tumor localization in vivo. 
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CHAPTER 7  
Loading DZNep into pegylated unliamellar Liposomes 
by forming transition phenylboronic acid-drug 




DZNep is a carbocyclic nucleoside analogue which has emerged as a very potent 
epigenetic-modulation drug against different solid malignancies (64). Unfortunately, the 
preclinical pharmacokinetic studies indicated that, following intravenous administration to SD 
rats, DZNep had an undesirable pharmacokinetic profile with such as a short elimination half-
life (Chapter 6). DZNep also showed a low protein binding in plasma and a low partitioning to 
erythrocyte, but had extensive tissue distribution, and predominant renal excretion (Chapter 6). 
Besides, DZNep appeared to induce the nephrotoxicity and renal atrophy in a dose-dependent 
manner in previous acute toxicity study in SD rats (Chapter 4).  
To overcome these shortcomings of DZNep in its pharmacokinetic properties and 
toxcity, the drug can be reformulated in a delivery system that has minimal interaction with 
healthy cells, and to release drug at an appropriate time from the sequestering carrier at the 
tumor site. Generally, several drug delivery systems, namely liposomes, microparticles, 
nanoparticles, polymeric micelles, dendrimers, hydrogels, polyplex nanogels and cyclodextrin 
inclusion complexes (192), have been introduced to overcome some limitations of drug in vivo. 
Liposomal formulation, in particular, offers the simplest possibility to modulate the 
biopharmaceutical properties of drug and thus would be employed in this study.  
The stealth liposomes with polyethylene glycol polymer chains (PEG) coating has been 
proven to possess a longer circulatory life in the drug delivery (282). Moreover, the small 
unilamellar liposomes (SUV) with size level around 100 nm are capable of efficient 
extravasation through fenestrated endothelium of tumor blood vessel walls (283).  Due to the 
 156
presence of a readily protonable amino group in the DZNep molecule (pKa = 6.22, Sparc on-
line calculator) at a weakly acidic condition, a remote-loading technique is likely to be suitable 
for the preparation of DZNep pegylated liposome (L-DZNep). The principle of this technique is 
that the free alkaline drug would diffuse inside the liposome following pH gradient (4.0 to 7.0), 
where protonation of the drug occurs and in turn results in its accumulation inside the liposomes 
(200, 284). Boric acids, such as phenylboronic acid (PBA), were found to facilitate the transport 
of ribonucleosides or nucleoside analogs containing vicinal hydroxyl groups (cis diol) through 
lipid bilayers, which are involved in a transient formation of a lipophilic, trigonal boronate ester 
(285, 286). Since DZNep also possesses a cis diol in its cyclopentenyl moiety as well as a 
protonable amino group, it was thus hypothesized that the encapsulation of DZNep in the 
pegylated unilamellar liposomes was feasible using the remote-loading technique with the aid 
of PBA, and that this formulation was capable of prolonging the retention of DZNep in the 
systemic circulation of SD rats as compared to the free drug. Thus, the main purpose of this 
study was to improve the pharmacokinetic characteristics of DZNep in vivo through developing 
a pegylated unilamellar liposomal formulation. 
 
7.2 Materials and methods 
7.2.1 Materials 
3-deazaneplanocin A (DZNep, purity > 99%) was purchased from OKeanos Tech. Co. 
(Beijing, China). Tubercidin (purity >99%) was from Sigma (St. Louis, MO, USA). 
Phenylboronic acid (PBA, purity > 955), Ribavirin and ammonium sulfate were also from 
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Sigma. Lipids: cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(Polyethylene glyco)- 2000] 
(Ammonium salt) (PEG2000-DSPE) were obtained from Avanti Polar Lipids (Alabaster, AL, 
USA). HPLC grade acetonitrile was obtained from TEDIA (Fairfield, USA). Deionized water 
was purified using a Milli-Q system (Millipore, Milford, MA, USA). All other chemicals and 
solvents used were obtained from standard vendors, and were of the high quality available.  
7.2.2 HPLC assay for the determination of DZNep and an additive, 
PBA in vitro 
7.2.2.1 Instrument and Chromatographic conditions 
Shimadzu HPLC system (Shimadzu, Kyoto, Japan) used was equipped with an SCL-
10Avp system controller, LC 10 ATvp pump, DGU-14A degasser, SIL-10ADvp autosampler 
and SPD-M10Avp UV/Vis photodiode array (PDA) detector. Chromatographic separation was 
conducted on a phenyl reversed phase column (XTerra™ Phenyl, 4.6 x 150 mm, particle size of 
5 μm). The mobile phase consisted of a 20 mM phosphoric acid solution in water. The flow rate 
was 1.5 mL/min and the temperature was ambient. The eluent of DZNep, PBA and ribavirin (IS) 
was monitored at a wavelength of 215 nm. Chromatographic peaks were electronically 
integrated and recorded using Class VP software (ver.6.12, Shimadzu, Japan).  
7.2.2.2 Preparation of calibration standards 
Calibration standards were prepared daily by spiking an appropriate quantity of the 
intermediate standard solution (DZNep, PBA and IS) into PBS (pH 7.4) solution in the presence 
or absence of blank liposome lysis (blank liposome lysed by the 2 % Triton X-100). Briefly, 
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calibration standards at final concentrations of 0.5, 1, 5, 10, 20, 50, 100 μg/mL of DZNep and of 
1, 5, 10, 50, 100, 500, 1000 μg/mL of PBA were prepared. All standards were spiked with final 
concentration of 5 μg/mL IS. The final lipid concentration was around 4 mM. Samples prepared 
were aliquoted into 1.5 mL microtubes and stored at 4 oC before analysis. 
7.2.2.3 Sample preparation 
DZNep liposomes (L-DZNep) were diluted 5 times with PBS buffer (pH 7.4). 100µL of 
diluted L-DZNep was spiked with 10 μL of 100 μg/mL of ribavirin as the internal standard. 
Then, DZNep and PBA encapsulated in the diluted L-DZNep were released by lysing liposomes 
with 90 μL of 2 % Triton X-100 solution. Then, each sample was incubated in a water bath at 
60 oC until the cloud point of the detergent was observed. In the same way, blank liposome lysis 
was obtained through lysing blank liposomes. Each prepared sample (200 µL) was pipetted into 
an autosampler vial, and 20µL was injected onto column for analysis. 
7.2.2.4 Method validation 
The method validation for assaying DZNep and PBA in liposomes was as follows. 
The selectivity of the method was evaluated by comparing the chromatograms of five 
blank samples with the corresponding spiked samples at the lower limit of quantitation (LLOQ) 
level. The peak areas of interference compounds co-eluting with DZNep and PBA should be 
less than 20% of the peak area of the LLOQ standard. 
The calibration curves were fitted by a linear least-squares regression method through 
the measurement of the peak-area ratio of DZNep to IS versus the corresponding known spiked 
concentrations. The coefficient of determination (R2) greater than 0.99 was set as the acceptable 
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linearity for calibration curves. The accuracy and precision at the LLOQ for each sample were 
required within 20% of the nominal concentration and less than 20 % RSD (n=5), respectively. 
7.2.3 Two physicochemical properties of DZNep  
7.2.3.1 Measurement of the logarithm of the water-octanol partition coefficient of 
DZNep (LogKow) 
The LogKow of DZNep in pH 7.4 (unionized basic compound) was measured using the 
shake flask method, in accordance with the Guidelines for Testing of Chemicals by the 
Organisation for Economic Cooperation and Development (OECD) (287). Briefly, water-
saturated 1-octanol solution and 1-octanol-satured PBS buffer (pH 7.4, 1stBase) were prepared, 
and DZNep was then dissolved in the 1-octanol-satured PBS buffer at the final concentration of 
5, 10 and 50 µg/mL. 5 mL of the above DZNep solution was added to 5 mL of the water-
saturated 1-octanol solution in a glass flask. The heterogeneous mixture was stirred (180 rpm) 
at room-temperature overnight and then centrifuged for 10 min at 4500 g using a Sigma203 
Centrifuge (Deisenhofen, Germany). Following separation, 100 µL of aqueous sample and of 1-
octanol sample were collected. 1-octanol was evaporated using a stream of nitrogen at 45 oC 
overnight. The residue was reconstituted in 100 µL of PBS buffer (pH 7.4). Concentrations of 
DZNep in octanol and aqueous phase were analyzed using the HPLC-UV method (Section 
7.2.2). LogKow was calculated by taking the logarithm of the ratio of the concentration of 
DZNep in 1-octanol to the corresponding concentration in PBS buffer.  
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7.2.3.2 Thermostability of DZNep in acidic and neutral aqueous buffers 
Due to the high temperature (60OC) and pH gradient (4.0 to 7.0) involved in the remote-
loading method for preparation of liposome containing DZNep, a thermostability test was 
performed through incubating DZNep in acidic and neutral aqueous solution at 60oC. 50 μg/mL 
of DZNep in citrate buffer (pH 4.0) and 5% glucose (pH 7.0) were prepared. Aliquots (0.5 mL) 
of DZNep samples were sealed in 1.5 mL Eppendorf tubes and incubated in the water bath at 60 
OC for 2 h. Thereafter, DZNep concentration in each sample was measured using the HPLC-UV 
method (Section 7.2.2). Freshly prepared DZNep samples (50 μg/mL) with different pH value 
served as control.  The fraction of remaining DZNep was determined by dividing DZNep 
concentration in the incubated sample by that in the control sample. 
7.2.4 Preparation of DZNep-loaded Liposomes (L-DZNep) 
L-DZNep was obtained using three different preparation methods: the reversed-phase 
evaporation (REV), remote-loading in the absence of PBA (R-wo-PBA) and remote-loading in 
the presence of PBA (R-w-PBA). The molar input ratio of DSPC, cholesterol, and PEG2000-
DSPE was 60: 35: 5, while that of DZNep and lipids was 1: 10. The liposomes were prepared 
by sequential extrusion at 60 OC through Nuclepore® Polycarbonate membranes (Whatman®, 
USA ) with pore sizes of 0.2 µm and 0.1µm using a mini-extruder set (Avanti Polar Lipids, Inc., 
USA). 
7.2.4.1 Reversed-phase evaporation method (REV) 
As REV method is an effective way of encapsulating hydrophilic drugs (288), it was 
initially selected for optimization. L-DZNep was prepared using the reverse-phase evaporation 
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(REV) method as described previously (289) with minor modifications. In brief, lipid materials 
were first dissolved in 15 mL of a solvent mixture containing chloroform, isopropyl ether (1:2, 
v/v) and sonicated in a bath-type sonicator (Ultrasonicator FB 15057, Fisher Scientific) at 45 OC 
for 1 min under N2 to ensure homogeneous mixing. The water phase containing 1 mg/mL of 
DZNep in 5% glucose solution (equal to 1/3 volume of solvent mixture) was added to the 
organic solvent phase and the mixture was sonicated for 4 min. The organic solvent was 
removed under vacuum on a rotary evaporator at 60 OC for about 1 hour, leaving white and gel-
like multilamellar (MLV) liposomes. Size reduction of liposomes was carried out by sonication 
followed by sequential extrusion at 60 OC. As such, the DZNep-loaded small unilamellar (SUV) 
liposomes were obtained. The final lipid concentration was approximately 40 mM while the 
DZNep concentration around 1 mg/kg. 
The coarse L-DZNep was then subject to five consecutive dialysis cycles against 50 mL 
of 5% glucose solution to remove unencapsulated DZNep, each for one hour. L-DZNep 
prepared by this REV method was stored at 4 OC. 
7.2.4.2 Remote-loading in the absence of PBA (R-wo-PBA) 
7.2.4.2.1 Preparation of blank SUV liposomes and formation of ammonium sulphate 
gradient 
Blank liposomes were prepared using the reverse-phase evaporation (REV) method with 
some modifications. Of notice, the water phase consisted of 250 mM ammonium sulphate 
solution instead of 1 mg/mL of DZNep in 5% glucose and other procedures were same as the 
above mentioned REV method until the extrusion step. SUV blank liposomes containing 250 
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mM ammonium sulphate solution were then subject to five consecutive dialysis cycles against 
50 mL of 5% glucose solution, each for eight hours. This dialysis removed most of the 
unencapsulated ammonium sulphate and established a trans-membrane ammonium sulphate 
gradient. The prepared liposomal mixtures were stored at 4 OC for at most one day. 
7.2.4.2.2 Drug uptake in Liposomes 
10 mg/mL of DZNep in 5 % glucose solution was incubated with blank 
liposomes with a volume ratio of 1: 10 at 60 OC for 2 hours. The final DZNep 
concentration in the mixture was approximately 1 mg/mL. The mixtures were allowed 
to cool to room temperature (25 OC) and any unencapsulated DZNep was removed 
through 5 consecutive dialysis cycles with 50 mL of 5% glucose solution using dialysis 
membrane tubing (Spectra/Por Biotech, USA), each for one hour.  
7.2.4.3 Remote-loading in the presence of PBA (R-w-PBA) 
For R-w-PBA, PBA was mixed and incubated with DZNep in 5 % glucose solution in 
the molar input ratio of 8: 1 for 5 min before this mixture was incubated with blank liposomes. 
The final DZNep concentration was around 1 mg/mL. Then, this mixture was incubated with 
blank liposomes at 60 OC for 2 hours. The subsequent steps were similar to the preparation of R-
wo-PBA as described above.  
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7.2.5 Characteristics of L-DZNep 
7.2.5.1 Encapsulation Efficiency of DZNep in liposomes 
The encapsulation efficiency of DZNep into liposomes was determined by dialysis. 
Briefly, L-DZNep samples were collected equally before and after the unencapsulated drug 
were removed by dialysis. One treated by dialysis was denoted as dialysis sample. The other 
was denoted as initial sample. Two sets of samples were diluted to the same volume using 5% 
glucose solution. Both were subject to treatment with 2 % Triton X-100 solution as described in 
the section 7.2.2.3 to release encapsulated drugs. DZNep concentration was quantified using the 
validated HPLC-UV method. Thus, encapsulation efficacy was determined using the following 
equation, 







Where [Drug]initial refers to the DZNep content in the initial sample while [Drug]dialysis to 
the encapsulated DZNep in the dialysis sample. 
7.2.5.2 Zeta potential and size of L-DZNep 
The Zeta potential, size and polydispersity of L-DZNep were measured using dynamic 
light scattering (Zetasizer 3000HS).  
7.2.5.3 Microscopic observation of L-DZNep 
The L-DZNep was observed with a transmission electron microscopy (TEM). A drop of 
the sample dispersion was placed on a 100 mesh copper grid, and then the excess dispersion 
was removed with a piece of filter paper. A drop of 2% phosphotungstic acid solution (pH 7.4) 
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was added to the grid and then dried for 1 h in a desiccator. The morphology of the L-DZNep 
was observed by TEM (JEM-3010, JEOL, Japan). 
7.2.5.4 In vitro release of encapsulated DZNep from L-DZNep 
The in vitro release of encapsulated DZNep from L-DZNep was performed as described 
by Meng et al. (290). Briefly, the release of DZNep from L-DZNep was performed against 5% 
glucose solution using the dialysis membrane tubing (Spectra/Por Biotech, USA) with 
molecular weight cut-off of 12 kDa. Aliquots of 1 mL of L-DZNep diluted with 5% glucose or 
plasma at 1:1 ratio were placed in dialysis tubing, which were immersed in 100 mL of 5% 
glucose and then incubated at 37 OC with constant stirring (500 rpm) using magnetic heat stirrer. 
At 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36 and 48 h, 100 µL of the exterior medium were aliquoted out 
and replaced with 100 µL fresh medium. As the recipient samples contained substances from rat 
plasma, the concentration of DZNep in such a medium was analyzed using a LC-MS/MS 
method as described previously in Chapter 5. The cumulative release percentages of DZNep 
were calculated as the DZNep content in the exterior medium at each time point divided by the 
DZNep initially added in the dialysis tubing. 
7.2.6 Pharmacokinetics studies of L-DZNep 
7.2.6.1 Animals 
The female Sprague Dawley (SD) rats were provided by Laboratory Animal Center 
(National University of Singapore, Singapore), and housed in temperature controlled room 
(25OC) with a 12-h light-dark cycle. The research protocol was approved in advance by the 
Animal Ethics Committee of National University of Singapore. Sterile polyethylene cannulas 
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(PE50, I.D. 0.58mm, Becton Dickinson) were implanted in the jugular vein of rats under 
ketamine/xylazine anesthesia as described by Thrivikraman et al. (264), and animals were 
allowed to recover from surgery for 1 to 2 days.  
7.2.6.2 Pharmacokinetic experiments 
12 Female SD Rats were randomly divided into two groups (each group consisting of 
six rats). One group was given a single intravenous dose of DZNep solution at 1 mg/kg while 
the other a single dose of L-DZNep, also at 1 mg/kg, via the vein tail (both preparations 
consisted of 0.5 mg/mL DZNep in 5 % glucose solution). At 0, 0.016, 0.083, 0.17, 0.5, 1, 3, 6, 9, 
12, 24, 48 h after dosing, 0.2 mL blood samples were collected via the jugular vein cannula in 
heparinised polypropylene tubes. The plasma was separated by centrifuging the blood samples 
for 10 min at 2000 g and stored at -20OC until analysis using the LC-MS/MS method with a 
modified sample pretreatment. Briefly, 10 µL 10 % Triton X-100 were added to aliquots of 100 
μL of plasma samples. The mixture was vortexed for 1 min to release the remaining of 
encapsulated DZNep in L-DZNep. The subsequent procedure was then subject to the same 
assay method for rat plasma samples containing free DZNep.  
7.2.6.3 Pharmacokinetics analysis 
The plasma pharmacokinetic parameters describing the DZNep plasma concentration 
curve were assessed using model-independent non-compartmental analysis with WinNonLin 
5.0.1 (Pharsight, Mountain View, CA),. The initial concentration (C0) after intravenous 
injection was determined by extrapolating the curve to t = 0 obtained through linear regression 
on the logarithmic transformation using the first several data points. The terminal plasma half-
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life (t1/2, λz) was calculated as 0.693/λz. The volume of distribution during the terminal phase (Vz) 
was estimated as CL/λz. The other PK parameters were estimated including the plasma 
clearance (CL), AUC from time zero to infinity (AUC0-∞), the mean residence time (MRT),  the 
volume of distribution at steady state (Vss) as described previously in Chapter 6, section 6.2.2.2.  
7.2.7 Statistical analysis 
All data were shown as means ± standard deviation (SD). Statistical analysis was 
performed using SPSS 10.0 (SPSS Inc., USA). Comparisons between two groups were made 
using Student’s independent-samples t-test and with more than two groups, one-way analysis of 
variance (ANOVA) was performed followed by the Tukey tests used for post hoc multiple 
comparisons between individual groups. The statistical significance level was set to be p < 0.05. 
 
7.3 Results  
7.3.1 HPLC-UV method development 
Under our chromatographic condition, the elution time for ribavirin (IS), DZNep and 
PBA was 1.72 ± 0.05 min, 2.08 ± 0.05 min and 12.80 ± 0.20 min, respectively (Figure 7.1B and 
1C). Injection of blank liposome lysis showed the interference signals was negligible at the 
location of IS, DZNep and PBA in the chromatogram (Figure 7.1A). As shown in Table 7.1, the 
coefficient of determination (R2) was greater than 0.99 in all in vitro samples. The LLOQ for 
DZNep and PBA was determined as 0.5 μg/mL and 1 μg/mL (Figure 7.1B and C), respectively. 
At the LLOQ, the RSD of both compounds was lower than 10 % and the accuracy was within ± 
15 % of the nominal values.  
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Table 7.1 Validation characteristics of HPLC-UV method for assaying DZNep and PBA in the 
presence of blank liposome lysis  
  DZNep PBA 
Standard curve y =  0.0933x + 0.0486 y = 0.0608x - 0.2491 
Linear range 0.5 ~ 100 μg/mL 1.0 ~ 1000 μg/mL 
Coefficient of determination (R2)  0.9997 0.9998 
LLOQ  0.5 μg/mL 1.0 μg/mL 
Accuracy of LLOQ 84 ~ 108% 93 ~ 107% 
Precision of LLOQ 9.9% 6.4% 
 
 
Figure 7.1 HPLC-UV chromatogram of (A) a blank liposome lysis, (B) a blank liposome lysis 
spiked with DZNep at 0.5 μg/mL (LLOQ) and IS at 5 μg/mL, (C) a blank liposome lysis spiked 
with PBA at 1 μg/mL (LLOQ) and IS at 5 μg/mL, (D) a L-DZNep lysis spiked with IS at 5 
μg/mL after drug loading and before removing encapsulated DZNep and PBA by the dialysis. 
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7.3.2 LogKow at pH 7.4 and stability of DZNep in weak acidic and 
neutral aqueous buffers at 60OC 
As shown in Table 7.2, within the concentration range of 5-50 µg/mL at pH 7.4, the 
experimental LogKow was -1.09 ± 0.03 in a concentration-independent manner (p = 0.10). In 
addition, after 50 μg/mL of DZNep were incubated in citrate buffer (pH 4.0) and 5% glucose 
solution (pH 7.0) at 60oC for 2 h, the recovery of DZNep was found to be 97.6 ± 1.2 % (pH 4.0) 
and 98.3 ± 1.3 % (pH 7.0), respectively.  
Table 7.2 LogKow of DZNep in PBS buffer (pH 7.4) 
DZNep spiked (µg/mL) 50 10 5 p 
LogKow -1.08 ± 0.03 -1.13 ± 0.04 -1.07 ± 0.02 0.104
Mean of LogKow -1.09 ± 0.03        
 
 
7.3.3 Optimization of the preparation method of L-DZNep by the 
determination of encapsulation efficiency 
The encapsulation efficiency of DZNep within SUV liposomes using the REV method 
was 5.90 ± 0.50 % while that using the R-wo-PBA method was 6.8 ± 0.7 % (Figure 7.2). In 
contrast, the encapsulation efficiency of DZNep in L-DZNep reached 47.5 ± 4.1 % using the R-
w-PBA method, which was significantly higher than those using the other two methods (p < 
0.01). As seen from Figure 7.3, after 5 times dialysis against 5 % glucose solution, the 
remaining PBA in the liposomes was 8.0 µg/mL (0.3 % of initial input) while the remaining 
DZNep in the liposomes was 350 µg/mL (43.9 % of initial input).  
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Figure 7.2 Encapsulation efficiency of L-DZNep prepared using various methods (mean ± SD, 
n = 3). R-w-PBA, remote loading in the presence of PBA; R-wo-PBA, remote loading in the 
absence of PBA; REV, reverse-phase evaporation. ** p < 0.01 (R-w-PBA was compared with 
the other two methods). 
 
 
Figure 7.3 HPLC-UV overlapped chromatogram showing the comparison of the amount of 
DZNep and PBA in the liposomes, before (blue line) and after (red line) removing free 
compounds using dialysis bag against 5% glucose solution (sink condition) 5 times, each for 1h. 




7.3.4 Physicochemical characteristics of L-DZNep 
Figure 7.4 shows that the mean size of L-DZNep was 98.0 ± 2.7 nm and the 
polydispersity index was 0.20. As shown in Figure 7.5, the L-DZNep appeared mostly spherical 
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and uniform in size ranging around 100 nm as measured by a transmission electron microscopy 




Figure 7.4 Particle size of L-DZNep (mean: 98.04 ± 2.7338 nm and polydispersity: 0.20) 
produced by extrusion of MLVs or LUVs through 0.1 µm polycarbonate membrane filters 10 
times.  
 
Figure 7.5 Transmission electron microscopy (TEM) photograph of L-DZNep stained with 2% 
phosphotungstic acid solution. The liposomes obtained are relative homogenous in dimensions 
(right x 10K, 100KV) and, at higher magnification (left x 50K, 100KV). All the liposomes were 
produced by extrusion of MLVs or LUVs through 0.1 µm polycarbonate membrane filters 10 
times. 
 
7.3.5 In vitro drug release  
The in vitro release profiles of DZNep from pegylated liposomes and free drug solution 
(control) in both 5 % glucose solution and rat plasma are shown in Figure 7.6. The release of 
free DZNep in both media was completed in 1 h. Approximately 30 % and 45 % of DZNep 
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were rapidly released over a period of 6 h from L-DZNep in 5 % glucose solution and rat 
plasma, respectively. After this initial burst, the DZNep was then released steadily, with the 
maximal release percentage at around 45 % and 65 % in 5% glucose and rat plasma, 
respectively. Total amount released from L-DZNep in rat plasma was significantly higher than 
that in 5 % glucose (p < 0.05). 













L-DZNep in 5% glucose
L-DZNep in rat plasma
DZNep in rat plasma



















Figure 7.6 In vitro cumulative DZNep release from L-DZNep (0.36 mg/mL) in 5% glucose (■) 
or plasma (□). In vitro cumulative DZNep release from free drug (0.36 mg/mL) inside dialysis 
bag in 5% glucose (●) or plasma (〇) served as the control groups. Data are shown as mean ± 
SD (n = 3). *, p < 0.05 for the in vitro cumulative DZNep release from L-DZNepat each time 
point after 6 h between 5 % glucose and rat plasma. 
 
7.3.6 Pharmacokinetic studies of L-DZNep 
The plasma concentration-time profiles of DZNep following intravenous bolus dosing of 
1mg/kg DZNep as free drug or pegylated liposomes in SD rats are shown in Figure 7.7. The 
plasma DZNep concentration declined dramatically in the free drug group, which was lower 
than the effective level (622 ng/mL, Chapter 2, section 2.2.1) after 10 min postdose and finally 
fell below LLOQ (20 ng/mL, Chapter 5, section 5.3.4) after 3 h postdose. In contrast, after an 
identical dose of DZNep in liposomes group was administered to rats, the plasma DZNep 
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concentration declined slowly and was maintained above the effective dose level up to 24 h and 
above the LLOQ for a period of at least 48 h postdose. The mean pharmacokinetic parameters 
of DZNep after intravenous administration of the two formulations in SD rats are summarized 
in Table 7.3. The area under the plasma concentration-time curve (AUC0-∞) was also markedly 
increased by approximately 138-fold in L-DZNep group (74.8 ± 9.0 h·µg/mL) in comparison 
with the free DZNep group (0.54 ± 0.03 h·µg/mL). The plasma clearance of DZNep following 
administration of L-DZNep (CL, 13.5 ± 1.6 mL/h/kg) to SD rats was substantially reduced by 
99.3 % as compared to that of the free DZNep (1850.1 ± 91.1 mL/h/kg). The steady state 
volume of distribution (Vss) of DZNep encapsulated in liposomes was found to be 0.13 ± 0.01 
L/kg, which was about one-tenth of that of the free drug (1.34 ± 0.16 L/kg). Thus, encapsulation 
of DZNep in pegylated liposome caused a 6-fold increase in the elimination half-life (T1/2,z: 1.1 
± 0.1 h in the free DZNep versus 8.0 ± 1.4 h in the L-DZNep, p<0.01)  and a 13-fold increase  
in the mean residence time (MRT: 0.7 ± 0.1 h in the free DZNep versus 10.1 ± 1.5 h in the L-
DZNep, p<0.01) as compared to the free DZNep.  
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Figure 7.7 Plasma DZNep concentration-time profiles following i.v. injection of DZNep 
solution (▲) and L-DZNep solution (△) in SD rats. The dose for two formulations was 1 
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mg/kg BW. Each value represents mean ± SD (n = 6). The lower dotted line indicates the LLOQ 
(20 ng/mL) of LC-MS/MS method for quantifying DZNep in the rat plasma. The upper dotted 
line indicates the effective level (655 ng/mL or 2.5 µM) which induced time-dependent cell 
death and reactivation of EZH2 related repressed genes in various solid tumors. 
 
Table 7.3 Pharmacokinetic parameters (mean ± SD) of DZNep after intravenous injection of 
DZNep solution or L-DZNep in six SD rats at the dose of 1 mg/kg BW 
Parameter Units Free DZNep L-DZNep ** 
λz 1/h 0.63 ± 0.04 0.09 ± 0.01  
T1/2,z h 1.1 ± 0.1 8.0 ± 1.4  
C0 µg/mL 6.7 ± 0.7 13.8 ± 0.8 
AUC0-∞ h·µg/mL 0.54 ± 0.03 74.8 ± 9.0 
Cl mL/h/kg 1850.1 ± 91.1 13.5 ± 1.6 
MRT h 0.7 ± 0.1 10.1 ± 1.5 
Vss L/kg 1.3 ± 0.2 0.13 ± 0.01 
Vz L/kg 2.9 ± 0.1 0.15 ± 0.02 
** p < 0.01 for all the PK parameters between two groups. 
 
7.4 Discussion 
The main purpose of this study was to improve the disposition characteristics of DZNep 
in vivo through the development of a unilamellar pegylated liposomal formulation. A reliable 
and simple HPLC-UV method was developed for quantification of DZNep and PBA in in vitro 
samples, except those containing rat plasma. As both DZNep and ribavirin are nucleoside 
analogues, sharing similar chemical structure and close hydrophilicity (ACD/LogD, pH 5.5: -
2.21 for DZNep and -2.26 for ribavirin) in acidic condition, ribavirin was chosen as an IS in 
HPLC-UV method development. In addition, the HPLC-UV assay method for of ribavirin (169) 
was employed and optimized for the quantification of DZNep in vitro. Although the HPLC-UV 
method  was not as sensitive (e.g., LLOQ:  DZNep, 0.5 μg/mL and PBA, 1 μg/mL; Table 7.1)  
as the LC-MS/MS method (e.g., LLOQ: DZNep, 20 ng/mL; Chapter 5), its application in 
quantification of DZNep and PBA in vitro for liposome preparation was sufficiently adequate 
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as the expected concentration range of DZNep was from 5 to 200 μg/mL while that of PBA was 
from 1.5 to 750 μg/mL.   
As the octanol-water partition coefficient (Kow) best measures the behaviour of a 
compound toward a membrane, it plays an important role in encapsulation efficiency of the 
compound in the liposomes (291). It has been reported that the liposomes would favourably 
encapsulate drugs with a high LogKow value (> 5) but not those with an intermediate LogKow 
value (1.7 ~ 4) (292, 293). Additionally, those with a low LogKow value (< -0.3) often possess 
the low entrapment and high leakage properties (292, 293). The concentration-independent 
LogKow of DZNep determined was -1.09 ± 0.03 (Table 7.2), indicating the high hydrophilicity 
of DZNep in a physiological condition. Thus, the conventional DZNep liposome would have 
the potentially low encapsulation efficiency and high leakage of DZNep if the conventional 
preparation methods such as the REV or the R-wo-PBA method were employed (Figure 7.2). 
Moreover, the in vitro stability test showed that the content of DZNep remained constant in the 
weakly acidic and neutral aqueous solution at 60OC. This ensures that DZNep would be highly 
stable for a L-DZNep preparation using the remote-loading method.  
The REV method was initially employed as a formulation optimization for its known 
efficient way of encapsulating hydrophilic drugs (288).  To obtain a desired formulation size 
(around 100 nm), which is a key factor for the efficient extravasation of an antitumor vesicle 
through fenestrated endothelium of tumor blood vessel walls (283), the sequential extrusion at 
60 OC through Nuclepore® Polycarbonate membranes with pore size of 0.2 µm and 0.1µm was 
applied. However, the encapsulation efficiency of DZNep inside SUV liposomes was found to 
be as low as 5.9 % (Figure 7.2). Obviously, the REV method was ineffective for encapsulating 
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DZNep. Possibly, the extrusion might induce heavy leakage of encapsulated DZNep by 
breaking lipid membrane and diminishing interior aqueous volume. In addition, a remote-
loading procedure in the absence of PBA (R-wo-PBA) did not significantly improve any 
encapsulation efficiency (6.8 ± 0.7%) (Figure 7.2). The hydrophilic property of DZNep, owing 
to the presence of three hydroxyl groups in cyclopentenyl sugar moiety, might considerably 
compromise the pH gradient driving force. In light of the purification mechanism of ribavirin 
containing vicinal hydroxyl groups (cis diol), which specifically bind to phenylboronic acid 
(PBA) at basic or neutral pH using Bond Elut PBA SPE columns (169), the remote-loading 
procedure was modified by incubating PBA and DZNep for 5 min before DZNep was added 
into blank liposomes. The remote-loading method in the presence of PBA (R-w-PBA) was 
effectively optimized to obtain a significantly better encapsulation efficiency of DZNep (47.5 ± 
4.1%), as compared to both the REV and R-wo-PBA methods (Figure 7.2), suggesting that PBA 
plays a key role in the accumulation of DZNep inside the liposomes. A transient complex of 
PBA and DZNep could be produced in the neutral outer phase of the liposomes, which could 
readily enter the inner phase through the lipid bilayer (285). Then, the complex would be 
spontaneously dissociated in the acidic environment as depicted by the chemical reaction in 
Figure 7.8A. Due to the presence of a protonable amino group in the DZNep molecule (pKa = 
6.22), the free DZNep would be protonized immediately and thus retained within the liposome 
interior.  
As PBA is not a pharmaceutically acceptable additive, the riddance or reduction of the 
amount of PBA encapsulated in the liposomes is required. The 5 times dialysis method using 
5% glucose solution appeared to reduce more selectively the amount of PBA (0.27% of initial 
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input) than that of DZNep (43.9% of initial input) (Figure 7.3). This might be due to the 
differences in pKa and LogKow between the two compounds. Without any protonable moiety, 
PBA always presents neutral form both inside and outside the liposomes. This enables PBA to 
readily and passively transport across the lipid membrane. Coupled with the intermittent 
ACD/LogKow (1.59), which is close to the intermediate partition coefficients (1.7 < logKow < 4)  
(292, 293), PBA would partition effortlessly between the lipid and aqueous phases. Therefore, 
PBA is a satisfactory shuttle in improving the encapsulation efficiency of DZNep while being 
easily washed off at the end of the dialysis.  
Based on these findings in the liposomal preparation, the chemical reaction of the 
DZNep-PBA complex and the remote-loading model in the presence of PBA are summarized in 
Figure 7.8. Of notice, hydrophilic compounds with both a cis diol group and a pKa value of 
greater than 4, such as DZNep (pKa = 6.22), could be protonized and entrapped inside the 
acidic inner of liposomes using the remoting-loading method. However, this proposed 
underlying mechanism may be different from Zalipsky’s model (286) which deals with the 
other compounds containing a cis diol group, whose pKa values are less than 4, such as 
ribavirin (pKa = -1.59), riboflavin (pKa = 2.56), fluorouridine (pKa = -5.81), 8-chloroadenosine 
(pKa = 3.31), could  not be protonized at the inner acidic condition (around pH 4.0) of 
liposomes prepared using R-w-PBA. Thus, one would expect that these compounds could not 
be firmly incorporated in the liposomes. The relatively high leakage of these compounds from 
the intraliposome would occur during storage.  
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Figure 7.8 (A) A chemical reaction involved in the product of the reversible DZNep-PBA 
complex through dehydration in the external solution of the liposomes. (B) Schematic 
representation of diffusion and entrapment mechanism of DZNep in the presence of PBA. In the 
beginning, a transmembrane pH gradient (neutral outer phase and acidic inner phase) is formed 
through the dialysis to remove the outer ammonium sulfate. A transiently stable lipophilic 
DZNep-PBA complex in the neutral external solution is generated, which is capable of diffuse 
across the bilayer. As for the free DZNep in the outer space, the diffusion rate is limited by the 
hydroxyl groups in cyclopentenyl sugar moiety. Dissociation of the complex occurs in the 
acidic inner compartment of liposomes. Due to the presence of a protonable amino group in the 
DZNep molecule (pKa = 6.22), the dissociated DZNep is ionized at once in the acidic condition. 
The protonized form of DZNep is impermeable to the liposome lipid bilayer, thus, remains 
entrapped in the liposomes. As PBA cannot be protonized readily and possesses an intermediate 
LogKow (1.59), it could easily traverse the lipid bilayer and return to the exterior space of 
liposomes to shuttle another drug molecule. For the same reason, PBA can be easily removed at 
the end of the experiment. 
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The size and surface zeta potential of liposomes are key determinants for the level of the 
residence time of liposomes in blood, the transfer of liposomes from blood to tumor tissue 
interstitial spaces, the local retention of liposomes in the tumor tissue and the efflux of 
liposomes from the tumor tissue to the blood (193). Generally, the optimal size for elevating the 
level of tumor accumulation of the peylated liposomes is around 100 nm (294). As shown in 
Figure 7.4, the mean size of L-DZNep was 98.04 nm with the polydispersity index of 0.20, 
suggesting that L-DZNep possesses a satisfactory formulation size and a homogenous size 
distribution. The zeta potential of L-DZNep was found to be mildly negative at -12.70 mV 
(RSD = 4.38%). Although charged liposomes demonstrate a better physical stability than 
neutral liposomes while being stored (295), the negatively charged liposomes tend to have a 
short elimination half-life in blood than their neutral counterpart (296). 
The release of free DZNep in both 5 % glucose solution and rat plasma was completed 
around 1 h, indicating that drug penetration through dialysis membrane was not a limiting step 
(Figure 7.6). The rapid release of DZNep over a period of 6 h from L-DZNep in both the media 
(Figure 7.6), possibly was due to the leaked DZNep during storage or the liposomes with small 
diameters  (e.g. around 50 nm). A larger curvature of these liposomes might result in the release 
of the drug more readily (193). DZNep released from L-DZNep was significantly increased in 
the presence of rat plasma (p < 0.05) (Figure 7.6), indicating that the plasma protein could 
speed up the leakage of DZNep from the liposomes. Two possible mechanisms could account 
for the enhanced leakage: i. the interaction of liposomes with serum proteins leads to the 
transfer of liposomal lipids to serum lipoproteins (297); and ii. the insertion of complement 
components results in the formation of a 10 nm diameter pore-like membrane attack complex 
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(MAC) (298). Besides, serum proteins have been implicated in opsonisation, i.e., the process of 
binding of serum proteins, such as complement components, which promote the recognition and 
uptake of foreign particles by the mononuclear phagocyte system (MPS) (299, 300). Thus, the 
release of contents in liposomes is facilitated in vivo, but not in in vitro conditions, suggesting 
that in vitro release study can only partially predicts in vivo drug release. 
Since the two plasma concentration-time profiles of free DZNep and L-DZNep were 
best described by the three-compartment and two-compartment disposition models (data not 
shown), respectively, the noncompartmental PK analysis was performed for comparing the PK 
parameters of these two formulations. In comparison with the free drug, encapsulation of the 
DZNep in pegylated liposome markedly increased AUC as a result of the 99.3 % reduction of 
the plasma clearance and 90 % reduction of the steady-state volume of distribution, and thus 
increased the plasma elimination half-life by 6-fold and the mean residence time by 13-fold 
(Table 7.3). The steady-state volume of distribution of the drug encapsulated in liposomes (0.13 
L/kg) was significantly less than the total tissue water (0.79 ± 0.012 L/kg) in rats (188), 
suggesting that L-DZNep is largely confined between the systemic circulation and the 
extracellular space in the body. Therefore, this liposome formulation could effectively prolong 
the retention of DZNep in the systemic circulation. The more liposomes circulate in blood for a 
longer period, the greater their accumulation in tumor may occur (193). Accordingly, this 
formulation (L-DZNep) is highly likely to increase the DZNep’s tumor localization as well as to 
improve the drug therapeutic index in further preclinical studies with animal models bearing 
human tumor xenograft. 
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In summary, a reliable and simple HPLC-UV method for quantification of DZNep and 
PBA in in vitro samples (except those containing rat plasma) was developed. DZNep is a 
hydrophilic compound and highly stable in the weakly acidic and neutral aqueous solution at 
60OC. The remote-loading method in the presence of PBA was effectively optimized to obtain 
an appropriate encapsulation efficiency of DZNep, a satisfactory vesicle mean size, a 
homogenous size distribution, a mildly negative zeta potential value and a sustained-release 
property for DZNep in vitro, all of which suggest that the L-DZNep is a suitable candidate for 
the in vivo delivery of DZNep to rats via intravenous injection. The entrapment of DZNep 
within a pegylate liposomal carrier noticeably ameliorated the pharmacokinetic parameters of 
DZNep, including the marked increase in the distribution half-life, the elimination half-life, the 
initial plasma concentration, the mean residence time and the area under the concentration-time 
curve, as a result of substantial decrease in the plasma clearance and the steady-state volume of 
distribution. Therefore, the liposome formulation could effectively prolong the retention of 
DZNep in the systemic circulation, and hopefully improve the DZNep’s tumor localization and 
the drug therapeutic index in future preclinical and clinical studies. This study also provides a 
valuable example for the liposomal development of the hydrophilic nucleoside analogues 
containing a cis diol group and a pKa value of greater than 4.  
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CHAPTER 8  




3-deazaneplanocin A (DZNep) has been found to inhibit the tri-methylated histone H3 at 
lysine 27 (H3K27me3) by depleting enhancer of zeste homolog 2 (EZH2) protein and 
preferentially induce apoptosis in breast cancer cells. The ultimate goal of this study is to 
characterize the relationship of EZH2 with other epigenetic events by the pharmacological 
disruption using the EZH2 inhibitor, DZNep, in combination with the other two epigenetic 
compounds, trichostatin A (TSA) and 5-aza-2’-deoxycytidine (AZA) in breast cancer cells and 
to perform the preclinical study of DZNep in female Sprague Dawley (SD) rats.  
In Chapter 1, recent understandings of epigenetic events including histone modification 
and DNA methylation, which are involved in cancer progression, and of the development of 
EZH2 inhibitor, DZNep and other epigenetic enzyme inhibitors in cancer therapy are reviewed. 
In addition, due to limited information of DZNep in the literatures, physicochemical, 
metabolism, toxicity, pharmacokinetic and systemic delivery properties of DZNep in animals 
are assessed via the available information of other nucleoside analogs. The rationales for the 
investigation of the relationship between EZH2 and other epigenetic events through the 
pharmacological disruption using DZNep in combination with other epigenetic agents in breast 
cancer cells and of the preclinical properties of DZNep in SD rats are provided, and the 
objectives of this thesis are listed. 
In Chapter 2, coupled with chromatin immunoprecipitation and gene knockdown by 
RNA interference, three distinct expression response patterns (D pattern, D+T pattern and 
D+T+A pattern) were found through gene clustering analysis in MCF-7 cells treated with 
 183
various combinations of three drugs (DZNep, TSA and AZA). Those patterns observed in 
MCF-7 cells were extended to one representative gene, GAGE2, in other breast cancer cell lines 
(SK-BR-3 and BT-474 cells), demonstrating that they could appropriately explain the 
relationship between EZH2 and other epigenetic events (HDAC and DNA methylation) in the 
breast cancer cells. The data indicated that the gene transcription could be regulated by EZH2-
H3K27me3 alone (D pattern) or in combination with HDAC (D+T pattern), but seldom be 
simultaneously regulated by EZH2 combined with HDAC and DNMT (D+T+A pattern) (< 5%). 
However, of this small set of D+T+A patterns genes, GAGE2 was verified that its reactivation 
had implications in clinical immunotherapy for breast cancer. Of notice, a prominent set of 
genes regulated by EZH2 plus HDAC was implicated in inflammation and immunity network. 
From this set of genes, TNF, a cell death gene, was found to be associated with the DZNep plus 
TSA induced cell death in breast cancer cells through pharmacological perturbation of EZH2 
and HDAC (Chapter 3). Therefore, In addition to yielding novel insights into epigenetic 
regulation, this study provides a new perspective for epigenetic therapy: the best strategy lies in 
the development of combinatory approach that targets multiple regulatory components or 
mechanisms.  
As the only EZH2 inhibitor with specific antitumor function by far, the preclinical 
toxicity study of DZNep was performed in Chapter 4. It was found that DZNep caused 
nephrotoxicity and renal atrophy in rats in a dose-dependent manner but had no apparent effect 
on the hematological system of rats. The median lethal dose (LD50) was around 26 mg/kg 
DZNep. Most importantly, no observable adverse effect level/dose (NOAEL) of DZNep 
determined was 10 mg/kg body weight, based on various endpoints (body weight, organ weigh, 
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clinical signs and clinical chemistry parameters). These results provide valuable information 
regarding initial safe dose and target organs for toxicity, which serves as a firm basis for further 
investigation of DZNep in preclinical and clinical phase.  
In Chapter 5, a sensitive, selective and reliable liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS) method for the quantification of DZNep in rat 
biosamples was established. A Zorbax hydrophilic interaction chromatography (HILIC) column, 
capable of achieving satisfactory retention and separation of small, polar analytes, was used for 
separation of DZNep and tubercidin (internal standard) in rat biosamples. The Bond Elute PBA-
SPE cartridges were used to minimize the matrix effects and achieve the acceptable extraction 
recovery through cleaning up rat biosamples. To our knowledge, it is the first report of LC-
MS/MS method for the determination of DZNep in biosamples. The assay was demonstrated to 
be ruggedly and successfully used for the routine analysis of varied biosamples to generate 
ADME parameters of DZNep in the preclinical study. 
In Chapter 6, the disposition characteristics of DZNep was thoroughly investigated in 
the SD rats in an attempt to examine whether further antitumor study of this compound in 
human tumor xenografts animals would be feasible. The present preclinical studies indicated 
that, following an intravenous bolus administration, across the investigated dosage range (1, 5, 
and 10 mg/kg body weight), DZNep had a dose-independent pharmacokinetic profile with a 
short elimination half-life (1.1 h) and a short mean residence time (0.9 h). DZNep also showed a 
low protein binding in plasma (18.5 %) and low partitioning to erythrocyte (0.78), but had 
extensive tissue distribution, especially in kidney (21.25 ± 2.12 µg/g at 5 min), and predominant 
renal excretion (80.3 % excreted in urine by 72 h). In addition, DZNep was not extensively 
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metabolized in vivo (totally 86.80 % recovery of unchanged DZNep from urine and feces by 72 
h). Overall, these results provide clear evidence that DZNep has an undesirable PK profile for 
further clinical application. 
In Chapter 7, to overcome the shortcoming of a short elimination half-life and the short 
mean residence time of DZNep, a unilamellar pegylated liposomal formulation was developed. 
A remote-loading method in the presence of phenylboronic acid (PBA) was effectively 
optimized to obtain an appropriate encapsulation efficiency of DZNep (47.5%), a satisfactory 
vesicle mean size (around 100 nm), a homogenous size distribution, a mildly negative zeta 
potential value (-12.7 mV) and a sustained-release property for DZNep in vitro release test, all 
of which suggest the L-DZNep a suitable candidate for the in vivo delivery of DZNep to rats via 
intravenous injection. The entrapment of DZNep within a pegylated liposomal carrier 
noticeably ameliorated the pharmacokinetic parameters of DZNep as compared to the free drug 
in rat plasma, including the marked increases in the elimination half-life (6.2 fold), the mean 
residence time (13.4 fold) and the area under the concentration-time curve (138 fold), as a result 
of substantial decreases in the plasma clearance by 99.3 % and the apparent steady state volume 
of distribution by 90 %. Therefore, the liposome formulation could effectively prolong the 
retention of DZNep in the systemic circulation, and hopefully improve the DZNep’s tumor 
localization and the drug therapeutic index in future preclinical and clinical studies. This study 
also provides a valuable example for the liposomal development of the hydrophilic nucleoside 
analogues containing a cis diol group and a pKa value of greater than 4.  
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8.2 Future Directions 
There are several interesting directions for future works according to the current 
findings in this dissertation.  
In Chapter 2, it was found that the triple combination treatment (DZNep, TSA and AZA) 
did not induce GAGE2 gene transcription in normal breast cells (MCF10A) due to the 
enrichment of tri-methylated histone H3 at lysine 9 (H3K9me3) at GAGE2 locus and thus 
would not induce DZNep-related side-effects in normal breast cells. In future works, it is 
worthwhile to explore the effect of such a triple treatment on the GAGE2 at protein level and its 
potential application in cancer vaccines development in vivo. 
In Chapter 3, TNF, a cell death gene, was found to be associated with the DZNep plus 
TSA induced cell death in breast cancer cells. However, the function analysis is still needed for 
further validating the role of TNF in DZNep plus TSA induced cell death through blocking the 
TNF signalling pathway by TNF siRNA or TNFR1 neutralization in sensitive breast cancer cells. 
In Chapter 4, it was found that DZNep caused nephrotoxicity and renal atrophy in rats in 
a dose-dependent manner. However, the underlying mechanism of DZNep-induced 
nephrotoxicity remains obscure and needs to be further examined through investigation of 
microscopical renal changes and intracellular structural changes by histopathological techniques 
and electron-microscopy in a future study. 
Regarding LC-MS/MS assay, it took twelve minutes to accomplish the elution of one 
biosample in the Zorbax HILIC column (Chapter 5). Therefore, Acquity UPLCTM BEH 
hydrophilic interaction chromatography (HILIC) UPLC column as well as a UPLC-MS/MS 
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system can be applied and optimized to significantly shorten the elution time as well as to 
improve the sensitivity of DZNep in future works.   
The pharmacokinetic characteristics of DZNep in vivo were significantly improved 
through developing a unilamellar pegylated liposomal formulation of DZNep (L-DZNep) 
(Chapter 7). Therefore, in future works, it is worthwhile to evaluate the accumulation of DZNep 
in the tumor site using the microdialysis technique and the pharmacodynamic characteristics of 
L-DZNep in animal models bearing human breast cancer xenograft.  
Among the various combination treatments of three epigenetic compounds (DZNep, 
TSA and AZA), the DZNep plus TSA treatment showed the strongest induction of gene 
transciption and cell death in breast cancer (Chapter 2). Thus, it is important to further 
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Figure S1 qRT-PCR analysis of 12 genes confirms the results from Illumina microarray 
analysis. The left panel with blank histogram shows Illumina microarray data and the right 








Figure S2 Gene cluster showing the expression profiles of 148 EZH2 targets in MCF-7, SK-
BR-3 and MCF10A cells treated with DZNep (D), TSA (T) and DZNep plus TSA (D+T). 
 210
 
Figure S3 Mass chromatograms of DZNep (m/z, 263.3 / 135.1) in blank samples (urine, feces, 
heart, liver, spleen, lung, stomach, adipose, muscle and brain) under MRM mode. 
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Figure S4 Mass chromatograms of IS (m/z, 267.2 / 135.0) in blank samples (urine, feces, heart, 
liver, spleen, lung, stomach, adipose, muscle and brain) under MRM mode. 
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Figure S5 LLOQ biosamples spiked with DZNep at 20 ng/ml and IS at 100 ng/ml; biosamples 
consist of urine, feces, heart, liver, spleen, lung, stomach, adipose, muscle and brain. 
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Figure S6 Tissue samples (urine, feces, heart, liver, spleen, lung, stomach, adipose, muscle and 
brain) were obtained at 1h after an intravenous dose of 5 mg/kg DZNep administered in a 
healthy rat. A urine sample and a feces sample were obtained at 6 h and 24 h, respectively, after 











Figure S7 Observed (shown as circle) and model predicted DZNep plasma concentrations 
(shown as  line) versus time after a single intravenous dose of DZNep solution (10 mg/kg BW) 
in female SD rats using the reduced model (left) and full model (right) with a weighting factor 




Figure S8 Representative weighted residuals (shown as circle) versus time for the reduced 
model (left) and full model (right) with a weighting factor of 1/C after a single intravenous dose 
of DZNep solution (5 mg/kg BW) in female SD rats. 
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APPENDIX B. Supplementary Tables 
Table S1 the sequences of the PCR primer for RT-PCR, MSP, BGS and ChIP analysis for 
indicated genes 
 
Primers for RT-PCR 
Primer Sequence  
GAGE2-F 5’-CCGAGCAGTTCAGTGATG-3’  
GAGE2-R 5’-GACCCTGTTCCTGGCTAT-3’  
GAPDH-F 5’-CAAAGTTGTCATGGATGACC-3’ 
GAPDH-R 5’-CCATGGAGAAGGCTGGGG-3’ 
F: forward primer R: reverse primer 
 
 
Primers for MSP    
Primer Sequence Location (bp)  T (OC) Cycles
GAGE2-MF 5’-AGTTTTTTTTAGTTTATAGTCGCGT-3’  
GAGE2-MR 5’-AACTCCCTAACGTTCTTCACGTA-3’   59 33 
GAGE2-UF 5’-AGTTTTTTTTAGTTTATAGTTGTGT-3’  
GAGE2-UR 5’-ACAACTCCCTAACATTCTTCACATA-3’  -99～+13 60 33 
TNF-MF 5’-GGTTTAGAAGATTTTTTTCGGAATC-3’ 
TNF-MR 5’-TAAACCCTACACCTTCTATCTCGAT-3’ 56 32 
TNF-UF 5’-TTTAGAAGATTTTTTTTGGAATTGG-3’ 
TNF-UR 5’-TAAACCCTACACCTTCTATCTCAAT-3’ -273～-135 55 32 
CCL2-MF 5’-GGTTTGAAGGTAAGTTGGTAGC-3’  
CCL2-MR 5’-AAAAATTCTACTTTCTCTAAAACGAA-3’ 56 30 
CCL2-UF 5’-GTGGTTTGAAGGTAAGTTGGTAGT-3’  
CCL2-UR 5’-AAAAATTCTACTTTCTCTAAAACAAA-3’ -371～-272 58 30 
KRT17-MF 5’-GACGGGTTTGAGATTAGAGGTAC-3’   
KRT17-MR 5’-ATAAACCACCAAATAAACGTAACGA-3’  56 33 
KRT17-UF 5’-GTGATGGGTTTGAGATTAGAGGTAT-3’  
KRT17-UR 5’-AAACCACCAAATAAACATAACAAT-3’   -248～-47 56 33 
M: methylated U: unmethylated    
 
 
Primers for BGS     
Primer Sequence  Location (bp) T (OC) Cycles 
GAGE2 BGS-F 5’-TTTATTTTTAATGAGGATGGGTATG-3’   
GAGE2 BGS-R 5’-CCATTCAAAAAATCTACCCTATATC-3’   -154～+392 56 35 
 
Primers for CHIP  
Primer Sequence  Location (bp) 
GAGE2-1F 5’-TGTATGCCTTTAGGGTCA-3’  
GAGE2-1R 5’-TTTCCAACATAGGAGCAG-3’  -2413～-2276 
GAGE2-2F 5’-AACTCCTGACCTCGTGATT-3’  
GAGE2-2R 5’-AAGGCCGCTGGATAGAAA-3’  -1878～-1760 
GAGE2-3F 5’-ACATCCTTGTCTTATCCCTG-3’  
GAGE2-3R 5’-CGCTGTGGTAATCGAAAT-3’  -1423～-1234 
GAGE2-4F 5’-TCCAAACATCTTAGGACCAT-3’  
GAGE2-4R 5’-ACAGGACAGCCAGAGTGA-3’  -606～-505 
GAGE2-5F 5’-GGTGGTTTACCTGTCTTCCC-3’  
-328～-172 
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GAGE2-5R 5’-TGCTGTTTCCTATGCCTCT-3’  
GAGE2-6F 5’-CACGAGGTCGTCCTCCTTC-3’  
GAGE2-6R 5’-GCACTCACCCCGTCTTCA-3’  190～325 
GAGE2-7F 5’-AAACAGTGGGAAGGAGTGG-3’  
GAGE2-7R 5’-CCCGCAGACAGAGGTCAT-3’ 542～726 
GAGE2-8F 5’-AACGGCAAGTTTACATTTATCC-3’  
GAGE2-8R 5’-AAGCACTCACCCGCATAG-3’  1028～1214 
GAGE2-9F 5’-CCAGCCCGAGCAGTTCAGT-3’  
GAGE2-9R 5’-TTCCCTTTCCCTCACCTT-3’  1660～1805 
GAGE2-10F 5’-TGGAGGTGCCAGGATTGT-3’  
GAGE2-10R 5’-ATTCAGCGACTCGGTTTT-3’  2040～2272 
TNF-1F 5’-CCAGTGGCATCTACTTCGT-3’  
TNF-1R 5’-GCCCTGGATACACCATCT-3’  -2189～-2022 
TNF-2F 5’-ACACCTCCCTGAACCATC-3’  
TNF-2R 5’-TGTGCCTGCTCTTCCTCT-3’  -1697～-1561 
TNF-3F 5’-TGAAGCCCAATAAACCTC-3’  
TNF-3R 5’-TCCATCACATATCCCTGAA-3’  -1277～-1099 
TNF-4F 5’-GGGTCAGAATGAAAGAAGAAG-3’  
TNF-4R 5’-CTCAGGAAAGGCTGGGTG-3’  -677～-560 
TNF-5F 5’-GAATCGGAGCAGGGAGGAT-3’  
TNF-5R 5’-TGGAGGAAGCGGTAGTGGG-3’  -253～-120 
TNF-6F 5’-TTCTGCCTGCTGCACTTT-3’  
TNF-6R 5’-CTTTCACCCATCCCATCTC-3’ 311～441 
TNF-7F 5’-AGGGAAAGAGCTGTTGAA-3’  
TNF-7R 5’-CCAGAGGGCTGATTAGAG-3’  802～995 
TNF-8F 5’-GCCTGTAGCCCATGTTGT-3’  
TNF-8R 5’-CTGTTCCTCCACCCTTCC-3’  1223～1375 
TNF-9F 5’-CCAAGCCCTGGTATGAGC-3’  
TNF-9R 5’-TTTGGGAAGGTTGGATGTT-3’  1823～1992 
TNF-10F 5’-AAGCAACAAGACCACCAC-3’  
TNF-10R 5’-CAGATGTCAGGGATCAAAG-3’  2104～2240 
CCL2-1F 5’-ATTCATACCCTTCACCTT-3’  
CCL2-1R 5’-AGTGTTCACATAGGCTTC-3’  -2478～-2352 
CCL2-2F 5’-CAAGAGGCACAAGCAAAG-3’  
CCL2-2R 5’-TGGAGAATCCCAGAGCAG-3’  -1823～-1706 
CCL2-3F 5’-TTCTAAGGTCTTTGGGTT-3’  
CCL2-3R 5’-AGCAGTGGAGGAGTATTT-3’  -1168～-1056 
CCL2-4F 5’-TGACTTAGCCATGAGGAA-3’  
CCL2-4R 5’-CATACTGCTGGAAGGAAA-3’ -941～-810 
CCL2-5F 5’-TGGTCAGTCTGGGCTTAA-3’  
CCL2-5R 5’-CAGGAAGTAGGAAAGGGA-3’  -244～-133 
CCL2-6F 5’-AAACTGAAGCTCGCACTC-3’  
CCL2-6R 5’-TGGATGGTCCATGATAACT-3’  45～214 
CCL2-7F 5’-TCCGTCTTAATGACACTT-3’  
CCL2-7R 5’-GACCCAATGACTCAGTTT-3’  664～777 
CCL2-8F 5’-GGGACAAGCCTCATAAAC-3’  
CCL2-8R 5’-TGTTCTGAATAGGCACCC-3’  1117～1254 
CCL2-9F 5’-TCACTCCACAACCCAAGA-3’  
CCL2-9R 5’-AAGGCATAATGTTTCACA-3’  1556～1669 
CCL2-10F 5’-CTCCACTGGGTGGTCTCCT-3’ 
CCL2-10R 5’-GGGTTGGGCTCTTGCTAA-3’  2060～2204 
KRT17-1F 5’-CGCTAATTTCTGTGCATTCC-3’  
KRT17-1R 5’-GGCCAGGGACAAGGAGTA-3’  -2425～-2251 
KRT17-2F 5’-GCATGGCCTGTTGTCTTT-3’  
-1869～-1763 
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KRT17-2R 5’-GGCATTGAACTTGGAGCA-3’  
KRT17-3F 5’-TTGCTTTGGTGGCTTGGC-3’  
KRT17-3R 5’-GCTGGGTGGAATGTGGTCAT-3’  -1250～-1124 
KRT17-4F 5’-CTAGAGTGCATTCCTGGGTG-3’  
KRT17-4R 5’-ATCAAGCCTCGGAGACCA-3’  -683～-571 
KRT17-5F 5’-GGCACTCAGCACGAGGATT-3’  
KRT17-5R 5’-GGCGTAGCGATTACAACAGG-3’  -215～-62 
KRT17-6F 5’-CCTCCATCCGCCAGTTCA-3’  
KRT17-6R 5’-GCCACCACCAGAGCCAAA-3’  56～252 
KRT17-7F 5’-TGGTTTGGCTGTGGCTTAG-3’  
KRT17-7R 5’-TCCACGAGGGAGAAACTGA-3’  590～732 
KRT17-8F 5’-TGGTTGCCTCATACTCCC-3’  
KRT17-8R 5’-CTGAAGGGCTGAAAGGTG-3’  1256～1370 
KRT17-9F 5’-GAGAAGTAAGGAAGCTGGTGG-3’  
KRT17-9R 5’-AGGAGTTGGAAGGGCTGA-3’  1846～1953 
KRT17-10F 5’-AAGATGCTGAGGAGTGGGTG-3’  
KRT17-10R 5’-CCTGGGAGGTTCCTTGTG-3’  2229～2426 
1-10: primer site on the genome 
 
Table S2 Model discrimatination between the reduced (2-compartment) and full (3-
compartment) model using the goodness-of-fit criteria 
 
Group A: 1 mg/kg DZNep 
WRSS DF AIC +/- F value
Rat 2 3 2 3 2 3 2 3  
Weighting  uniform 
Rat1 0.0164 0.0041 6 4 -33.1 -43.0 3 7 6.0 # 
Rat2 0.0175 0.0201 6 4 -32.5 -27.1 3 6 -0.3 # 
Rat3 0.0085 0.0007 6 4 -39.7 -61.1 3 7 23.4 * 
Rat4 0.0127 0.0020 6 4 -35.6 -50.2 3 7 10.8 * 
Rat5 0.0149 0.0044 6 4 -34.0 -42.4 3 6 4.9 # 
Rat6 0.0113 0.0030 6 4 -36.9 -46.1 3 6 5.5 # 
Weighting 1/C 
Rat1 0.0104 0.0011 6 4 -37.7 -56.1 5 7 16.9 * 
Rat2 0.0125 0.0047 6 4 -35.8 -41.7 4 6 3.4 # 
Rat3 0.0058 0.0003 6 4 -43.5 -67.9 4 7 32.2 * 
Rat4 0.0093 0.0010 6 4 -38.8 -57.5 4 7 17.4 * 
Rat5 0.0096 0.0008 6 4 -38.4 -58.9 4 6 21.1 * 
Rat6 0.0093 0.0008 6 4 -38.8 -59.4 4 6 21.3 * 
Weighting  1/C2 
Rat1 0.0017 0.0002 6 4 -55.8 -72.4 4 7 13.7 * 
Rat2 0.0021 0.0008 6 4 -53.4 -59.3 4 6 3.3 # 
Rat3 0.0014 0.0001 6 4 -57.8 -80.2 4 7 26.2 * 
Rat4 0.0014 0.0004 6 4 -57.7 -66.2 5 7 5.0 # 
Rat5 0.0016 0.0001 6 4 -56.6 -82.3 4 6 37.2 * 
Rat6 0.0018 0.0001 6 4 -55.5 -76.4 4 6 22.3 * 
Group A, intravenous administration of DZNep solution (2 mg/mL in 5 % glucose 
solution) in female SD rats at the dose of 1 mg/kg BW. The critical value of the F 




Group B: 5 mg/kg DZNep 
WRSS DF AIC +/- F value
Rat 2 3 2 3 2 3 2 3  
Weighting  uniform 
Rat1 0.1972 0.0447 7 5 -9.9 -22.2 3 6 8.5 * 
Rat2 0.2431 0.1178 7 5 -7.6 -11.5 3 5 2.7 # 
Rat3 0.2608 0.0913 7 5 -6.8 -14.3 3 6 4.6 # 
Rat4 0.1373 0.0324 7 5 -13.8 -25.7 2 6 8.1 * 
Rat5 0.3455 0.0832 7 5 -3.7 -15.4 3 7 7.9 * 
Rat6 0.2648 0.0757 7 5 -6.6 -16.4 3 6 6.2 * 
Weighting 1/C 
Rat1 0.0426 0.0047 7 5 -26.7 -47.0 3 6 20.3 * 
Rat2 0.0483 0.0131 7 5 -25.3 -35.7 3 6 6.7 * 
Rat3 0.0514 0.0069 7 5 -24.6 -42.8 3 6 16.3 * 
Rat4 0.0490 0.0073 7 5 -25.2 -42.2 3 5 14.4 * 
Rat5 0.0716 0.0107 7 5 -21.0 -37.9 3 7 14.2 * 
Rat6 0.0518 0.0174 7 5 -24.6 -32.5 3 6 4.9 # 
Weighting 1/C2 
Rat1 0.0018 0.0002 7 5 -61.4 -82.9 4 5 23.2 * 
Rat2 0.0022 0.0008 7 5 -59.2 -66.2 5 6 4.3 # 
Rat3 0.0012 0.0001 7 5 -66.0 -88.6 4 6 25.8 * 
Rat4 0.0022 0.0004 7 5 -59.2 -74.9 4 6 12.5 * 
Rat5 0.0014 0.0003 7 5 -64.0 -75.8 5 7 8.0 * 
Rat6 0.0054 0.0014 7 5 -49.5 -60.5 4 5 7.3 * 
Group B, intravenous administration of DZNep solution (2 mg/mL in 5 % glucose 
solution) in female SD rats at the dose of 5 mg/kg BW. The critical value of the F 
distribution (0.05, 2, 5) is 5.79. * F-test, p < 0.05. 
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Group C: 10 mg/kg DZNep 
WRSS DF AIC +/- F value
Rat 2 3 2 3 2 3 2 3  
Weighting  uniform 
Rat1 0.4668 0.2196 7 5 -0.4 -4.7 2 3 2.8 # 
Rat2 0.7054 0.2587 7 5 4.2 -2.9 2 3 4.3 # 
Rat3 0.6000 0.1981 7 5 2.4 -5.8 2 3 5.1 # 
Rat4 0.3359 0.1472 7 5 -4.0 -9.1 2 3 3.2 # 
Rat5 0.4731 0.1794 7 5 -0.2 -6.9 3 3 4.1 # 
Rat6 1.2869 0.3864 7 5 10.8 1.5 3 3 5.8 * 
Weighting  1/C 
Rat1 0.2481 0.0383 7 5 -7.3 -23.9 3 5 13.7 * 
Rat2 0.1695 0.0243 7 5 -11.5 -28.9 3 6 14.9 * 
Rat3 0.1982 0.0178 7 5 -9.8 -32.3 3 5 25.3 * 
Rat4 0.1198 0.0217 7 5 -15.3 -30.1 3 5 11.3 * 
Rat5 0.0902 0.0109 7 5 -18.5 -37.7 3 7 18.2 * 
Rat6 0.5180 0.1363 7 5 0.8 -9.9 3 7 7.0 * 
Weighting  1/C2 
Rat1 0.0128 0.0019 7 5 -39.9 -57.1 5 5 14.5 * 
Rat2 0.0104 0.0017 7 5 -42.3 -58.0 4 6 12.5 * 
Rat3 0.0071 0.0003 7 5 -46.4 -76.5 4 5 52.9 * 
Rat4 0.0050 0.0016 7 5 -50.2 -58.7 4 5 5.3 # 
Rat5 0.0026 0.0002 7 5 -57.5 -79.6 4 7 24.1 * 
Rat6 0.0172 0.0116 7 5 -36.7 -37.0 5 6 1.2 # 
Group C, intravenous administration of DZNep solution (2 mg/mL in 5 % glucose 
solution) in female SD rats at the dose of 10 mg/kg BW. The critical value of the F 
distribution (0.05, 2, 5) is 5.79. * F-test, p < 0.05. 
 
 
 
